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Abstract 
 
Carcinogenesis is a multi-step process which involves genomic instability and abnormal 
cellular growth over long period of time which eventually develop tumour. Cancer testis 
antigens consistently reported in many types of cancer which suggest its oncogenic role. But, 
it’s functional role in cancer still unknown and need further investigation. Also, cancer testis 
antigens might be used as potential targets for cancer immunotherapy due to their main 
presence in normal testis cells and abnormally exist in several types of human cancer. Their 
aberrant expression in cancer makes them useful to target human malignancies by 
immunotherapy. 
TEX19 one of the novel CT gene was identified in this study. TEX19 show interesting 
expression pattern due to its confined in normal testis and expressed in many cancer tissues. 
This expression may indicate the oncogenic activity of TEX19 gene in somatic tissue. Thus, 
the possible approach to use this gene as target for cancer immunotherapy and cancer prognosis 
and diagnosis.  
In addition, TEX19 might play a role in stemness state, this was observed in TEX19 depleted 
cells, the stem cell markers genes such as OCT$, NANOG, SOX2 were affected after the 
knockdown of TEX19. However, Tex19 was not affected after differentiating NT-2 cancer cells 
using Retinoic acid and HMBA.   
We also studied the relation between TEX19 and transposable genetic elements by knockdown 
TEX19 in NT-2 and A2780 cancer cells. The qRT-PCR results show that human ERVK family 
gene expression was affected by TEX19 depletion. 
Moreover, our RNA sequencing data of TEX19 depleted sample and qRT-PCR analysis reveal 
the influence of TEX19 depletion on some differentially expressed genes. Interestingly, these 
genes were upregulated and down regulated after the depletion of TEX19 in four types of 
human cancer cell lines. 
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Abbreviation list 
AD 
 
 
 
Alzheimer's disease 
ALT Alternative lengthening of telomeres 
AML Acute Myeloid Leukemia 
APC Antigen presenting cells 
APL Acute promyelocytic leukemia 
ATCC American Type Culture Collection 
BBB Blood brain barrier 
BET Bromodomain and extra-terminal 
BTB Blood-testis barrier 
CML Chronic myeloid leukemia 
CT Cancer Testis 
CTA Cancer-testis antigens 
CTL Cytotoxic T-lymphocytes 
DF Degrees of freedom 
DSB Double strand breaks 
EC Embryonal carcinoma 
ECACC European Collection of Cell Cultures 
EG Embryonic germ 
ELDA Extreme limiting dilution analysis 
ESC Embryonic Stem Cells 
EST Expression sequence tag 
FBS Foetal bovine serum 
GCC Germ cell cancers 
HLA Human leukocytes antigens 
HPV Human papilloma virus 
HR Homologous Recombination 
IHCC Intra-hepatic Cholagio-carcinoma 
  
LE Lateral elements 
LFT Liver function tests 
LINE Long interspersed transposable elements 
LTR Long terminal repeat 
MBD Methyl-CpG-binding domain 
MLL Mixed Lineage Leukemia 
MPSS Massively parallel signature sequencing 
NRT No reverse transcription 
NTC No template control 
NVU Neurovascular unit 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
PGC Primordial germ cells 
RA Retinoic acid 
RI Refractive index 
SAGE Serial analysis of gene expression 
SC Synaptonemal complex 
SINE Short interspersed transposable elements 
SNP Single nucleotide polymorphisms 
TE Transposable elements 
TGE Transposable genetic elements 
TSG Tumour suppressor genes 
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1. Introduction 
1.1 Human malignancies 
Cancer is a disease characterized by abnormal and uncontrolled cell divisions leading to 
invasion of adjacent tissues and it is capable of metastasis to distant organs. Cancer is 
considered as one of the leading causes of death in many countries. In UK, approximately 
162,000 people died of cancer in 2012 (Cancer Research UK, 2014). These facts emphasize 
the importance of understanding cancer genetics to find new and better methods for cancer 
diagnosis and treatment. 
1.1.1 Carcinogenesis 
Cancer is a disease where normal cells undergo a malignant transformation, leading to 
uncontrolled and abnormal cell division, which can result in invasion of the adjacent tissues. 
In addition, aggressive malignant tumours can undergo metastasis, in which, cancerous cells 
spread from the primary site, and infiltrate different sites of the body through haematogenous 
or lymphatic routes (Pitot, 2002). 
The process of cancer spreading is referred to as carcinogenesis. It is a multi-step process in 
which a normal cell undertakes an abnormal cellular division and growth, achieving various 
levels of neoplastic phenotype. Cancerous cells are characterised by genomic instability and 
abnormal balance of chromosomes. The phenotypic features of the multi-step carcinogenesis 
include dysplasia, hyperplasia, anaplasia, abnormal cellular morphology, immortality, 
abnormal metabolism, significant growth, invasiveness, metastasis and drug resistance (Pitot, 
2002).  
In rodents, the kinetics of carcinogenesis is a slow and multi-step process in which, after 
exposure to an initiated dose of carcinogen, it takes several months for the normal cell to 
transform into a cancer cell and to develop cancerous phenotypes (Tani et al., 2016). 
However, most human carcinogenesis takes a lot more time, as much as decades are required 
to develop cancer after several occupational and accidental exposures to carcinogens.         
1.1.2 Hallmarks of Cancer 
The origin and progression of cancer is dependent on the cellular machinery and the genetic 
programming inside the cells. Out of 23,000 human genes present, approximately 3000-5000 
genes encode for the production of proteins which are almost always disrupted in cancer, or 
become part of the biochemical pathway deregulated by cancer (IARC, 1999). The modified 
or dysfunctional gene in case of cancers may lead to a number of outcomes: increase the 
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production of its protein or decrease it, produce abnormal protein incapable of carrying out its 
function or completely eliminate it from the cell. Mutations of such types are most common 
in the genes responsible for modulating the cell growth signal and they are modified in such a 
way that they remain activated inside the cell and hence promote cell proliferation at all 
times. They are also referred to as oncogenes and the most common example of an oncogene 
is the mutated KRAS gene which is found to be present in colorectal cancers, lung 
adenocarcinomas (IARC, 1999). However, cancer development may also rely on the 
permanent inactivation of a gene inside the cell, as is the case with the TP53 gene. It is 
responsible for the production of the protein which modulates and represses inappropriate cell 
growth or stops cell proliferation. After loss-of-function mutation in the gene, the protein 
product formed is unable to carry out its function and hence cancer growth is unregulated. 
These type of genes are referred to as tumour suppressor genes, as their normal protein 
product would have suppressed the growth of tumour (IARC, 1999). 
These disruptions in the genetic programming of the cells may contribute to the origin and 
progression of cancer from either one cell or from a small number of cells. In order to 
become cancerous in nature and spread to the later part of the cell, tissue, organ or body, the 
cell has to undergo genetic, phenotypic as well as biochemical changes. The origin is the 
series of changes in the oncogenes and the tumour suppressor genes that allow the cell to 
proliferate and form a cluster of cancerous cells (tumour). In the context where this tumour 
remains undisturbed and is not attacked by the body’s immune system, it continues to grow 
and gather more and more genetic modifications. Eventually the most aggressive cancerous 
cells are able to take over the weaker cells part of the tumour and the tumour becomes 
malignant and ready to spread to other parts of the body. Because of the numerous and 
unpredictable genetic modifications in the cancer, it is very difficult to treat. Even if a drug is 
capable of clearing out the majority of the tumour cells, a few cancerous left over cells can 
relapse into a more aggressive form of the cancer, worse than before. Therefore, it is a 
progressive disease which starts as a small and inconspicuous ball of cells and after some 
period of time, turns into a malignant cancer. However, if it is detected when it is still in the 
inconspicuous phase of development, it may be easily removed and would not contribute to 
the development of a full-grown cancer (Petrovic, 2016). 
The context of cancer development, however, is more complicated than as stated. Genetic 
modifications and conducive cellular environment are not the only precursors responsible for 
the development of cancer. Cancers can develop while hinging onto the cellular and 
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biochemical landscape established by other diseases in order to spread to other susceptible 
tissues or organs in the body. These diseases are often also referred to as precursor diseases 
of cancer and may include chronic inflammatory diseases such as liver cirrhosis, intestinal 
metaplasia etc. Using lymphatic and blood vessels, the cancerous cells can travel to 
neighbouring tissues to perturb their biochemical activities and transfer their malignancies 
through possible genetic modifications. The main reason that tumours can keep growing and 
facilitate their growth is tumour angiogenesis. They are capable of synthesizing new blood 
vessels to ensure constant supply of oxygen and essential nutrients to all cells in the tumour 
(Petrovic, 2016).  
The mutagenesis of the tumours or spread of the tumour creates complications for the 
oncologists and the cancer pathologists in the identification and possible cure of cancer. The 
two mechanisms discussed above represent the hallmarks of cancer. These are 6 basic 
mechanisms which the cell must acquire changes within before becoming cancerous. As we 
saw earlier how sustained angiogenesis, limitless replicative potential and tissue invasion and 
metastasis helps in the origination and progression of cancer, the remaining mechanisms 
pertain to how cancerous cells evade apoptosis, become self-sufficient in growth signals and 
gather insensitivity to anti-growth signals (Hanahan and Weinberg, 2011).  
1.1.3 Epigenetic origin of cancer 
The term ‘epigenetic’ is used to describe the heritable alteration of gene expression and the 
structure of chromatin that does not affect the DNA sequence directly. In normal eukaryotic 
cells, modifications of the chromatin take place mainly by at least three epigenetic 
mechanisms of DNA methylation, histone modifications and silencing of non-coding RNAs 
(Bernstein et al. 2007). 
 
In modern disease pathological studies, genetics and epigenetics both play a crucial part in 
determining the course of disease development. At cellular level, both epigenetics and 
genetics collaborate to manoeuvre transcriptional activities taking place and decide which 
genes are expressed and which stay in the repressed state. These epigenetic modifications 
represent stable changes of the epigenome that are inherited through phases of mitosis and do 
not include mutations of the DNA itself. Epigenetics has been, more than often, referred to 
being the study of these stable alterations of gene expression potential that is the result of 
development and cell proliferation and be outside conventional genetics (Shah and 
Allergrucci, 2013). These changes are not essentially inherited at the stage of embryogenesis 
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and can be present in mature humans by a random change or by the environmental stimuli. 
They can be incorporated as the posttranslational modifications of the DNA or the proteins 
associated with it. Therefore, the epigenetic regulation or modifications can arise through 
covalent modifications of the DNA (methylation, ubiquitylation, acetylation etc) and histone 
molecules, nucleosome rearrangement or positioning with respect to the DNA. These 
epigenetic changes have been found to be recurrent in tumours and participate in gene 
silencing. Therefore, studying the mechanism by which the three aspects of DNA 
methylation, Histone modifications and nucleosome remodeling bring about modifications in 
the gene expression profile of diseased individuals can give a head start at determining the 
sites that need to be regulated for controlling the progress of diseased states. Furthermore, the 
epigenetic modifications can also be assessed for their therapeutic potential against cancer 
development and progression since they have been recognized as the emerging hallmarks of 
cancer (Shah and Allergrucci, 2013). 
1.1.3.1 DNA methylation:  
In eukaryotes, gene expression homeostasis is regulated by DNA methylation and it is the 
addition of a methyl group covalently to the 5th position of the cytosine ring of CpG 
dinucleotides and is the primary epigenetic mechanism for promoting or repressing 
expression of genes during the stages of development and embryogenesis. Therefore, it 
involves modifications at the 5' of cytosine within CpG (Wu and Zhang, 2010). CpG 
dinucleotides, are not evenly spread across the human genome and are found in high 
concentrations near the regions of high repetitive sequences, including centromeric repeats 
and retrotransposon elements often referred to as ‘CpG islands’. Most of these sites have 
been reported to be methylated, however, majority of the CpG islands remain unmethylated 
during the stages of development and differentiation. In cases of long-term transcriptional 
inactivation, X-chromosome inactivation and imprinted genes, the promoters of CpG islands 
become methylated naturally at the time of development. Tissue-specific methylation has also 
been reported to occur, in cases of developmentally important genes, in a variety of somatic 
tissues (Wu and Zhang, 2010). In sharp contrast, the repetitive genomic sequences present 
across the human genome are found to be highly methylated and therefore, prevent 
chromosomal instabilities by silencing the non-coding DNA and transposable elements. DNA 
global hypomethylation and promoter-specific hypermethylation are known to be key role-
players in cancer epigenome that lead to genomic instability and they largely target these 
repetitive elements along with intergenic regions and gene bodies. This loss of DNA 
methylation is followed by de novo hypermethylation of important tumour suppressor genes 
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(TSG) promoters and the genes that are localized in CpG islands to initiate permanent gene 
silencing. Of these two epigenetic mechanism, the hypermethylation of promoters in CpG 
islands are better characterized with respect to cancer development. The human genome 
contains approximately 29,000 CpG sequences and approximately 50–60% of gene 
promoters sites are located within CpG islands (Pradhan et al., 2009). The research study by 
Frigola and colleagues in colorectal cancer showed how the entire chromosome band was 
remodeled epigenetically to cause gene repression and promote the growth of the cancer. 
Therefore, while we acknowledge the incidence of promoter-specific and cancer-specific 
DNA hypermethylations, we should also remain open to the fact that in more than one 
incidences, whole gene neighborhoods or entire chromosome bands have been affected. 
Another hallmark of cancer besides disruption of DNA methylation patterns in the recurring 
global loss of Histone H4 Lysine 16 (H4K16) acetylation and Histone H4 Lysine 20 (H4K20) 
trimethylation patterns along with increased expression of BMI1 and EZH2. BMI1 has been 
characterized as a component of Polycomb Repressive Complex 1 and EZH2 is part of 
Polycomb Repressive Complex 2 (PRC2) and both are involved in silencing gene expression 
( Sharma et al., 2010). These type of modifications have been credited with bearing high 
prognostic value in regards to cancer. Furthermore, in a series of recent studies it has been 
shown that the targets of or genes associated with PRC are likely to become methylated in 
cancer in Embryonic Stem Cells (ESC) and thereby linking other epigenetic silencing 
mechanism to bring about collective genome repression and progression of cancer (Ohm et 
al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007). The proteins responsible for 
causing these epigenetic modifications leading to cancer are those enzymes that catalyze 
DNA methylation, bind methylated DNA at promoters and cause gene silencing, catalyze 
histone acetylation, deacetylation, methylation and demethylation and are found to be targets 
of tumor initiation and progression pathways. These proteins help in identification of 
epigenetic genes that are being modified in the course of specific cancers and whether they 
are being altered through somatic or germ-line mutations. Furthermore, a detailed literature 
review was conducted to make sure that these epigenetic genes belonged to the families of 
DNMTs, MBD (methyl-CpG-binding domain), HAT (histone acetyltransferases), HDAC 
(histone deacetyltransferases), HMT (histone methyltransferases) and histone demethylases 
(Miremadi et al., 2007). These specific families were essentially chosen because they mediate 
epigenetic modifications in the genome and we can study each family in detail and elaborate 
on the different mutations they go through in different cancers. 
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DNA methyltransferases: 
DNA methylation is achieved by DNA methyltransferases enzyme (DNMTs) which causes 
inactivation of the gene (Rodriguez-Paredes and Esteller, 2011). DNMTs enzymes are 
categorized into three main types, the first one is DNMT1, plays a role during the DNA 
methylation after DNA replication. The other two types of enzymes are DNMT3A and 
DNMT3B, which are highly expressed during embryogenesis and these enzymes are involved 
in DNA methylation directly on unmethylated CpGs (Burge et al., 2009). Another family 
member of DNA methylation is known as DNMT-3L which lacks the intrinsic 
methyltransferase enzyme activity, but plays an important role in transposable elements 
methylation through interaction with DNMT3A and DNMT3B (Fuks et al., 2002). This 
process occurs in repetitive genomic regions such as satellite DNA and transposable genetic 
elements (TGE) which include long interspersed transposable elements (LINEs) and short 
interspersed transposable elements (SINEs), and this process is crucial for the maintainence 
of genomic integrity (Robertson, 2005). 
CpG dinuleotides are covalently modified through DNMTs in order to suppress 
transposons ad repetitive DNA sequences to confer genomic stability (Yoder et al., 1997). 
These dinucleotides are enriched in stretches of DNA that range from 0.5 to several 
kilobases, CpG islands, and are often present along with promoter regions. The methylation 
laid out during early embryogenesis via DNMT1, DNMT3A and DNMT3B at these CpG 
islands controls the normal development of an organism. Targeted deletions of these genes in 
mouse models resulted in embryonic lethality and disrupted development. In human tumours, 
these DNMTs have been found to present moderate-high levels, representing their 
overexpression. DNMT1 has been reported for causing Fos-induced transformation of mouse 
fibroblast cells and maintaining repression of tumor-suppressor loci in human cancer cell 
lines, whereas, DNMT3A has also been reported in pathways mediating cancer cell’s survival  
(Beaulieu et al., 2002; Robert et al., 2003). Somatic mutations in DNMT1 have been 
repeatedly reported in 2 types of colorectal cancers out of a total of 29 suggesting that the 
inactivation or repression of DNMT1 is involved in carcinogenesis. Due to a decrease in 
aberrant methylation of TSG, mice deficient in DNMT1 show a tumor resistant phenotype, 
whereas, reduced expression of DNMT1 result in a global DNA methylation level that is 
reflective of genomic instability. DNMT1-deficient mice were also reported to have 
developed sarcomas at an earlier age and the mice which were carrying hypomorphic and a 
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null allele for DNMT1 developed aggressive T cell lymphomas, displaying a high frequency 
of genomic rearrangements.  Lastly, ESC deficient for DNMT1 displayed increased 
frequency of chromosomal rearrangements required for tumor formation. 
Furthermore, DNMT3B germ-line mutations reveal that in cases where it is non-functional, 
we observe immunodeficiency, centromeric instability and facial abnormalities (Hansen et 
al., 1999; Xu et al., 1999). Mouse embryo fibroblasts which are deficient for DNMT3B also 
reveal resistance to being transformed by SV40 largeT and activated RAS oncogenes, 
meaning that epigenetic mechanisms work in collaboration with genetic mechanisms during 
cellular transformation (Soejima et al., 2003). Furthermore, germ-line SNPs (single 
nucleotide polymorphisms) in DNMT3B have been reported to be associated with breast 
cancer (Yamane et al., 2006), lung adenocarcinoma (Lee et al., 2005) and lung cancer (Shen 
et al., 2002) and all of these modifications have been found to be present in the promoter 
region of DNMT3B. However, the alteration in the DNA methylation levels of 6 suggested 
genes in CpG island (RARβ2, CDH1, ER, BRCA1, CCND2, p16 and TWIST) were not 
confirmed in the study by Ceberian et al which used the biggest sample size and therefore 
modification of methylation at CpG island promoter is highly unlikely (Cebrian et al., 2006; 
Li et al., 2006). 
Furthermore, gene expression’s inhibition occurs directly by binding of specific transcription 
factors and indirectly by the involvement of methyl-CpG-binding domain (MBD) proteins. 
There are six members of methyl-CpG-binding proteins identified in mammals, including 
methylcytosine binding protein 2 (MECP2), MBD1, MBD2, MBD3, MBD4 and Kaiso 
(Bogdanovic and Veenstra, 2009). Their somatic as well as germline variants have been 
associated with multiple cancers either through their overexpression or deregulated 
mutations.  Except for MBD4 which is involved in DNA mismatch repair, other MDB 
proteins are involved in transcriptional repression. Methyl-CpG-binding proteins have been 
reported to be associated with histone modifying enzymes to maintain the transcriptional 
silenced state and MBD proteins have been found to be associated with aberrantly methylated 
promoter regions of TSG (Nguyen et al., 2001) and DNA repair gene (MGMT) 
(Nakagawachi et al., 2003). 
Three SNPs in MBD1 (634G>A, 501delT and Pro401Al) have been associated with the 
development of lung cancer (Jang et al., 2005) and the presence of these polymorphisms 
increases the overall risk for lung cancer and lung adenocarcinoma. MBD4’s SNP has been 
suggested to regulate the risk of cancer. The neutral amino acid substitution has been reported 
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to lie in unknown functional domains of the protein, whereas, the Lys/Lys genotype has been 
reported in esophageal squamous cell carcinoma and subsequently increase its risk of 
incidence (Hao et al., 2004).  
 
Moving on, although role of somatic changes in MBD proteins in cancer is still unclear, 
however, it has been shown that MBD2 binds to the aberrantly methylated promoter of TSG 
and represses its expression, as highlighted earlier. These TSG include p14/ARF and 
p16/Ink4A, which have been found to be associated with MBD2 in colon cancer lines 
(Magdinier and Wolffe, 2001). Since these alterations are not yet clear, they may as well be 
due to increased cell proliferation in these cancer cell lines. Furthermore, when the mice 
deficient in MBD2 were crossed to APCMin/+ background, they were found to be resistant to 
the development of intestinal tumours. Varying the dosage of MBD2 also was observed to 
resul in varying tumor resistant effects (Sansom et al., 2003). Moreover, MeCP2s 
overexpression and mutations have been observed in breast cancer and have been shown to 
be related to estrogen receptor positivity (Müller et al., 2003). However, there is evidence that 
MeCP2, MBD2 and MBD4 are down-regulated in cancers as shown here, however, no firm 
connections with cancer development for either one of them have been found as yet. MBD1 
and MBD2 are present on chromosomal locus of 18q21, which is often found to be lost in 
cancer, however, mutation analysis of human lung and colon cancers reveal few changes in 
these proteins, thereby limiting their role in cancers (Bader et al., 2003). 
 
Furthermore, DNA methylation can also be achieved by nucleosome remodeling complex 
(NuRD) interaction with DNA methylation binding protein MBD2, which directs the NuRD 
complex to methylate DNA (Bogdanovic and Veenstra, 2009; Lai and Wade, 2011). Table 
1.1 shows a list of DNA methylation genes disorders in some types of human malignancies 
(Kanwal, and Gupta, 2012).  
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Table 1.1 DNA methylation gene changes in various human cancers (Kanwal, and Gupta, 2012). 
DNA 
methyltransferase 
Function Alterations Cancer type 
DNMT 1 
Maintenance of methylation, 
repression of transcription 
Upregulation, 
mutation 
Colorectal cancer, 
ovarian cancer 
DNMT3a 
De novo methylation during 
embryogenesis, imprint 
establishment, repression 
Upregulation 
Colorectal cancer, 
breast cancer, ovarian 
cancer, esophageal 
squamous cell 
carcinoma 
DNMT3b 
De novo methylation during 
embryogenesis, repeat 
methylation repression 
Upregulation 
Breast cancer, 
hepatocellular 
carcinoma, colorectal 
cancer, 
DNMT3L 
Interacts with DNMT3a &b 
and facilitate methylation 
Upregulation  
MeCP2 Transcription repression 
Upregulation, 
Mutation 
Prostate cancer, Rett 
syndrome, 
MBD1 Transcription repression 
Upregulation, 
Mutation 
Prostate cancer, colon 
cancer, lung cancer 
MBD2 Transcription repression 
Upregulation, 
Mutation 
Prostate cancer, colon 
cancer, lung cancer 
MBD3 Transcription repression 
Upregulation, 
Mutation 
Colon cancer, lung 
cancer 
MBD4 
DNA repair, glycosylase 
domain, repair of 
deaminated 5-methylC 
Upregulation, 
Mutation 
Colon cancer, gastric 
cancer, endometrial 
cancer 
Kaiso Transcription repression Upregulation 
Colon, intestinal, lung 
cancer 
 
However, in cancer, hypermethylation of CpG island promoters leads to inactivation of 
transcription and hypomethylation of the genome are observed which involved in various 
types of cancer (Sincic and Herceg 2011). The cellular pathways affected by transcription 
inactivation include BRCA1 (breast cancer 1)], Ras signaling {RASSF1A [Ras association 
(RalGDS/AF-6) domain family member 1], NOREIA}, and p53 network [p14 ARF , p73 (also 
known as TP73 ) (Kanwal, and Gupta, 2012). 
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1.1.3.2 Histone Modifications: 
Another process play a role in malignancy and epigenetic regulation is histone modifications, 
which influence the chromatin structure (Cedar and Bergman, 2009). In eukaryotes, the 
highly condensed chromatin structure consists of two strands of DNA sequences wrapped 
around core histones, H2A, H2B, H3 and H4 which form nucleosomes (Luger et al. 1997). 
This composition gives the chromatin the ability to condense, protect, preserve and control 
the genetic information and gene expression (Fyodorov and Kadonaga 2001). The molecular 
function of chromatin is regulated by histones, which undergo numerous posttranslational 
modification including acetylation, methylation, phosphorylation, ubiquitination and poly 
(ADP) ribosylation (Margueron et al. 2005). Some epigenetics changes happened during the 
generation of DNA double strand breaks (DSBs) in both mitosis and meiosis. For example, 
the induction of DSBs leads to a changes in the chromatin through phosphorylation of the 
histone H2AX (Mahadevaiah et al. 2001).  
 
Although a number of histone modifications have been found to be associated with epigenetic 
deregulations, however, acetylation and methylation are the most important with regards to 
having been found recurrently in pathological samples from cancer cells. In human cancer, an 
alteration of histone modification processes has been observed in some studies. A change of 
the histone modification levels reflects alteration of gene expression. High levels of 
H3K4me3, H3K27ac, H2BK5ac and H4K20me1 in the promoter and H3K79me1 and 
H4K20me1 of the gene were observed in the active transcribed genes (Karlic et al., 2010). 
Therefore, specific loss of acetylation and methylation of specific residue present on core 
histones of H3 and H4 have been identified as markers for tumor cells (Fraga et al., 2005; 
Seligson et al., 2005). 
 
Histone Acetyltransferases (HATs), Histone Deacetyltransferases (HDACs) and Histone 
Methyltransferases (HMTs): 
The acetylation on these core histones of H3 and H4 controls and regulates chromatin 
assembly, transcription and gene expression. This acetyl mark is introduced by the opposing 
activities of HATs and HDACs. There are around 3 main families of HATs that introduce 
acetyl marks on the lysine residues of the nucleosome core histones which include the MYST 
family, GNAT family and CBP/p300 family (Inche and La Thangue, 2006; Wang et al., 
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2007). They are recruited by the transcription factors as co-activators of transcription for 
large chromatin complexes’ remodeling. CBP, p300 and PCAF also acetylate multiple non-
histone proteins which play an active role in oncogenesis (Davis and Brachmann, 2003; 
Glozak et al., 2005; Kouzarides, 2007; Wang et al., 2007). When hematological and solid 
cancers were analyzed, altered activity for HATs was reported which had been caused by 
either inactivation of HAT through gene mutation or deregulation by viral oncoproteins 
involved in cellular transformation (eg E1A and SV40 T antigen proteins targeting 
p300/CBP) (Rasti et al., 2005). These viral oncoproteins cause global hypoacetylation of 
H3K18, relocalization of p300/CBP HATs to promoter of specific genes that regulate cell 
growth and division, hyperacetylation of H3K18 and transcriptional activation of specific 
genes (Ferrari et al., 2008). Therefore, cellular transformation is undertaken by 
reprogramming epigenetic landscape of the cell, especially through interaction of the viral 
oncoproteins with HATs. Missense mutations of p300 have been reported in colorectal, 
gastric, breast and pancreatic cancers (Davis and Brachmann, 2003). Furthermore, Tip60, that 
participates in regulating tumorigenesis, when expressed less than its threshold results in 
hypoacetylation of p53 and consequently, defective apoptic signaling cascade and thereby 
increasing the risk for malignant transformation. Mono-allelic loss of Tip60 has been widely 
reported in lymphomas, mammary carcinomas, and head and neck tumours (Gorrini et al., 
2007). Moreover, chromosomal translocations taking place in regard to HATs and their 
subsequent fusion proteins have been reported in the development and progression of acute 
leukemia (Davis and Brachmann, 2003). MLL-CBP is a fusion protein caused by the 
translocation t(11;16)(q23;p13) results in combination of Mixed Lineage Leukemia (MLL) 
protein and CBP (HAT) and is present in Acute Myeloid Leukemia (AML) and Acute 
Lymphoblastic Leukemia (ALL) (Ayton and Cleary, 2001). More examples of chromosomal 
translocations leading to the formation of fusion proteins including MOZ-CBP and TIF2-
MOZ have been reported in hematological malignancies (Cairns, 2001; Panagopoulos et al., 
2001) and cause the onset of acute leukemia (AML and ALL).  
      Moving on, the main role of HDACs is to oppose the activity of HATs thereby 
causing transcriptional activation by removing acetyl marks from the lysine resides of the 
core histones H3 and H4 and through deacetylation of non-histone substrates (Bolden et al., 
2006). There are four classes of HDACS that are present in different compartments of the 
cell, operating in a context-dependent manner. Class I HDACs consists of HDAC 1, 2, 3 and 
8 and are localized in the nucleus, class II consists of HDACs 4, 5, 6, 7, 9 and 10 that are 
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present both in the cytoplasm and the nucleus, class III consists of sirtuins 1-7 and lastly, 
class IV consists of HDAC 11 that resembles the first two classes of HDACs (Glozak and 
Seto, 2007). Even within the classes of HDACs, the different deacetyltransferases do not 
operate in a similar fashion and are part of distinct repressor complexes. Deleting or knocking 
down these HDACs would result in a variety of cellular responses and effects (Witt et al., 
2009).  Knockdown of HDAC1 and HDAC2 result in suppression of proliferation of colon 
carcinoma cells in vitro (Weichert et al., 2008) and sensitized the chronic lymphocytic 
leukemia cells to TRAIL-induced apoptosis (Inoue et al., 2006). Knockdown of HDAC3, on 
the other hand, resulted in more effective inhibition of the growth of different set of colon 
carcinoma cells as compared to HDAC1 and HDAC2 (Wilson et al., 2006). Moreover, 
knockdown of both HDAC3 and HDAC2 did result in inducing DNA damage and 
consequently, apoptosis (Bhaskara et al., 2008). Knockdown of HDAC4 also resulted in 
inhibition of cell proliferation and apoptosis was induced in the cells, which means that it 
helps in the growth of colon cancer cells (Wilson et al., 2008). Knockdown of HDAC7 on the 
other hand did not affect cell growth or survival, however, it did inhibit the capacity of the 
cells to migrate and form capillary tube-like structures which is an important step in 
angiogenesis (Mottet et al., 2007). Like HATs, the chromosomal translocations of HDACs 
have also been implicated in promoting tumorigenesis in leukemias and is most evident in the 
case of APL (acute promyelocytic leukemia). In APL, due to chromosomal translocations of 
t(15;17) and t(11;17) results in the formation of a fusion protein RARα-PML and RARα-
PLZF resulting in transcriptional silencing of RAR-targeted genes and repression of cell 
differentiation (Cress and Seto, 2000; Lin et al., 2001; Pandolfi, 2001; Zelent, 1994). In 
addition to their aberrant transcriptional pathways, the alteration in their expression profiles 
have also been widely reported. HDAC1 has been found to be overexpressed in prostate, 
gastric, colon and breast carcinomas (Choi et al., 2001; Halkidou et al., 2004; Wilson et al., 
2006; Zhang et al., 2005). HDAC2 is overexpressed in colorectal (Zhu et al., 2004), cervical 
(Huang et al., 2005) and gastric (Song et al., 2005) cancer. HDAC6 is overexpressed in breast 
cancer (Zhang et al., 2004) . Therefore, we can observe that aberrant expression of HDACs 
can result in tumorigenesis and they can provide a molecular model for targeting HDAC 
activity in tumours.   
 Lastly histone methylation can be found in mono, di or tri state on lysine and arginine 
residues and has been reported to be an enzymatically dynamic process (Lan et al., 2008). 
Methylation at H3K4, H3K36 and H3K79 resides leads to transcriptional activation and the 
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methylation marks at H3K9, H3K27 and H3K20 are transcriptional repressor marks 
(Kouzarides, 2007). There is limited information present with respect to how the 
methylations vary across different cancers, however, evidence does exist that they are related 
to the onset and growth of tumours. Cell-specific loss of trimethylation of H4K20 in tumours 
(Fraga et al., 2005) and knockout of HMT SUV39H makes the cells susceptible to 
tumorigenesis, as experimented in mice (Peters et al., 2001). The development of new 
techniques and methods is required to study the epigenomic landscape of cells in tumours to 
understand the changes in the methylation levels with the progression of diseased state. 
Therefore, what we can clearly see is that how epigenetics along with genetics controls the 
progression of the cells from normal to tumorigenic states. Since these states are heritable and 
reversible, they are strong candidates for cancer therapeutics and aiding in reversing the 
diseased phenotype to normal through inhibitory drugs. 
1.2.1 Meiotic homologous recombination 
Meiosis is a unique cell division required for sexual reproduction among eukaryotes, during 
which four haploid gametes are formed from a diploid progenitor cell. It involves two 
chromosomal segregation events preceded by one round of DNA replication. Following pre-
meiotic DNA replication, meiosis I (MI) and meiosis II (MII) both occur in four sequential 
steps; Prophase, Metaphase, Anaphase and Telophase. Homologous Recombination (HR) is 
fundamental in maintaining genomic stability, and ensures proper distribution of the genetic 
information (Loidl, 1990). 
 
The reductional segregation of the homologous chromosomes takes place in MI. It is initiated 
during prophase I by homologous chromosomes aligning, pairing and conjoining via the 
establishment of homologue recombination events; these ultimately become chiasmata, which 
play a critical role in bivalent alignment of the metaphase I plate. Meiotic recombination 
events are initiated by the programmed formation of DNA double stranded breaks (DSBs), 
which are generated by the conserved meiosis-specific protein Spo11 (Keeney and Kleckner, 
1995). Repairing the DSBs in most eukaryotes is associated with synapsis.  Synapsis of 
homologous chromosomes relies on the formation of a complex proteinacious structure called 
the synaptonemal complex (SC). The SC is a scaffold protein structure which consists of 
lateral elements (LEs) connected by transverse filaments (Figure 1.1). In mammals there are a 
number of known meiosis-specific proteins which are components of the SC, SYCP2, 
SYCP3, which are attached to LEs, and central element proteins, including SYCE1, SYCE2 
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and TEX12. SYCP1 is an additional SC protein which serves to form the transverse filaments 
(Figure 1) (Hamer et al., 2008). 
 
In meiosis, cohesion is established between the two sister chromatids during pre-meiotic 
DNA replication (Figure 2). This is generated by a protein complex called the cohesin 
complex (Winters et al., 2014). The meiotic cohesin complex differs from the mitotic cohesin 
complex majorly in the proteins involved in the processes respectively. In budding yeast, the 
difference lies in the existence of meiosis specific Rec8 instead of Scc1 (Klein et al., 1999). 
In addition, in mammals, the meiosis-specific variant Smc1β replaces Smc1 in some 
complexes (Revenkova et al., 2001). Scc1 is also replaced by the meiosis-specific Rec8, and 
the Scc3 orthologues, SA1 and SA2, are replaced by the meiosis-specific variant STAG3 
(Prieto et al., 2001). In Caenorhabditis elegans, depletion of the Rec8 orthologue causes 
separation of the two sister chromatids in the first meiotic prophase indicating Rec8 is 
centrally important for sister chromatid cohesion (Spike et al., 2014). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Synaptonemal complex illustrating central (CE) and lateral (LE) elements connected 
by transverse filaments (Hamer et al., 2008). 
 
In fission yeast, the deletion of the Rec8 gene leads to cohesin loss (Watanabe and Nurse, 
1999). Moreover, in Saccharomyces cerevisiae, the deletion of Rec8 gene again causes the 
loss of cohesin between the two sister chromatids leading to aneuploid gametes formation 
(Klein et al., 1999). When the programme of genetic recombination and/or synapsis fails, 
chromosome mis-segregation occurs which can result in aneuploidy in the meiotic daughter 
cells; this in turn can result in genetic diseases, such as Down syndrome, stillbirths and 
infertility in humans (Fledel-Alon, 2009). In MII, sister chromatids are segregated into four 
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haploid nuclei via a segregation event similar to mitotic sister chromatid separation (Uroz and 
Templado, 2012). 
  
 
 
 
 
Figure 1.2 Meiotic recombination mechanism show creation of cohesin between sister 
chromatids and pairing between homologous maternal and paternal chromosomes generates 
chiasmata (Longhese et al., 2009) 
 
Initiation and repair of meiotic DSBs 
In humans, it is estimated that ten spontaneous DSBs take place within the cell in every cell 
cycle, mainly during DNA replication. This damage is caused by either endogenous agents 
such as free radicals or exogenous agent such as ionizing radiation (Van Gent et al., 2001). 
However, in meiosis, meiotic DSBs are initiated by the meiotic-specific protein Spo11 that is 
encoded by a gene that is conserved from yeast to mammals (Keeney, 2001).  
 
In budding yeast DSB location is influenced by promoter regions, which are enriched with 
GC content (Baudat and Nicolas, 1997; Keeney, 2001). DSBs are initiated by meiotic 
recombination protein Rec12 in Schizosaccharomyces pombe, and Mei-W68 in Drosophila, 
the respective orthologues of Spo11 (McKim and Hayashi-Hagihara, 1998). DNA DSBs are 
generated by a Spo11 homodimer (Keeney, 2008); upon break formation, one Spo11 subunit 
remains attached to each side of the break by generating a phosphodiester link between its 
catalytic tyrosine residue and the newly created DNA 5' ends (Keeney, 2001). Spo11 is 
removed from the DNA strand and then the 5'ends are resected by exonucleases, forming a 
single stranded 3' overhang either side of the DSB. Thus, one 3' overhang strand invades a 
homologous non-sister, which is vital for generating chiasmata (Hunter and Kleckner, 2001) 
(Figure 1.3). 
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Figure 1.3 Mechanism of DSB repair in meiotic recombination shows how Spo11 initiates DSBs 
in DNA duplex. After Spo11 removal, DSB ends are resected to generate 3'ended ssDNA tails. 
One 3' ended ssDNA tail invades the duplex homologous DNA sequence (red lines). Capture of 
the second ssDNA end and DNA synthesis create a double Holliday junction (dHJ), whose 
resolution can occur in either plane at both junctions (triangles) to generate crossover or non-
crossover products. Red arrows indicate the 3' ends of the newly synthesized strands (Longhese 
et al., 2009) 
 
Spo11 null mutants in yeast do not generate DSBs and as a result block recombination 
initiation and synapsis leading to the formation of aneuploid spores (Klapholz et al., 1985). 
Mouse Spo11 null mutants cause cell arrest and create infertile, mutant spermatocytes that 
show many meiotic pairing, synapsis and recombination defects (Romanienko and Camerini-
Otero, 2000). Furthermore, mammalian SPO11-/- spermatocytes and oocytes undergo high 
level of apoptosis (Scott and Pandita, 2006). These mutant models consistently prove that 
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Spo11 play an important role in the initiation of the DSBs in meiotic homologous 
recombination. However, in S. cerevisiae, Spo11 alone is not sufficient to cause DSB 
formation and requires at least nine additional proteins to create DSBs, including Mei4, 
Mer2, Rec102, Rec104, Rec114, Ski8, Mre11, Rad50 and Xrs2 (Borde, 2007). 
 
Whilst homologous recombination is important in the creation of genetic variation and 
diversity, it is also a potential hazard for genome stability because chromosomal breaks need 
to be faithfully repaired. Inaccurate repair or failure to repair may force the cell to undergo 
apoptosis or drive tumourgenesis. In humans, there are some genetic diseases characterised 
by an insufficient response to repair the DSB which commonly share typical characteristics 
such as development and immunodeficiency and cancer predisposition (Scott and Pandita, 
2006; Segurel, 2013). 
 
An early response for the DNA DSBs is the Mre11–Rad50–Nbs1 (MRN) complex which is 
composed of Mre11 (Rad32 in S.pombe), Rad50 which is a member of the Rad52 epistasis 
group and Nbs1 (Xrs2 in S. cerevisiae). It is a highly conserved complex, which plays an 
important role in both homologous recombination (HR) in meiotic cells and mitotic DNA 
damage repair (Lamarche et al., 2010). 
 
1.3 Cancer Testis (CT) antigens  
1.3.1 Overview 
Extensive research has been carried out to investigate the possible use of tumour antigens as 
targets in cancer immunotherapy and cancer vaccination (Sharpeand Mount, 2015; Adelmann 
et al., 2008). The main requirement for tumour antigens to be considered as potential targets 
for immunotherapy is to have restricted or limited expression in normal tissues.  Some 
antigens are found to fulfill this requirement, such as viral antigens [e.g., human papilloma 
virus (HPV) antigens in cervical cancer], and differentiation antigens (e.g., CD20 in B-cell 
lymphoma (Tay, 2012). 
In the last decade, an emerging category of antigens known as cancer testis (CT) antigens 
have been uniquely defined as a group of potential antigen targets for cancer immunotherapy 
due to their presence in normal testicular cells and in some types of human malignancies, 
including breast cancer, ovarian cancer, and lung cancer. These Antigens are a group of 
protein antigens transcribed by testis-specific genes and characterized by their restricted 
expressed in gametogenic tissue, but abnormally activated and expressed in some types of 
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human neoplastic tissues (Caballero and Chen, 2009). Number of studies suggest that CT 
antigens could potentially be employed in cancer specific immunotherapy and novel 
biomarker tools for cancer diagnosis and prognosis (Kulkarni, et al., 2012). Some CT genes 
are meiosis-specific genes, which have a role in meiotic cell division, including SPO11 gene, 
Synaptonemal Complex genes such as SYCP1 and SYCP2 which both contribute and 
facilitate sister chromatids pairing and meiotic chromosomal recombination. However, their 
aberrant expression in some types of cancer is currently poorly understood (Handel and 
Schimenti, 2010). Their confined expression in normal somatic cells and aberrant occurrence 
in some types of cancerous tissues makes them interesting candidates as CTA genes 
(Koslowski et al., 2002) and (Tureci et al., 1998). 
The first CT antigen was identified by van der Bruggen’s group in 1991 who used the 
melanoma cell line MZ2-MEL and autologous CTL clones cytolytic to this line. The tumour 
antigen discovered by host cytotoxic T-lymphocytes (CTL) resulted in the molecular cloning 
of MAGE-1 (Kawakami et al., 1994). Further research which followed by several groups 
identified more CT antigen family members including MAGE-A3, MAGE and GAGE (Van 
der Bruggen et al., 1991). 
1.3.2 Identification of CTAs 
Several approaches have been used to identify and characterized CT antigens, one of these 
approaches is T-cell epitope cloning by cloning epitopes recognized by cytotoxic T-
lymphocytes. This method was helpful in discovering multiple CT antigens including the first 
CT antigen MAGE-1 (Van der Bruggen et al., 1991; Boon et al., 1994). Another approach 
used to identify new CT antigens is the serological analysis of recombinant cDNA expression 
library, termed as SEREX. This is carried out by immunological screening of tumour cDNA 
expression library from the sera from autologous patients. This method identified many CT 
antigens including SSX-2 (Gure et al., 1997), SCP-1 (Tureci et al., 1998) and NY-ESO-1 
(Chen et al., 1997). Furthermore, another powerful tool used in detection of new CT antigens 
is differential gene expression analysis. This method identified CT antigens based on their 
mRNA expression profile by comparing the mRNA expression profile of tumours versus 
normal tissues, or comparing the mRNA expression profile between testicular and other non-
germ tissue. Using this approach, many new CTA genes have been identified such as MAGE-
C1CT7 (Lucas et al., 1998), PAGE-1 (Chen et al., 1998), LAGE-1 (Lethe et al., 1998). 
Recently testis expressed meiosis specific gene TEX19 was identified as potential CTA gene 
(Feichtinger et al., 2012) by this method. 
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Finally, bioinformatics using numerous public gene expression data such as serial analysis of 
gene expression (SAGE) and expression sequence tag (ESTs) can be used for detecting many 
new CTA genes. New CTA genes identified by applying this approach included PAGE-4 
(Brinkmann et al., 1998) and CT9 (Scanlan et al., 2000). In addition, using millions of short 
sequence tags of different RNA preparation are compared between the normal testicular 
tissue and variety of tumours to the massively parallel signature sequencing data (MPSS). 
Using this approach the CTA CT45 was found repeatedly in lung cancers (Chen et al., 2005). 
Recently, several CTA candidate genes were identified using this application tool 
(Feichtinger et al., 2012). 
Recent research was able to identify and characterize CTAs present in the non-small-cell lung 
cancer. The RNAseq data from around 1999 NSCLC tissues was collected and compared 
with normal transcriptional information from 142 samples, from a variety of 32 samples of 
the normal, non-cancerous organs (Djureinovic et al., 2016). Of all the CTAs identified, 232 
were already confirmed agents and present in the Cancer Testis Database and 96 new CTAs 
were identified as potential biomarkers, even after strict conditions were applied on the 
RNAseq data. Of these identified agents, 55 genes were not annotated in the database and 
directly represented the newly identified CTA agents, including, TKTL-1, TGIF2LX, VCX 
and CXORF67. Moreover, another important finding of this research study was methylation 
as the regulatory mechanism controlling the expression of the cancer testis antigens.    
1.3.3 Classification and expression of CTAs 
CT genes are characterized by their X chromosome localisation. generally, most of the well-
characterized CT antigens, such as MAGE-1, NY-ESO-1, CT7/MAGE-C1, CT10 and SAGE, 
are encoded by multigene family located on the chromosome X between Xq24 to Xq28. 
Moreover, some CT antigens genes are located in the centromeric position of the X 
chromosome, Xp11.2-11.4, such as SSX and GAGE (Caballero and Chen, 2009). Moreover, 
most of the CT genes located on chromosome X are encoding approximately 10% of the 
protein (Ross et al., 2005). This noticeable clustering of CTA genes on the X chromosome 
lead to the classification of the CT antigen into two categories according to their location, 
they are termed as CT-X and non-X CTA genes (Simpson et al., 2005). One characteristic of 
CT-X genes includes the fact that they are mainly multi-copy paralogues which are formed 
due to gene duplications. However, most of the non-X CTA genes are genes with a single 
copy and show no chromosomal clustering as in CT-X genes. Thus, these differences support 
the CT-X antigens as a target in the promising cancer immunotherapy (Mueller et al., 2008). 
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The expression pattern of CTA genes is restricted to the germ cell tissue, where they are 
negative in the other testicular tubular cells such as Leydig and Sertoli cells. This explains the 
high expression of CTA genes in the seminomas germ cell cancer compared to the non-
seminomas (Yuasa et al., 2001).  In contrast, some other CTA genes including NY-ESO1 and 
MAGE show low level of expression in normal non-germ cell tissue such as placenta 
(Jungbluth et al., 2001). 
Furthermore, recent studies suggest the useful correlation between the level of expression of 
CTA and prognosis (Rousseaux et al., 2013). In a research study which was conducted on 89 
patients with Intra-hepatic Cholagio-carcinoma (IHCC), high expression levels of CTA genes 
MAGEA3/A4 were correlated with large tumour size, of more than 5cm (Zhou et al., 2011).       
1.3.4 Function of CT genes 
The functional role of CT-X genes in normal testicular tissue and their aberrant expression in 
some tumours is still poorly understood. Some proteins identified as CT antigens play a vital 
role in meiosis such as SYCE which is part of the LE and CE of the SC, and HORMAD1⁄ 
CT46 (Hamer et al., 2006). However, HORMAD1 expression have been observed in human 
epithelial ovarian carcinoma (Shahzad, et al., 2013).  During meiotic recombination, some 
CTA genes functions are described, such as the CTA SYCP-1 is part of SC and forms a 
transverse filament that plays an important role in chromosomal synapsis in meiosis (Tureci 
et al., 1998). In addition, the induction of DSB in meiosis is carried out by the endonuclease 
activity of the conserved meiotic-specific protein Spo11 where has been reported to be a CT 
antigen (Romanienko and Camerini-Otero, 1999).   
  
In cancer, recent studies demonstrate the potential role of CTA genes in human tumorigenesis 
such as the over expression of MAGE-A4 in human embryonic kidney cells which influences 
the activation of apoptosis. But, it shows a different effect in squamous lung cancer through 
inhibition of Caspase-3 activity (Peikert et al., 2006). Also, CTA MAGE-A11 plays a role in 
maintaining the function of the nuclear androgen receptors (Bai et al., 2005). MAGE-A2 
plays an important role in down-regulating the activation function of P53, which is a tumor 
suppression protein (Monte et al., 2006). Similarly, the CT antigen GAGE-7 show anti-
apoptotic activity and prevent the cells to undertake apoptosis by the influence of IFN-γ or 
Fas (Cilensek et al., 2002). These anti-apoptotic activities that drive the cells to resist the 
clinically induced apoptosis agents lead to correlate between the expression of GAGE and 
poor prognosis. Moreover, recent clinical and research studies suggest that CT antigens are 
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potential target for cancer immunotherapy and vaccination. This study revealed through a 
clinical treatment of recurrent melanoma patient showed that the development of CD4+ T-
cells were specific to the tumor-associated antigen melanoma-associated antigen NY-ESO-1, 
leading to tumor regression and the patient start to produce its own T cells against the tumor 
antigens. This study support further medical and clinical application approaches for antigen-
specific CD4+ T cells in the treatment of some malignancies (Hunder et al., 2008). 
Furthermore, in one of the recent research studies, photodynamic therapy (PDT) was used to 
measure its efficacy against the expression of cancer/testis antigens in squamous cell 
carcinoma, normally present in the head or the neck (Theodoraki et al., 2016).  PDT 
represents a form of palliative treatment technique against cancer and it induces inflammatory 
responses which are the basis of antitumor immunity. Even though they have proved to 
markers for tumurs in the body, however, CTA are still responsible for poor prediction of 
multiple cancer types, for example, head and neck squamous cell carcinoma. This study 
analyzed the samples of tumor tissue before and after the treatment by PDT, using four 
distinct CTAs for measuring the effects on their expression patterns. It was observed that the 
expression levels for MAGEs decreased, whereas, NY-ESO-1 increased slightly due to 
epigenetic regulation of CTA expression or immunological pressure (Theodoraki et al., 
2016). 
Moreover, the role of CTA genes is still under a great amount of investigation and new 
researches are helping in the assessment of how they might be able to help in the control and 
treatment of cancer. Nettersheim and colleagues were able to prove in their recent study that 
the CTA agent, PRAME, supports the pluripotency network and it also plays an essential role 
in the repression of somatic and germ cell differentiation programs in seminomas 
(Nettersheim et al., 2016). To reinforce, CTAs play an important function of acting as 
regulators of gene expression, cell cycle and spermatogenesis. Therefore, they are popular 
targets for immune-based therapies. CTA PRAME is specifically produced in various cancers 
where it antagonizes retinoic acid signaling and is specifically regulated by the DNA 
methylation and histone acetylation processes. It is the master regulator of PGCs SOX17.The 
molecular function of the gene was analyzed in the PGC (primordial germ cells) and the 
testicular GCC (germ cell cancers). In this study, the own regulation of PRAME in 
seminomatous TCam-2 cells had no influence on the levels of SOX17 levels, however, 
resulted in the down regulation of LIN28, PRD14 and ZSCAN10. The somatic and germ cell 
differentiation markers were observed to be upregulated. Therefore, PRAME acts 
downstream SOX17 and regulates the germ cell differentiation and pluripotency chemical 
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pathways. The interesting finding of the study was also that PRAME in these cell lines did 
not make them susceptible to retinoic acid where it has been already established to antagonize 
retinoic acid signaling.  
 
1.4 Cancer immunotherapy 
1.4.1 Overview 
The introduction of the cancer immuno-surveillance hypothesis by Frank MacFarlane Burnet 
and Lewis Thomas in 1957, raised hope for cancer immunology (Burnet, 1957). Later in 
1990s, some studies promoted the concept of immune-surveillance through new 
technological application such as monoclonal antibodies and mouse genetics (Dunn et al. 
2002; Dunn et al. 2004a). Some studies showed different aspects of the tumor escaping 
capabilities from immune system, and sometimes the involvement of the immune system in 
immunogenicity and cancer occurrence (Shankaran et al., 2001). 
Consequently, the whole picture of cancer immunology focused on the cancer immune-
editing theory that concludes that three consecutive phases of elimination, equilibrium and 
escape determine the efficacy of cancer immunotherapy (Dunn et al. 2004a). The first phase 
of elimination represents the hypothesis of cancer immune-surveillance and after the 
successful inactivation of the immune mediation in the tumor, it resembles the equilibrium 
phase. Eventually, they are followed by the escape phase, which features the expansion of the 
tumor and breaks the immunological restrain during the equilibrium phase (Figure 1.4) (Dunn 
et al. 2004b). 
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Figure 1.4 The Cancer Immuno-editing three phases including elimination, equilibrium and 
escape. The normal cells in (gray) under the process of transformation to become tumor cells 
(red).the initiation of cancer immune-editing (bottom). In the first phase of elimination, cellular 
and immunological interaction represent the cancer immune-surveillance. Later, transformed 
cells may enter the equilibrium phase. Later the escape phase feature the immune evasion (Dunn 
et al. 2004b). 
The evolution of anti-cancer monoclonal antibody engineering and bone marrow 
transplantation shows positive results in the treatment of some types of cancers including 
hematologic and solid malignancies (Dougan and Dranoff , 2009). In these instances, the 
donating cells and antibodies play a passive immune role to induce endogenous immune 
reaction against the malignant cells (Dougan and Dranoff , 2009). Thus, several anti-cancer 
monoclonal antibodies were engineered and approved to target some proteins associated with 
hematological and solid cancer including Anti- EGFR, Her-2/neu, CD20, CD33 CD52 and 
VEGF (Mellman et al., 2011). 
Several research groups have been suggesting the use of cancer antigens as potential targets 
in cancer immunotherapy by generating an immune response through cytotoxic T-cell 
lymphocyte (CTL) which is specifically directed against the tumour cells. This is achieved by 
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presenting antigenic protein fragment on the surface of the tumour cells by human leukocytes 
antigens (HLA) class II, present on the surface of antigen presenting cells (APCs) that 
mediate the immune-response. Thus, identification of these epitopes by the immune system is 
crucial for the production of tumour specific vaccine (Dalerba et al., 1998) 
Since the main objective of the cancer immunotherapy is to suppress the environment which 
allow for the growth of the tumours and thereby use it to produce anti-tumour specific-
immune responses. However, due to the complexity of the immune-inhibitory mechanism of 
tumours in humans, anti-tumour specific vaccines are unable to produce positive results in 
abundance (Berrong, 2016). Therefore, a revision of the research techniques now focuses on 
the increased therapeutic efficacy of tumour vaccination. This is done by combing different 
immunological approaches that target multiple immunosuppressive pathways and hence 
enhance the efficacy of the vaccines by T cell agonists. For example, OX0 is a co-stimulatory 
receptor which is expressed on the surface of the T cells and plays an important role in the 
proliferation and enhancement of the T cell effector function in presence of its ligand. It can 
also be induced to carry out its function when targeted with agonist antibody.  
All in all, in cancer treatment, tumour antigens have been employed as a potential approach 
for cancer immunotherapy. CTAs are a potential target for cancer immunotherapy due to their 
restricted or limited expression in normal tissues and hence they are only confined in the 
germ cell tissues. Thus, because of the nature of the testis blood barrier, the germ cell tissues 
show no expression of HLA Class I molecule thereby making the CT antigens potential 
targets for cancer immunotherapy (Bart et al., 2002). 
1.4.2 Ipilimumab and melanoma 
Several developments in the field of cancer immunotherapy emerged in the last few years 
such as the recent trials data of the Ipilimumab Phase III that was used in the late stage 
metastatic melanoma cases. Due to its activating mechanism towards T cells in order to 
initiate endogenous response of T cells against malignant melanoma cells, the survival rate of 
the metastatic melanoma patients was greatly enhanced (Mellman et al., 2011; Delyon et al., 
2015). 
Ipilimumab is a monoclonal antibody against CTLA4 (cytotoxic T-lymphocyte-associated 
protein 4), which plays an important role in T cell regulation and function. CTLA4 is member 
of the immunoglobulin family and is normally expressed on the surface of the T helper 
cells and play a negative inhibitory role towards the T cells (Chambers et al., 2001) (Figure 
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5). The ligation of CTLA4 consequently inhibits the immune response against the malignant 
cells. Furthermore, CTLA4 reflects its important role in controlling T cell function which was 
successfully described in studies involving the knockout mice CTLA4-/-. These changes 
caused mortality in young age due to aggressive lymphoproliferative disorder (Waterhouse et 
al., 1995). The implementation of Ipilimumab monoclonal antibody to melanoma patient 
block the negative regulatory effect of CTLA4 and activate the immune response against the 
malignant cells in melanoma patients (Mellman et al., 2011). 
 
 
Figure 1.5 the biological role of CTLA4 and Ipilimumab (Mellman et al., 2011). 
In contrast, many chemotherapeutic cytotoxic agents initiate a direct response against 
malignant cells leading to cancer shrinkage and death. The activation of T cells by 
Ipilimumab in order to kill malignant cells may take several months to show results. 
Meanwhile, cancerous melanoma cells may keep growing in size and expand, which is an 
important challenge to treat melanoma with monoclonal antibody Ipilimumab (Hodi et al., 
2010; Sharma and Allison, 2015). 
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As most cancer therapeutic agents are toxic, Ipilimumab show relatively low toxicity in few 
patients due to the inflammation that could be the autoimmune response such as colitis and 
hypophysitis, occurring in 23% of all patients treated by Ipilimumab (Mellman et al., 2011). 
Moreover, 20% of the patients treated with Ipilimumab in conjugation with dacarbazine, 
showed significant raises of the liver function tests (LFT). These inflammatory effects may 
occur due to the blockage of CTLA4 as we mentioned previously in the research study 
conducted on mice (Mellman et al., 2011; Sharma and Allison, 2015). 
Regardless of these challenges and limitations, Ipilimumab is a reliable treatment that 
provides hope for many melanoma patients, especially in the later stages of the disease. Also, 
Ipilimumab and its activity against CTLA4 has opened doors towards further research that 
can help in finding new antibodies for activation of T cell response against malignant cells 
(Mellman et al., 2011; Sharma and Allison, 2015). 
1.5 Transposable genetic elements 
1.5.1 Overview 
Transposable genetic elements or transposons (TEs) are non-coding DNA sequences that are 
mobilized and move their positions within the human genome through RNA copy and paste 
mechanism. The prevalence of TEs vary between plants, animals, and human. In mammalian 
genome, TEs fragments represent up to 50% of the entire genome sequence. However, in 
some plants, they represent up to 90% of the genome as well (SanMiguel et al., 1996). In 
eukaryotes, TEs cause genomic instability due to their mobility and this may lead to genetic 
mutation or disruption of several protein products if they transpose between their gene 
sequences (Ayarpadikannan, and Kim, 2014).  
Previously, the mobile genetic elements were considered as ‘junk DNA’. Nevertheless, after 
the discovery of TEs by Barbara McClintock (1950) for the first time, the importance of these 
elements has increasingly been recognized. TEs modify both gene structure and expression 
(McClintock, 1950). By the process of mobilization, transposons promote ectopic 
rearrangement, reshuffle sequences and create novel genes. Unlike common belief, it is very 
rare that TE insertions result in conditions leading to a genetic disease (Beck et al., 2011).  
1.5.2 Classification of TEs 
There are two main classes of TEs, DNA transposons and Retrotransposons. DNA 
transposons, are inactive in the human genome now, but were mobilize within the genome by 
changing its location to new site tens of millions years ago (Craig et al., 2002; Pace and 
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Feschotte, 2007). On the other hand, Retrotransposons are the active type of TEs that undergo 
replication by forming RNA intermediates through reverse-transcription, generating DNA 
sequences that mobilize and insert sequences into new genomic locations accordingly (Pace 
and Feschotte, 2007). Retroelements are sub-categorized into two classes based on the 
existence of long terminal repeats as LTR transposons and non-LTR transposons (Figure 1.6). 
In human genome, LTR transposons are referred to as human endogenous retroviruses 
(HERVs) and they have been estimated to have been inserted into the human genome more 
than 25 million years ago (Lander et al., 2001).  The second group of non-LTR 
retrotransposons represent the active form within the genome and include LINE-1, Alu, and 
SVA elements (Belancio et al., 2008). 
 
Figure 1.6 The structural classification of transposable genetic elements. DRs, direct repeats; 
ITRs, inverted terminal repeats; TSD, tandem site duplication; LTRs, long terminal repeats; 
UTRs, untranslated region; ORF, open reading frame; L, left; R, right; SINE, short interspersed 
nuclear element (Ayarpadikannan, and Kim, 2014). 
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1.5.3 Retrotransposons in cancer 
There are many tumor antigens including those which are presented to human cytotoxic T 
lymphocytes (CTL) by human leukocyte antigen (HLA) class I molecules have emerged as 
safe immunotherapy targets, due to their absence in normal tissues. Amongst such tumor 
specific antigens an important category is that of CTA genes which include BAGE, CAGE, 
GAGE, HAGE, LAGE, MAGE, PAGE, NY-ESO-1, SCP and SSX gene families (Simpson et 
al., 2005). Expression of these genes has been found in many types of tumours except for 
adult tissues including spermatogonia. The normal adult cells are devoid of HLA molecules 
and thus are unable to present the antigens to T cells. Although these antigens are generally 
expressed in many types of human tumours, but a few CTA genes have also been found to be 
expressed in different hematological malignancies related to blood cells (Roman-Gomez et 
al., 2007). Expression of CTA in cancer cells involves a unique mechanism through 
epigenetic regulations. Amongst these epigenetic events, DNA methylation has been found to 
have a crucial role in gene expression and correlating with hypomethylated CpG 
dinucleotides in CTA promoters. Moreover, the expression of CTA antigens has been evident 
in neoplastic tissues and cell lines (Cho et al., 2003; Grunau et al., 2005; Lim et al., 2005; 
Wang et al., 2006). Therefore, it is evident that the CTA genes expressed in different tumor 
conditions can be induced by DNA demethylation or by inhibiting deacetylation of histone 
documented for cutaneous melanoma (Sigalotti et al., 2004). It has also been documented that 
in case of chronic myeloid leukemia (CML), the promotor hypomethylation of CTA genes 
results in activation of the LINE1 retrotransposon and disease progression from the nascent to 
the advanced phase (Roman-Gomez et al., 2007).  
1.6 Stem Cells 
1.6.1 Background  
Stem cells are undifferentiated cells that have the capability to differentiate into different 
types of specialised cells. These cells are present in embryos and in adult tissues and are 
therefore named as embryonic and adult (or somatic) stem cells respectively.  
Embryonic stem cells (ESCs) are derived from inner blastocyst cell mass of the gastrula 
containing totipotent cells (Donovan and Gearhart, 2001). If we separate these ESCs from the 
developing embryo/blastocyst, followed by inducing the arrest for further embryonic 
development, the majority of ESCs of this mass can be maintained in an undifferentiated 
state. However, evidence still exists where some of these ESCs still undergo early embryonic 
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development, differentiating into different cell lineages forming embryoid bodies 
(Donovan and Gearhart, 2001; Surani, 2001). Thus ESCs are a potential source of the cells 
possessing a capability for diverse differentiation and self-renewal. In fact, these cells are 
“uncommitted” progenitors of three embryonic germ layers; ectoderm, mesoderm and 
endoderm. Therefore, they possess the ability to develop into any type of somatic or germ 
line cells (Donovan and Gearhart, 2001; Lovell-Badge, 2001; Spradling et al., 2001; Surani, 
2001; Fonseca et al., 2015). 
Furthermore, adult stem cells can be derived from different organs throughout the body in 
animals and humans. They also possess the capability to differentiate into specific types of 
cells they were originally derived from and therefore have the potential to regenerate the 
complete organ. They can be potentially used in different medical therapies, such as in bone 
marrow transplantation. Currently the research on stem cells involves their artificial growth 
and differentiation or transformation into specific types of cells such as nerves, muscles etc. 
(Mariano et al., 2015). Moreover, ESCs and autologous ESCs (developed by transfer of 
somatic cell nucleus) have been recognized as the potential candidates for future therapies, in 
part due to their associated biomarkers (Tuch, 2006).   
1.6.2 Stem Cells Markers 
Recently, a number of different types of molecular and surface markers have been reported as 
important characteristic feature of undifferentiated ESCs, particularly in humans (Zhao et al., 
2012). The cell fate decision functions have also been described to be performed by different 
proteins involved in signaling pathways (Zhao et al., 2012). Amongst these proteins, lectins 
are most prominent along with other similar proteins and peptides which can specifically bind 
to ESCs, thereby, helping in the identification of the markers. However, there are common 
markers expressed both in ESC and tumour stem cells, making the distinction between the teo 
type difficult and complicated. Therefore, identification of more specific and unique markers 
is necessary the isolation of ESCs.  
 
Moreover, explaining the underlying mechanisms regulating the pluripotency of human ESCs 
(hESCs) remains a challenge for the scientific community. ESCs in humans differ from 
mouse ESCs in many aspects including cellular morphology, growth factor signaling and 
chromosome X’s epigenetic state (Prowse et al., 2007; Fonseca et al., 2015). Therefore, 
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specific studies on human ESCs for their mechanisms of pluripotency and self-renewal 
potential are necessary despite the amenability of mouse ESCs.  
 
Moving on, stem cell markers belong to different types of functional proteins/molecules 
including surface antigens (such as SSEA-1, SSEA-3, and SSEA-4, CD9, CD24, and CD133, 
TRA-1-60 and TRA-1-81), transcription factors (including Oct4, c-Myc, Sox2, and Klf4) 
(Brimble et al., 2007), signal pathway related intracellular markers (examples are; LIF-
STAT3, BMP-SMAD, TGF- β /Activin/Nodal, IGF-IR, FGFR and Wnt-β-catenin) (Hao et 
al., 2011), enzymatic markers (ESCs express high levels of alkaline phosphatase and 
telomerase) and some other markers (lectins and short peptides) belonging to different 
categories (Huang et al., 2014). These markers are present on ESCs, CSCs and other adult 
stem like cells and are therefore potential molecules for their identification. They can also 
serve to be potential therapeutic targets for diagnosis of the disease implicated by those 
specific cells.   
1.6.3 Stem Cells Differentiation Therapy 
Stem cell differentiation therapy has been associated with the establishment of human 
embryonic germ (EG) cells and embryonic stem cells (Shamblott et al., 1998; Thomson et al., 
1998), resulting in the development of a major area of research in medicine for studying the 
potential of pluripotency of different cells including ESCs. Due to pluripotency and self-
renewal characteristics of ESCs, these cells have become promising tools in cell replacement 
therapy. The basic scheme of these therapeutic treatments includes in vitro production of 
particular types of cells followed by transplantation into the patient with a functional 
disorder. These transplanted cells can restore the normal functions of these cells in case of 
diseases including Parkinson disease, Huntington disease, and heart failure. Although the 
efficacy of these diseases seems to be all-so-gold, however, the above-mentioned strategies 
face the challenge of tissue rejection in cases of organ transplants. A possible solution of this 
problem is producing the tissue from autologous ES cells or ES-like cells, which results in the 
growth of patient-histo-compatible tissue (Ramesh et al., 2009) and hence stands a chance 
against the immune system of the human body. Production of such histo-compatible tissues 
can be carried out by one of the three methods for reprogramming of differentiated cells; 
transfer of the nucleus of differentiated cell to enucleated oocyte exploiting their 
reprogramming capabilities, fusing the pluripotent cells with somatic/adult cells and 
reprogramming the fibroblasts by transfecting four transcription factors including Oct4, c-
Myc, Sox2, and Klf4 (Takahashi and Yamanaka, 2006; Maherali et al., 2007; Okita et al., 
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2007; Henzler,  et al., 2013; Wernig et al., 2007; Ramesh et al., 2009). Differentiation of the 
reprogrammed cells can be initiated by any of the above described mechanisms, but these 
differentiation events of reprogrammed cells are initiated through a regulatory cascade of 
reactions involving a stimulus/trigger of a specific cascade by different stimulating agents 
including certain chemicals such as retinoic acid (RA) and hexamethylene bisacetamide 
(HMBA) (Andrews et al., 1990).   
 
1.7 Aims and objectives 
CTA genes and their products may possibly be a target for cancer diagnosis, prognosis and 
immunotherapy due to their restricted expression in germ cells and some types of cancer. In 
addition, CTAs may be involved in oncogenesis. In this study, all these techniques with 
possible regenerative potential against cancer will be assessed and their efficacies will be 
quantified using different molecular assays. We aim: 
1. To identify novel CT genes by RT-PCR validation of an in-silico pipeline. 
2. To study the stem-like role of TEX19:  
• By knockdown TEX19 in NTERA2 cancer cell line and quantifying stem cell marker 
genes expression profile.  
• Differentiate NTERA2 cells using HMBA and RA, and observe the proteins of stem 
cell markers including Oct4, Sox2 and Nanog by western blot. 
3. Evaluate the influence of TEX19 on TE in NTERA2 and A2780 cells 
• Knockdown TEX19 in A2780 and NTERA2 cancer cell-lines, and validate the 
expression using qRT-PCR. 
4. To investigate the effect of TEX19 on differential gene expression in cancer. 
• By TEX19 knockdown in A2780, SW480, NTERA2 and H460 cancer cell-lines. 
Then, based on RNA sequencing data, quantifying the expression of 20 dysregulated 
genes by qRT-PCR. 
5. To detect Spo11-DNA covalent bounding in SW480 cells by DSB assay. 
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2. Material and methods 
2.1 Human cancer cell-lines source 
Most of cancer cell-lines were acquired from the European Collection of Cell Cultures 
(ECACC) including 1321N1, COLO800, COLO857, G-361, SW480, HCT116, HT29, LoVo, 
MCF7, MM127, and T84 cell lines. Professor P.W. Andrews (Sheffield University) kindly 
provided the testicular carcinoma NTERA-2 cell-line. Professor P. Workman of Cancer 
Research UK, Surrey UK generously gifted the A2780 ovarian carcinoma cell-line. The lung 
cancer cell-line H460 and the breast cancer cell-line MDA-MB-453 were obtained from the 
American Type Culture Collection (ATCC). The ovarian carcinoma cell-lines PE014 and 
T014 were obtained from Cancer Research Technology Ltd. All cell-line checked upon 
received and regularly for contamination including mycoplasma.  
2.2 Storage of cancer cell-lines 
Cells were culture in T75 tissue culture flasks, the confluent cells were washed twice using 
1x PBS (Phosphate buffer saline) and then trypsinised with 1x trypsin – EDTA (Invitrogen, 
GIBCO 1370163). The number of cells were counted using a haemocytometer slide. Cells 
were centrifuged at 100 x g for 5 minutes. The pellet of cells was suspended in a freezing 
media, which contain a 1 to 9 ratio of DMSO (Dimethyl sulfoxide) and FBS (foetal bovine 
serum) (Invitrogen; GIBCO 10270). The cells were transferred to the sterile, labelled 
cryotube with the required information (such as the identity of cell-line, number of cells). 
Initially the cryotube was stored at -80°C for 24 hours. Then cells were transferred into a 
liquid nitrogen cell bank. For any recently received cancer cell-lines a series of 
morphological and microbial check such as mycoplasma test taken before banking. 
2.3 Thawing of frozen cell-line storage 
Before removing any banked cells, updating the data sheet of tissue culture needed by 
removing the number and identity of cell-line going to used. The cryotube was obtained from 
liquid nitrogen and immediately placed into a 37°C water bath until defrosted. Then 
transferred into 5 ml of suitable warm media and mix gently. Cells were then centrifuged for 
5 minutes at 100 x g. After aspiration of the media, 10 ml of the required media was added 
and the cell suspension was split into two T25 flasks and incubated overnight according to 
CO2 requirement. Growing and maintaining the cancer cell-line was undertaken according to 
the supplier’s protocols. 
33 
 
2.4.1 Western blot 
2.4.2 Whole cell protein extraction 
After harvesting the cells and washing using PBS, the cells were added to the media and cell 
counted using a haemocytometer to standardised the number of cells used for each well 
during the running of western blot; approximately 65,000 cells applied per well were needed. 
Whole cell protein lysates were obtained from the cell lines using the  lysis buffer (50 mM 
Tris HCl pH 7.4, 200 mM NaCl, 0.5% Triton X-100, 1 mM AEBSF [4-(2-aminoethyl) 
benzenesulfonyl fluoride] (Sigma-Aldrich; A8456) with complete, mini, EDTA-free protease 
inhibitor cocktail (Roche Applied Science; 11836170001)) and an equal volume of 2x 
Laemmli buffer (Sigma-Aldrich; S3401). The protein lysate was then boiled at 100˚C until 
the cell pellet dissolved, with vortexing. 
2.4.3 Nuclear and cytoplasmic protein extraction 
Two fractions of protein were prepared, the cytoplasmic fraction was extracted by re-
suspending the cells in hypotonic buffer (50 mM Tris-HCl pH 7.4, 0.1 M sucrose, 1 mM 
AEBSF, Roche complete protease inhibitor) and an equal volume of lysis buffer C (1% 
Triton-X-100, 10 mM MgCl, 1 mM AEBSF, Roche complete protease inhibitor cocktail).  
Cells were incubated on ice for 30 minutes and centrifuged at 6,000 g for 2 minutes.  The 
supernatant were transferred to a clean Eppendorf tube and an equal volume of Laemmli 
buffer was added. 
Then, the nuclear fraction were obtained re-suspended the pellet in the lysis buffer N (50 mM 
Tris-HCl pH 7.4, 100 mM KAc, 1 mM AEBSF, Roche complete protease inhibitor cocktail) 
and an equal volume of Laemmli buffer was added. 
2.4.4 Western blotting protocol 
Protein samples were loaded in pre-cast NuPAGE® 4-12% Bis-Tris gel (Invitrogen; NP0322) 
together with protein marker Precision Plus Protein Dual Color Standards (Bio-Rad; 161-
0374). The gel was run for 1.45 hours at 120 Volt using (1x) MOPS running buffer 
(Invitrogen; NP0001). After running, the gel was transferred to an activated Immobilon-P 
(PVDF) membrane (Millipore; IPVH00010) at 400 mA for 3-4 hours using (1x) transfer 
buffer (380 mM glycine, 50 mM Tris). The membrane was incubated for one hour in 5% dry 
skimmed milk (1x) PBS/Tween (0.3%) buffer. then incubated overnight in the optimum 
concentration of the required primary antibody at 4˚C in the rotator. Then, the non-specific 
binding of the antibody was removed by washing the membranes three times using blocking 
buffer (1x) PBS/Tween (containing 5% of milk) for 10 minutes each. The membrane were 
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placed in the secondary antibody for one hour at room temperature. To reduce non-specific 
binding the membranes washed three times, 10 minutes each using the blocking buffer. To 
detect the signal Enhanced chemiluminescence (ECL; Thermo Scientific; 34087) used to 
detect the protein. Signal was visualise by exposing the membrane to X-Ray film (Thermo 
Scientific; 34091). 
Table 2.1 list of primary and secondary antibodies used. 
Antibody Source  Dilution  
Mouse polyclonal Anti-Spo11 Abnova Cat. No. H00023626-A01 1/500 
Mouse monoclonal Anti-Tubulin  Sigma  T6074 1/5000 
Goat polyclonal Anti-Lamin  Santa cruz  sc-7292 1/1000 
Polyclonal Anti-Tex19  R and D Catalog # AF6319 1/500 
Rabbit polyclonal Anti-Oct-4 
Abcam ab19857 
 
1/1000 
Donkey anti-rabbit  Jackson Immunoresearch  
711-035-152 
1/40000 
Donkey anti-mouse Jackson Immunoresearch  
711-035-150 
1/40000 
Rabbit Anti-goat Sigma  A5420 1/40000 
 
 
2.5 RNA isolation 
RNA isolation was carried out using the traditional Trizol (Invitrogen; 15596-026) protocol 
by homogenise the cells in 1 ml of Trizol per 5 x 106 cells at room temperature for 5 minutes. 
Then 200 µl of Chloroform was added to each sample followed by vigorous shaking for 15 
seconds and incubated for 5 minutes at room temperature. The sample were centrifuge at 
12,000 g for 15 minutes at 4°C. The top aqueous layer was transferred to a new Eppendorf 
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tube and mix with 0.5 ml of isopropanol and incubate at room temperature for 10 minutes. 
The samples were centrifuged at 12,000 g for 20 minutes. Sample were then the supernatant 
was aspirated and the pellet was washed with 70% ethanol and re-centrifuged at 7,500 g for 5 
minutes at 4°C. The supernatant was aspirated again and the cell pellet was left to dry at RT 
for 5-10 minutes until the alcohol residue evaporate and then 100 µl RNase free water 
containing 2 µl DNase I (Sigma; D5319) was added to each RNA sample. The samples were 
incubated at 37°C for 10 minutes and then at 75°C for 10 minutes. RNA yielded was 
measured by a NanoDrop (ND_1000) spectrophotometer and qualityof the ribosomal bands 
was checked on agarose gel. 
2.6 cDNA synthesis 
Total RNA was used to synthesise cDNA using SuperScript III First Strand Synthesis Kit 
(Invitrogen; 18080-051) according to the manufacture’s instructions. Positive control 
housekeeping gene β- Actin were used. 
2.7 Polymerase chain reaction (PCR) 
Primers were designed manually and the oligonucleotide properties calculated 
(http://www.basic.northwestern.edu/biotools/oligocalc.html). The primers design was based 
on the gene sequences obtained from the National Center for Biotechnology 
(NCBI;http://www.ncbi.nlm.nih.gov/). 2 µL of diluted cDNA (approximately 150 ng/µl) was 
used for PCR along with 1µl of both forward and reverse primers mixed with 25 µl of 
BioMixTM Red (Bioline; BIO-25006), and distilled water was added to 50 µl final volume. 
Samples amplification starting with a pre-cycling melt at 96°C for 5 minutes, followed by 40 
cycles of denaturing at 96°C for 30 seconds. The annealing step temperature vary between 
58-62°C for 30 seconds according to the primers in use and extension step at 72°C for 40 
seconds followed by a final extension step at 72°C for 5 minutes. PCR product were analysed 
by agarose gel electrophoresis. 
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Table 2.2 List of primers used in RT PCR and qRT PCR 
Gene  Primer  Sequence 5'-3' Annealing 
Tm (°C)  
Amplicon 
Size (bp) 
C16orf46 F 
R 
GTCTTCTCGATGTCAGTGAC 
CCTTCTCTTCTGACTGCAAG 
58.4 591 
GLIPR1L1 F 
R 
CTTGGGTCTGTGTTTGGTAG 
GGATTAAAGGCTGTCTGCTG 
58.4 630 
FTMT F 
R 
CTACGTGTACTTGTCCATGG 
GTGTCAAAAAGGTACTCCGC 
58.4 423 
TCTE3 F 
R 
CTAGCATGTTCGAGAAGGAG 
CAATGTCCCAGATCCATCTG 
58.4 417 
CXorf27 F 
R 
CAGACTCAAGACCCTTCTAG 
CATTCTTCCTGGATT TGGGC 
58.4 304 
FAM166A F 
R 
GAAACACGATCTCTTCACGC 
CGTTGGATTAGGTTAGGGTG 
58.4 624 
C5orf48 F 
R 
CCTACTTTGCCTAAACTCAC 
TGGGAAATCACAGTGCTTTG 
56.4 356 
SYNGR4 F 
R 
GTCTGGTTCATGGGTTTCTG 
AGCATAACTCAGGCTGTTGG 
58.4 476 
C12orf70 F 
R 
CAAGGGTATGTTGGAGCTAG 
CAGAACTGTGAGAGTCAGTG 
58.4 512 
CCDC54 F 
R 
CAACTGGATATCCCACTGTG 
CTAACTTGGTAGCACTGAGG 
58.4 681 
CCDC105 F 
R 
GCTTATTAACCAGCAGAGCG 
GGTTCTTTTCCAGGTACGTG 
58.4 
 
782 
TEX19 F 
R 
GCTTCAACATGGAGATCAGC 
GAAGCTCCTCAAATCTCCAG 
58.4 
 
386 
BRDT F 
R 
GAACCTGTTGAGAGTATGCC 
CATCCAGTAACCGCTTTTCC 
58.4 
 
691 
SHCBP1L F 
R 
GGACTGTAAGGCAGAAGATG 
CTACGCCTCAGAATTCTTGG 
58.4 720 
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C20orf70 F 
R 
TCAAGTACTTCCAGGACCAC 
GGCTAGTCTTAAAAGGTGCC 
58.4 371 
TRIML1 F 
R 
GAAGCTCAGGCTGTACTAAC 
CAAATCTTTCCGGGTTGTCG 
58.4 520 
IL31 F 
R 
CCGTTTACTACGACCAAGTG 
GGTCCATGCACTCTGAAAAC 
58,4 362 
PAPOLB F 
R 
CACAGCAGAACTCCACATAC 
CTACCTTCTGTTGAGTGTGC 
58.4 577 
FAM166A F 
R 
CCATGTCCAAACCCAAGTTC 
TGCGTTGGATTAGGTTAGGG 
58.4 468 
C5orf48 
 
F 
R 
CAACTGCTCTGATGAGAGTC 
CTGAAGCCATGGGAAATCAC 
58.4 389 
SOX2 F 
R 
GCAACCAGAAAAACAGCCCG 
CGAGTAGGACATGCTGTAGG 
58.4 590 
NANOG F 
R 
CTGCTGAGATGCCTCACACG 
GCTCCAGGTTGAATTGTTCC 
58.4 497 
OCT4 F 
R 
CTGGAGAAGGAGAAGCTGGA 
GCATAGTCGCTGCTTGATCG 
58.4 509 
*F: Forward; R: Reverse  
 
 
2.8 DNA purification and sequencing 
The purification of PCR product varies depending on the gene show one clear band in the 
expected size or show multiple bands. There was clear band the purification using the PCR 
product according to the manufacturer protocol using High Pure PCR Product Purification 
Kit (Roche Applied Science; 11732676001). However, in the multiple bands, cutting the 
specific band fragment out of the gel using sterile scalpel needed to undertake the purification 
process. Then, the purified DNA sample was sent for sequencing along with forward primers 
to the Eurofins MWG Company (Germany). The DNA sequencing results were analysed 
through BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and EMBL European 
Bioinformatics Institute  (http://www.ebi.ac.uk/). 
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2.9 Quantitative real time PCR 
RNA was isolated using the RNeasy Plus Mini kit (Qiagen; 74134) and according to the 
manufacture’s protocol. The synthesis of the cDNA was done using a SuperScript III First 
Strand Synthesis Kit (see above). The primers were designed manually, however, primers for 
the reference genes were ordered from Qiagen. The master mix qRT-PCR carried out using 
The Go Taq qPCR Master Mix (Promega; A6001) following the manufacturers protocol. 
Each well of a Hard-Shell® 96 well plate (BioRad; 9655) contained 1.5 μl cDNA in a final 
reaction volume of 20 μl, and in each reaction triplet repeat were done.  
The reaction were amplified with a pre-cycling step at 95°C for 3 minutes, followed by 40 
cycles of 95°C for 10 seconds. Annealing temperature setting at 60°C for 30 seconds, 
followed by 95°C for 10 seconds. A quantitative Bio-Rad CFX machine was used to do this 
analysis and the data was measured after normalising against the reference genes with Bio-
Rad CFX Manager Software (version 2). 
2.10 Knockdown gene by RNA interference 
Approximately 200,000 cells per well were seeded into each six wells plate and incubated 
overnight. 100 µl of serum free media was used to make the transfection complex of 10 nM 
siRNA approximately 1.2 µl (Qiagen) and 6 µl HiPerfect reagent (Qiagen; 301705). The 
complex was incubated for 40 minutes at room temperature. The complex was applied to the 
cells drop wise with gentle agitation. Non-interfering RNA was used as negative control 
(Qiagen; 1022076) which was prepared the same way. The plate were incubated overnight, 
the cells were wash using PBS, refreshed with new media, and a second and third hit was 
applied consecutively as described before. 
Table 2.3 list of siRNA used for gene knockdown. 
Gene  siRNA Qiagen cat. No.  Target sequence (5' -3 ') 
SPO11 Hs_SPO11_1 FlexiTube siRNA 
Hs_SPO11_2 FlexiTube siRNA 
Hs_SPO11_4 FlexiTube siRNA 
Hs_SPO11_6 FlexiTube siRNA 
SI00100366 
SI00100373 
SI00100387 
SI03024049 
CAGAGTGTACTTACCTAA CAA 
ACAACTAATGTTAACGCA TAA 
TACCTTCTACGATACAAC TAA 
CCACACAGCCGTAATGAC AAA 
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NI 
Hs_FLJ35767_1 FlexiTube siRNA 
Hs_FLJ35767_6 FlexiTube siRNA 
Hs_FLJ35767_7 FlexiTube siRNA 
Hs_FLJ35767_8 FlexiTube siRNA 
 
Non-interference RNA 
SI00409444 
SI04215176 
SI04247705 
SI04276937 
 
1022076 
 
AGGATTCACCATAGTCTCTTA 
TTCAACATGGAGATCAGCTAA 
 
 
AATTCTCCGAACGTGTCA CGT 
 
 
2.11 Extreme limiting dilution analysis (ELDA)  
 
12 well repeats were used for untreated cells, non-interference control siRNA, Hiperfect 
treated cells and gene small interference siRNA treated cells. The transfection complex made 
by adding 0.1 nM siRNA (Qiagen) containing 0.3 µl HiPerfect reagent (Qiagen; 301705) to 
4.7 µl serum free medium and incubating for 45 minutes at room temperature. In addition, 
non-interference siRNA (Qiagen; 1022076) was prepared in the same way. The siRNA 
transfection mixture, negative control siRNA and Hiperfect were added drop-wise to the cells 
in the 12 well repetitions for each condition. Then, the plate incubated for 10 days in a 
humidified incubator at 37°C with required CO2. On day 3 and 6, the Cells were 
supplemented with 50µl serum free medium and the transfection mixture as previously 
After 10 days of incubation, the analysis of number of cells observed by light microscope and 
the data analysis done using ELDA web tool to carry out the statistical analysis. 
(http://bioinf.wehi.edu.au/software/elda/). In addition, images of cells were taken from first 
day of seeding and day 10. 
2.12 Detection of SPO11 covalent bound to DNA Adapted from (Hartsuiker, 2011).  
Confluent SW480 cells were trypsinised and washed twice using PBS. Using a 
haemocytometer, approximately 2,500,000 cells were lysis in freshly prepared 1.1 ml lysis 
buffer (8 M guanidine HCl, 30 mM Tris pH 7.5, 10 mM EDTA, 1 % Sarcosyl, adjusted to pH 
7.5 with 10 M NaOH). The cell lysate were incubated at 65ºC for 15 minutes and then 
centrifuged at 16,000 g for 5 minutes. 
40 
 
Different density of CsCl gradients were prepared (1.45 g/ml density: 60.90 g CsCl dissolved 
in 100 ml distilled water. The refractive index (RI) was 1.3764; 1.50 g/ml density: 68.48 g 
CsCl in 100 ml distilled water, RI 1.3815; 1.72 g/ml density: 98.04 g CsCl in 100 ml distilled 
water, RI 1.4012; 1.82 g/ml density: 111.94 g CsCl in 100 ml distilled water, RI 1.4104) were 
loaded into polyallomer ultra-centrifuge tubes (Beckman Coulter Cat. No. 326819) beginning 
with CsCl 1.82 g/ml then very carefully layering 1 ml of CsCl 1.72 g/ml on top of the first 
layer; repeating this for the 1.50 g/ml and 1.45 g/ml CsCl solutions. A 1 ml sample of the 
lysed cells was then loaded as the top layer. The gradients were centrifuged for 24 hours at 
30,000 r.p.m. at 25ºC in ultra-centrifuge Beckman SW55Ti rotor.  
The remainder of the lysed cells were used for DNA quantification. The remaining cell lysate 
was incubated at 65ºC for 5 mins and centrifuged for 2 mins at 16,000 xg, then 10 μl of the 
supernatant was added to 90 μl of TE containing 0.5 μg/ml Rnase A (Sigma, Cat No. R6513) 
and incubated for 3 hours at 37ºC. The mix was centrifuged for 2 minutes at 16,000 g to 
remove any insoluble material, and then 50 μl of the supernatant was added to 50 μl of a 
1:200 dilution of Quant-iT PicoGreen dsDNA reagent (Invitrogen, Cat. No. P7581)  
Mixed in TE buffer, and incubated for 5 minutes at room temperature. A blank control (50 μl 
TE) and DNA standard (50 μl 100 ng/ml Lambda DNA [NEB, N3011] in TE) was prepared 
as well. An Invitrogen Qubit were calibrated using the blank control and DNA standard and 
then the DNA concentration in the samples was measured.   
After 24 hours, the tubes were taken from the ultracentrifuge. A centrifuge tube containing 
the gradient was clamped in a retort stand. Silicone tubing was fitted into a peristaltic pump 
and the end silicone tubing was attached to a needle. The needle was inserted into the bottom 
of centrifuge tube at a 45º angle. Using the peristaltic pump, the gradient was slowly pumped 
out of the tube and 0.5 ml fraction were collected in each tube.  
A nitrocellulose membrane (Whatman, Cat. No. 10402096) were immerse in 1X PBS and 
applied to a slot blotter (Hoefer PR648 slot blot filtration manifold unit). The fractions were 
loaded onto the slot blot for each sample equally, based on DNA concentration; the loadings 
for the slot blot were calculated as 150 ng for each sample. Once the samples were vacum 
extracted through the membrane, the membrane then dried face up on a piece of paper. Then, 
DNA was cross-linked to the membrane using a stratalinker (auto-crosslink, 120,000 
microjoules).   
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The membrane was blocked in milk solution (3% non-fat dry milk, 0.1% Tween 20 in PBS) 
for 30 minutes on a shaker and then incubated overnight at 4°C in anti-SPO11 antibody 
(Abnova, Cat. No. H00023626-A01), which was diluted 1/500 in milk solution. The 
membrane was then washed in milk solution twice for 10 minutes each time and then 
incubated for 1 hour at room temperature in Donkey anti-mouse secondary antibody (Jackson 
Immunoresearch, Cat. No. 711-035-150, also diluted in milk solution). The membrane was 
washed twice for 5 minutes in milk solution and three times for 5 minutes in PBS/Tween 20 
(0.3% w/v). Pierce ECL Plus Western Blotting Substrate (Pierce 32132) was used to detect 
SPO11 after exposure for 15 minutes to CL-XPosure Film (Thermo scientific, 34088). 
2.13 Statistical analysis 
In this project, several statistical approaches were employed regardless the fact of majority of 
data obtained were qualitative results. However, in ELDA assay we used a web page tool: 
(http://bioinf.wehi.edu.au/software/elda/).  
Densitometry was performed using Image J software to quantify the intensity of protein 
bands. and some statistical data were analysed using Excel statistical analysis tools to 
calculate p value. 
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3. Identification and validation of novel CT genes using 
bioinformatics tools 
3.1 Overview 
Tumour antigens have been employed as targets for cancer immunotherapy. The main 
requirement for tumour antigens to be considered as potential targets for immunotherapy is to 
have no presence in normal tissues. CTA (see introduction) have been defined as a group of 
potential antigen targets for cancer immunotherapy due to their presence in normal testicular 
cells and in several types of human malignancies (Caballero and Chen, 2009). A number of 
studies also suggest that CT antigens could potentially be employed as novel biomarker tools 
for cancer diagnosis and prognosis. A recent study on 142 patients suffering from 
hepatocellular carcinoma showed correlation between the expression of CT genes and poor 
prognosis. This suggest the possible use of CT genes to evaluate hepatocellular carcinoma 
outcomes. In addition, it might be a potential target for hepatocellular carcinoma 
immunotherapy (Wang et al., 2015). Previous work reveal the possible involvement of CT 
genes in cancer, such as possible role for MAGE-A2 influence on P53 tumour suppressor 
gene down regulation (Monte et al., 2006). Additionally, another study on multiple myeloma 
and CT gene SLLP1 expression, suggest SLLP1 as potential target for immunotherapy in 
multiple myeloma (Yousef, et al., 2015). 
Meiosis requires the expression of a number of specific genes that encode meiosis-specific 
functions. Some of these genes show significant expression in various types of cancer, such 
as the SPO11 gene, which is responsible for encoding the initiator of the meiotic 
recombination (Keeney, 2008). Other examples including SYCP1 and SYCP2, which make up 
parts of the meiosis-specific synaptonemal complex (see introduction). There confined 
expression in normal somatic cells and aberrant occurrence in some types of cancerous 
tissues, which is poorly understood, make meiotic genes potential candidate for CT genes 
(Koslowski et al., 2002; Tureci et al., 1998; Whitehurst, 2014). 
A subgroup of CT genes, are not affected by chromosome X-inactivation as they are 
autosomalic encoded. Meiosis-specific genes have been hypothised to be in this class as their 
activation must correlate with meiotic X inactivation. Identification and validation of these 
genes reveal understanding of oncogenic involvement of these genes (Feichtinger et al., 
2012). In addition, the expression of these meiosis-specific genes in some types of cancer 
might reveal a new sub-category of testis restricted CT genes (Feichtinger et al., 2012). The 
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potential use of meiosis-specific CT genes as cancer biomarkers and immunotherapy are 
increasing due to their immunogenicity and localized confined expression (Seoane and De 
Mattos-Arruda, 2014). 
Here we aim to identify novel CT genes by applying two approaches. Firstly, through manual 
literature searches we identified meiosis-specific genes known to have expression restricted 
to the testis. Secondly, we used in-silico analysis of EST data sets (done by my colleague Dr. 
Julia Feichtinger) that will be discussed in the results to identify novel CT genes. (Feichtinger 
et al., 2012). 
3.2 Results 
Initially a group of meiosis-specific genes was selected by a manual search of the literature. 
This list proved to be relatively small and so we took a more systemic approach. 744 mouse 
genes have previously been identified (Chalmel et al., 2007) that were reported to be specific 
to meiotic spermatocytes.  408 human orthologues of these genes were identified (Feichtinger 
et al., 2012). Then, validating these genes against human genes involved in mitosis 
(Mitocheck) and excluding possible non-testis specific genes (a schematic is shown in Figure 
3.1). 375 genes fit the requirements and these were fed into an express sequence tag (EST) 
analysis pipeline which search the gene list against ESTs for normal human and cancerous 
tissues , from this we identified 105 genes with predicted restricted expression and cancer 
tissue expression (Feichtinger et al., 2012). 9 genes were cancer/testis only restricted, 75 
genes were testis restricted (no cancer EST footprint) and 21 genes were cancer/testis/CNS 
restricted. These 105 genes were validated by RT-PCT screening in various normal and 
cancer human tissue (Feichtinger et al., 2012). 21 genes were assaigned randomly to me for 
RT-PCR validation (Table 3.1). 
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Figure 3.1 Illustrated flow diagram show step-wise approach applied for the candidate meiCT genes. 
744 mouse meiosis-specific genes were starting with. Then, 408 human orthologues were identified 
and 375 human meiosis-specific genes remain after Mitocheck. All 375 candidates as well as 3 
controls (MAGE-A1, GAGE1 and SSX2) were fed into the EST analysis. Afinal 105 candidate genes 
were validated by RT-PCR /microarray meta-analysis (Feichtinger et al., 2012), of which I was 
allocated 21 genes at random. 
 
 
 
Literature 
Meiosis-Specific Manual seach 
   Human orthologues 
Mitocheck 
EST screen 
RT-PCR analysis 
ID mapping 
Germ Online 
   Microarray metaanalysis 
21 genes 
validated by me 
 
Mouse genome 
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408 human 
meiosis-specific 
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105 candidate 
45 
 
Intron-spanning primers were designed using Primer3 software as possible 
(www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi). cDNA were constructed from 
isolated RNA according to manufacturers protocol. RT-PCR were performed using 2µL of 
diluted cDNA (approximately 150 ng/μl), distilled water and BioMix™ Red (Bioline™) were 
used for PCR amplification of total volume 50 µL. RT-PCR run for 40 cycles and PCR 
product were separated and visualised using on 1% agarose gels containing ethidium bromide 
(Feichtinger et al., 2012a).   
 The candidate genes were subjected to RT-PCR using RNA obtained from 21 human normal 
tissue, which included testis as a positive control sample. Candidate gene which show 
restricted expression to the testis and/or CNS/ one or two other normal tissues, were screened 
for expression in 33 different types of human cancer cells obtained from tumour biopsies or 
cancer cell-lines. Then, all  PCR product were validated by DNA sequencing.  
3.2.1 Evaluation and validation of meiosis-specific TEX19 as potential CT gene 
Our fist approach was to search the literature manually for meiosis-specific genes; TEX19 
was one of the genes selected in this approach. Two sets of TEX19 primers were designed. 
The first set were designed from the one translated exon and the second set were designed 
intron-spanning primers where the first exon is the untranslated exon. 
RT-PCR results  for RNA from normal human tissue using exon internal primers shows a 
clear band of TEX19 at the expected size (386 bp) (Figure 3.2) for the testis and a faint band 
in the thymus. However, using the intron-spanning primers, a clear band at the expected size 
(757 bp) was observed in testis only (Figure 3.2). The PCR product were purified and 
sequenced and gene identity were confirmed (Table 3.2) RT-PCR amplification of β-ACTIN 
using intron spanning primers was used to quality control the cDNA. 
Because of the restricted testis expression of TEX19, a panel of cancer cell RNA was used, 
RT-PCR show TEX19 band was detected in several types of cancer including colon cancer 
cells SW480 and HT29, lung cancer cells H460, breast cancer cells MCF-7, ovarian cancer 
cells PE014 and A2780, leukaemia cells K562, melanoma cells COLO857 and liver 
carcinoma cells HEP-G2 cancer cell-lines. Both sets of primers were used show similar bands 
in these cancer tissue (Figure 3.3). DNA sequencing of TEX19 band in SW480 reveal gene 
identity (Table 3.2). 
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Table 3.1 Functional role of predicted CT genes in EST analysis 
Gene  function Reference 
C16orf46 Unknown   
GLIPR1L1 Involve in spermatogenesis  Caballero et al. (2013)  
FTMT encodes Mitochondrial ferritin (FtMt) protein Drysdale et al., (2002) 
TCTE3 Involve in sperm motility Harrison et al., (1998). 
CXorf27 
Involve in Huntington's disease 
 
Butland et al., (2014) 
FAM166A Unknown   
SYNGR4 Unknown    
C12orf70 Unknown   
CCDC54 Unknown   
CCDC105 Unknown   
TEX19 Meiotic upregulated and involve in 
spermatogenesis 
Kuntz et al. (2008)  
Ollinger et al. (2008) 
 
BRDT encode Bromodomain testis-specific protein Shi and Vakoc (2014) 
SHCBP1L Involve in spermatogenesis Liu et al.,  (2014) 
C20orf70 Encode salivary protein parotid secretory  Abdolhosseini, et al., 
(2012). 
TRIML1 Play a role in protein ubiquitin  Marín, (2012) 
IL31  Involve in immune reaction Zhang et al., (2008). 
PAPOLB  Involve in spermiogenesis Matzuk et al., (2012). 
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βACT 
553 bp 
TEX19 
386 bp 
TEX19 
757 bp 
1000bp 
1000bp 
1000bp 
500bp 
500bp 
500bp 
Figure 3.2 RT-PCR of potential CTA gene TEX19 using human normal tissues. PCR product of 
TEX19 gene observed on the agarose gel at the expected size. βACT was used as a control for the 
cDNA quality. 
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Figure 3.3 RT-PCR of potential CTA gene TEX19 using human normal tissues. PCR product 
of TEX19 gene observed on the agarose gel in the expected size. βACT was used as a 
control for the cDNA quality. 
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3.2.2 Evaluation and validation of candidate CT genes in normal tissues using RT-
PCR analysis 
Candidate genes were analysed using RT-PCR on RNA extracted from 21 normal human 
tissues to assess their expression profile. According to RT-PCR results, some of these genes 
show multiple bands in many normal human tissues and therefore, they were classified as 
dismissed genes including C20orf70, FAM166A, GLPRIL, SCHCP1 and SYNGR-4 (Figure 
3.4). The RT-PCR analysis show clear bands at the expected size (512 bp) of C20orf70 in 
many normal tissues including testis, foetal brain, spinal cord, heart, lung etc. (Figure 3.4). 
DNA sequencing were performed from purified PCR product and confirm the identity of the 
gene in testis (Table 3.2) A band for FAM166A was observed at the expected size (468 bp) 
and multiple bands were detected in some normal tissues including testis, brain, foetal brain, 
spinal cord, heart, lung, thymus and trachea (Figure 3.4). DNA sequencing were performed 
and the identity of the gene confirmed in testis. However, DNA sequencing of lung sample 
did not confirm the gene identity (Table 3.2). Analysis of SCHCP1 showed multiple bands, 
one at the expected size (720 bp) and others lower than the expected size (Figure 3.4). These 
bands were observed in some normal tissues including testis, brain, prostate, liver, skeletal 
muscle, uterus and ovary. Purified PCR product from testis and skeletal muscle samples were 
used for DNA sequencing and did not confirm the gene identity (Table 3.2).In addition, 
SYNGR-4 analysis shows clear band in testis and multiple faint band in normal tissue in 
expected size (476 bp) including cerebrum, brain, spinal cord, prostate, bone marrow and 
skeletal muscle (Figure 3.4). DNA sequencing was performed from PCR purified product of 
testis confirm the identity of the gene. However, DNA sequencing of lung sample did not 
confirm the gene identity (Table 3.2). Finally, GLPRIL show several bands in many normal 
tissues including testis, cerebrum, brain, foetal brain, spinal cord, lung, prostate, skeletal 
muscle, uterus etc., some were detected in expected size (424 bp) and others were lower than 
expected size (Figure 3.4). The DNA sequencing from testis PCR product reveal the identity 
of the gene. However, DNA sequencing of skeletal muscle sample did not confirm the gene 
identity (Table 3.2). 
RT-PCR analysis defined some candidate CT genes as testis-restricted genes including 
BRDT, C5orf48, CCDC105, TCTE-3 and TRIML-1 due to their confined expression in testis 
only. Analysis of BRDT expression show clear band in testis detected at the expected size 
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(691 bp) (Figure 3.5). In addition, C5orf48 also show clear band in testis observed in 
expected size (389 bp) (Figure 3.5). Moreover, analysis of CCDC105 expression show clear 
band in testis detected at the expected size (782 bp) and no expression was detected in 
somatic tissue (Figure 3.5). Moreover, TRIML-1 show clear band in testis detected of the 
expected size (807 bp) and no band detected in the rest of normal tissue (Figure 3.5). Finally, 
analysis of TCTE-3 show clear band in testis detected at the expected size (417 bp) (Figure 
3.5). Purified PCR product from testis were used for DNA sequencing which confirm the 
identity of these genes (Table 3.2). 
Based on RT-PCR analysis, some candidate CT genes were classified as testis-selective 
genes including FTMT and IL-31 were expressed in testis and one somatic tissue. FTMT 
strong clear band in the testis and a faint band was detected in skeletal muscle and trachea 
(Figure 3.6) the observed band were at the expected size (423 bp) and DNA sequencing 
performed from testis sample confirm the gene identity (Table 3.2). In addition, IL-31 show 
clear and strong band in testis and faint band in thymus (Figure 3.6) the observed band was 
detected at the expected size (362bp) and DNA sequencing of purified PCR product of testis 
did not confirm the gene identity (Table 3.2). 
The expression of PAPOLB gene were analysed by RT-PCR and classed as testis-CNS 
restricted gene due to its confined expression observed in testis and cerebrum. The detected 
band was at the expected size (577 bp) for the testis. In addition, a faint expected size band 
were detected in cerebrum (Figure 3.7). PCR product were purified and DNA sequencing 
confirm the gene identity of testis sample (Table 3.2). 
However, two candidate CT genes were classed as testis-CNS selective genes according to 
their expression profile assessed by RT-PCR including CXorf27 and CCDC54. RT PCR 
analysis of CXorf27 show clear band in testis were detected in expected size (304 bp) and 
faint band were at expected size in the brain, foetal brain, spinal cord and uterus (Figure 3.8). 
DNA sequencing confirm the identity of the gene (Table 3.2). In addition, RT PCR analysis 
for CCDC54 showed a clear band for the testis at the expected size (681 bp) and a faint band 
in cerebrum, spinal cord, uterus and prostate were detected at the expected size (Figure 3.8). 
RT-PCR product were purified and DNA sequencing confirm the gene identity (Table 3.2)   
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Figure 3.4 RT-PCR of excluded genes using human normal tissues. PCR product of 
C20orf70, FAM166A, GLPRIL, SCHCP1and SYNGR-4 genes observed on the agarose gel at 
the expected size.  βACT was used as a control for the cDNA quality. 
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Figure 3.5 RT-PCR of predicted testis-restricted genes using human normal tissues. PCR product of 
BRDT, C5orf48, CCDC105, TCTE-3 and TRIML-1 genes observed on the agarose gel at the expected 
size. βACT was used as a control for the cDNA quality.  
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βACT 
553 bp 
FTMT 
423 bp 
IL31 
362 bp 
1000bp 
1000bp 
1000bp 
500bp 
500bp 
500
bp 
Figure 3.6 RT-PCR of some testis-selective genes using human normal tissues. PCR product of FTMT 
and IL31 genes observed on the agarose gel at the expected size. βACT was used as a control for the 
cDNA quality.  
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
βACT 
553 bp 
PAPOLB 
577 bp 
500bp 
1000bp 
1000bp 
500bp 
Figure 3.7 RT-PCR of testis-CNS restricted genes using human normal tissues. PCR product of PAPOLB 
gene observed on the agarose gel at the expected size. βACT was used as a control for the cDNA quality. 
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Figure 3.8 RT-PCR of testis-CNS selective genes using human normal tissues. PCR product of 
CXorf27 and CCDC54 genes observed on the agarose gel at the expected size. βACT was used 
as a control for the cDNA quality. 
 
56 
 
 
 
 
 
3.2.3 Evaluation and validation of candidate CT genes in cancer cell-lines and 
tissues using RT-PCR analysis 
RT-PCR analysis of testis-restricted genes including BRDT, C5orf48, CCDC105, TCTE-3 
and TRIML-1 showed that no expression was detected in cancer tissues and cell-lines and 
although a clear band was detected for the testis. 
The analysis of testis-selective genes including FTMT and IL-31 in cancer tissues, show 
interesting result compared to normal tissue screening. RT-PCR analysis of FTMT showed a 
clear band was detected at the expected size (423 bp) in the testis and a faint band was 
detected in several types of cancer tissue panel such as colorectal cancer SW480, NTERA2, 
TO14 and astrocytoma cell-line 1321N1 (Figure 3.10). DNA sequencing performed from 
SW480 sample confirm the gene identity. However, RT-PCR analysis of IL-31 showed a 
faint band for the prostate cancer cell-line PC-3 and SW480 at the expected size (362 bp) 
(Figure 3.10). DNA sequencing of purified PCR product from testis, PC-3 and SW480 failed 
to confirm gene identity (Table 3.2). 
Based on RT-PCR analysis, PAPOLB was categorised as testis-CNS restricted gene. 
Expression analysis of PAPOLB showed a clear band in the testis was observed at the 
expected size (577 bp) While, in the cancer tissue, a faint band was observed at the expected 
size in testicular cancer NTERA-2 cell-line (Figure 3.11). 
Interestingly, CXorf27 was classed as testis-CNS selective gene according to RT-PCR 
analysis, which showed a clear band for the testis and some cancer tissues including breast 
cancer cell-line MCF-7, melanoma cell-line COLO857, lung cancer cell-line H460 and 
ovarian cancer cell-line PE014 (Figure 3.12).The band were detected at the expected size 
(304 bp). In addition, RT-PCR of CXorf27 showed a faint band in some cancer tissues 
including NTERA2, colon cancer HT29, kidney tumour, liver cancer HEP-G2, lung cancer 
MRC-5, leukaemia K-562 and ovarian cancer T014. RT-PCR results show the band was at 
the expected size (304 bp) (Figure 3.12). DNA sequencing confirm the gene identity in testis. 
However, purified PCR product from HT29 were used for DNA sequencing did not confirm 
the gene identity. 
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Figure 3.9 RT-PCR of some testis-restricted genes using human cancer tissues. PCR product of 
BRDT, C5orf48, CCDC105, TCTE-3 and TRIML-1 genes observed on the agarose gel at the 
expected size. βACT was used as a control for the cDNA quality.  
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Figure 3.10 RT-PCR of some testis-selective genes using human cancer  tissues. PCR product of FTMT 
and IL31 genes observed on the agarose gel at the expected size.  βACT was used as a control for the 
cDNA quality. 
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Figure 3.11 RT-PCR of testis-CNS restricted genes using human cancer  tissues. PCR product of 
PAPOLB gene observed on the agarose gel at the expected size.  βACT was used as a control for the 
cDNA. 
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Figure 3.12 RT-PCR of testis-CNS selective genes using human cancer tissues. PCR product of 
CXOFR27 gene observed on the agarose gel at the expected size.  βACT was used as a control for 
the cDNA quality. 
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Table 3.2 DNA sequencing of purified RT-PCR product of candidate CT genes from different human tissues. 
GENE 
TISSUE 
SOURCE 
EXPECTED 
SIZE 
APPROXIMATE 
OBSERVED  SIZE 
PRIMER 
MWG 
RESULT 
NCBI Blast Result 
FTMT testis 423 420 F PASSED 
Confirmed (Query ID: 
lcl|1223) 
CXorf27 testis 304 300 F PASSED 
Confirmed (Query ID: 
lcl|2191) 
CCDC54 testis 681 680 F PASSED 
Confirmed (Query ID: 
lcl|46537) 
CCDC105 testis 782 780 F PASSED 
Confirmed (Query ID: 
lcl|49241) 
TEX19 testis 386 385 F PASSED 
Confirmed (Query ID: 
lcl|56117) 
PAPOLB testis 577 580 F PASSED 
Confirmed (Query ID: 
lcl|58421) 
SYNGR4 testis 476 475 F PASSED 
Confirmed (Query ID: 
lcl|39559) 
TRIML1 testis 807 810 F PASSED 
Confirmed (Query ID: 
lcl|5389) 
FAM166A testis 468 470 F PASSED 
Confirmed (Query ID: 
lcl|60873) 
C5orf48 testis 389 390 F PASSED 
Confirmed (Query ID: 
lcl|29855) 
BRDT testis 691 690 F1 PASSED 
Confirmed (Query ID: 
lcl|12139) 
IL31 testis 362 360 F FAILED 
Uncertain (Query ID: 
lcl|21455) 
C2orf70 testis 512 510 F PASSED 
Confirmed (Query ID: 
lcl|55305) 
GLIPR1L1 testis 424 425 F PASSED 
Confirmed (Query ID: 
lcl|62295) 
TCTE3 testis 417 420 F PASSED 
Confirmed (Query ID: 
lcl|14837) 
SHCBP1L testis 720 720 F FAILED 
Uncertain (Query ID: 
lcl|1837) 
FTMT SW480 423 420 F PASSED 
Confirmed (Query ID: 
lcl|48449) 
CXorf27 HT-29 304 305 F FAILED 
Uncertain (Query ID: 
lcl|10649) 
GLIPR1L1 
Skeletal 
muscle 
424 425 F FAILED 
Uncertain (Query ID: 
lcl|18635) 
SYNGR4 Lung 476 480 F FAILED 
Uncertain (Query ID: 
lcl|45731) 
TEX19 SW480 386 390 F PASSED 
Confirmed (Query ID: 
lcl|29373) 
FAM166A Lung 468 470 F FAILED 
Uncertain (Query ID: 
lcl|38065) 
SHCBP1L 
Skeletal 
muscle 
720 720 F FAILED 
Uncertain (Query ID: 
lcl|4003) 
IL31 SW480 362 360 F FAILED 
Uncertain (Query ID: 
lcl|19989) 
IL31 PC-3 362 360 F FAILED 
Uncertain (Query ID: 
lcl|52703) 
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3.3 Discussion 
The expression profile of CT genes and their antigen association with some types of cancer 
indicate their oncogenic contribution. Therefore, further CTA classification and validation 
might enhance our understanding to approach cancer treatment.  
3.3.1 Testis-restricted genes 
Based on RT-PCR analysis and DNA sequencing data of testis-restricted genes, there 
expression was observed only in the testis and no detection was found in the normal and 
cancer tissue, which refer them as testis-specific genes including BRDT, C5orf48, CCDC105, 
TCTE-3 and TRIML-1 (Figure 3.13 and Figure 3.13). BRDT gene is responsible for encode 
Bromodomain testis-specific protein, which plays an important role in mammalian 
transcription regulation and modification in normal tissue along with three other proteins 
including BRD2, BRD3 and BRD4 which collectively known as Bromodomain and extra-
terminal (BET) ( Lovén et al., 2013). However, recent study reveal oncogenic role of BET in 
some types of cancer. BET is involve in oncogenic activity through regulation of some 
oncogenes (Shi and Vakoc, 2014). In our study, BRDT expression was observed in testis only 
and no expression was observed in other normal and cancer tissue. 
The importance of this class is their confined expression in testis, which resides in immune 
privilege through blood-testis barrier (BTB), where sertoli cells (SC) control and prevent 
immune cells and antibodies entry into testis lumen (Mital et al., 2011). Therefore, the 
possible use of testis-restricted genes to target some types of cancer through immunotherapy 
can be achievable due to testicular immune-privilege. 
 
3.3.2 Testis-selective genes 
In the testis-selective gene category, FTMT observed in the testis, skeletal muscle and trachea 
of the normal tissue (Figure 3.13) but show expression in various types of cancer tissue such 
as colon cancer cell-line SW480, ovarian cancer cell-line TO14 and brain cancer cell-line 
1321N1 (Figure 3.14). The FTMT gene encodes Mitochondrial ferritin (FtMt) protein which 
is restricted in few human organs including the brain and testis (Drysdale et al., 2002). 
Overexpression of FTMT is observed in some neuro-degenerative diseases such 
as  Alzheimer's disease (AD) (Altamura and Muckenthaler, 2009) and neuronal tumour cells, 
which involve in the inhibition of tumour growth without initiation of apoptosis (Shi et al., 
2015).  
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The other gene in this category is IL-31 show clear band in the testis and faint band in the 
thymus, cerebrum and foetal brain of normal tissue (Figure 3.13). While in cancer tissue a 
faint band for the prostate cancer cell-lines PC-3 and SW480 was observed (Figure 3.14). 
Based on DNA sequencing of IL-31from testis, PC-3 and SW480 tissues. The CT 
classification of IL-31 is uncertain and its expression were inconclusive. 
 
3.3.3 Testis-CNS restricted genes 
The testis-CNS restricted gene PAPOLB show clear band in the testis and brain cerebrum of 
normal tissue (Figure 3.13). However, in the cancer tissue panel a faint band was observed in 
the NTERA-2 cancer cell-line (Figure 3.14). The significance of this class is the capability to 
target cancer via immunotherapy with least harm consequences for cancer patient. Because, 
CNS is protected by blood brain barrier (BBB) which consist of lining of endothelial cells 
forming tight junction to implement selective permeability and mediate the entry of immune 
cells and antibodies into the CNS (Neuwelt et al., 2011). In addition, there are supporting 
cells including astrocytes, neurons and pericytes which collectively forming neurovascular 
unit (NVU) to control the permeability to CNS (Muldoon et al., 2013). Moreover, deficiency 
of pericytes cause BBB failure, which consequently lead to neurodegeneration of the brain 
cells (Winkler et al., 2011). Therefore, the immune privilege feature of CNS allow to target 
some types of cancer using testis-CNS restricted genes, such as PAPOLB, without causing 
auto immunological damage to CNS. 
 
3.3.4 Testis-CNS selective genes 
In the category of testis-CNS selective gene CXorf27 show a clear band in the testis and 
spinal cord, and show faint band in the whole brain, foetal brain and uterus of the normal 
tissue (Figure 3.13). In addition, expression was apparent in variety of cancer tissue such as 
testicular cancer NTERA-2, lung cancer H460, breast cancer MCF-7, ovarian cancer PE014 
and melanoma COLO857 cancer cell-lines (Figure 3.14). These finding suggest the 
oncogenic role of CXorf27 that may play. Therefore, these findings make this gene 
interesting as a potential biomarker and for gene therapy applications due to its relatively 
confined expression in the testis and CNS which characterised by their immune-privilege 
through blood brain barrier (BBB) of the CNS. However, the expression detected in the 
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uterus can be intervened surgically by hysterectomy as selective option in female patient in 
case gene therapy applicable. 
3.3.4 Excluded genes 
The excluded genes category as its name suggests, the RT-PCR analysis of C2orf70, 
FAM166A, GLPRIL, SCHCP1and SYNGR-4 genes observed many signals in different normal 
tissue (Figure 3.13). Therefore, the RT-PCR analysis and validation of these genes in the 
human cancer tissue and cell-lines was not performed due to their expression profile in 
somatic tissues. 
 
3.3.4 Meiosis-specific genes 
The meiosis-specific gene TEX19 showed clear expression in the normal testis and thymus, 
while repetition of the RT-PCR using intron-spanning primers showed clear expression only 
in the testis. Therefore, according to RT-PCR analysis, TEX19 is testis-restricted/cancer CT 
gene (Figure 3.13). The RT-PCR analysis of TEX19 in the cancer tissue show clear 
expression in different cancer tissue such as colon cancer SW480 and HT29, lung cancer 
H460, breast cancer MCF-7, ovarian cancer PE014 and A2780, leukaemia K562, melanoma 
COLO857 and liver carcinoma HEP-G2 cancer cell-lines (Figure 3.14). The activation of 
TEX19 gene in many types of cancer tissue and its expression pattern make it a good 
candidate as CT gene according to the RT-PCR results and the DNA sequencing data. 
The genetic expression of somatic cells to germline transition may involve stimulating 
oncogenic activity lead to continuous, numerous and uncontrolled mitotic cell divisions. This 
suggest a possible oncogenic contribution of one or more CTA genes in the absence of the 
whole germline genetic environment. The expression of some CT genes in cancer may 
suggest other different functions of these genes in somatic tissue. Moreover, they might 
contribute in tumour initiation/ progression (McFarlane et al., 2014). 
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Figure 3.13 representation of RT-PCR analysis of tested genes in normal human tissue. The dark 
square reflect expression of the gene. (A) β Actin used as control for cDNA quality. (B) Excluded 
genes. (C) testis-restricted genes. (D) testis-selective genes. (E) testis-CNS restricted genes. (F) testis-
CNS selective genes. (G) meiosis-specific gene.(TEX19)  
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Figure 3.14 representation of RT-PCR analysis of tested genes in human cancer tissue. The dark 
square reflect expression of the gene. (A) β Actin used as control for cDNA quality. (B) meiosis-
specific gene (C) testis-restricted genes. (D) testis-selective genes. (E) testis-CNS restricted genes. (F) 
testis-CNS selective genes. 
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3.4 Conclusion 
The bioinformatics analysis pipeline tool provide us with a reliable interface platform to 
identify novel CTA genes and determine their precise expression in tissues. In addition, the 
identification and validation of these novel cancer biomarkers rises the questions of the 
function of these genes in normal and cancer cells, and suggest the unknown role of some of 
these genes that might play in some types of cancer. Moreover, the possible approach to use 
these genes in many clinical and research applications including cancer specific gene therapy, 
diagnosis and prognosis. 
In this chapter, a new class of CTA named as mei-CT genes, show high immunological 
privilege rather than testis-restricted (Feichtinger et al., 2012). TEX19 one of the novel 
meiCT gene show interesting expression pattern. This expression may indicate the oncogenic 
activity of TEX19 gene in somatic tissue. Consequently, the possible approach to employ 
these genes as a target for cancer immunotherapy and their possible use in cancer prognosis 
and diagnosis. 
Testis-CNS selective CXORF27 gene, might be promising as target for diagnosis, prognosis 
and immunotherapy of cancer based on RT-PCR results and DNA sequencing data regardless 
its expression in uterus. 
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Chapter 4 A potential role for TEX19 in regulation of stemness  
4.1 Overview  
The human teratocarcinoma-derived cell line NTERA2 consists of EC stem cells with 
property of pluripotency possessing the capability of differentiation induced by retinoic acid, 
forming different types of cells such as post-mitotic neurons (Andrews et al. 1984b; 
Andrews, 1984; Rend et al., 1989; Pleasure et al., 1992; Squires et al. 1996). In fact, the 
induction of differentiation of EC stem cells has been described for the association of specific 
changes in gene expression of cell surface antigens (Ackerman et al. 1994). The differential 
expression of surface antigens serves as an effective method for monitoring cell 
differentiation (Fenderson et al. 1987). In this context, for example, NTERA2 cells have the 
characteristic expression of surface antigens including SSEA3 and SSEA4, but lacking 
expression of SSEA1 (Andrews et al., 1996). Moreover, these cells also show the expression 
of antigens TRA-1-60 and TRA-1-81 (Andrews et al. 1984a; Badcock et al. 1999) along with 
other antigens TRA-2-49 and TRA-2-54 (Andrews et al. 1984c). In case of retinoic acid as 
differentiation inducer all the expressed antigens described above are down regulated coupled 
with the expression of other silent genes such as SSEA1 and many other gangliosides 
glycolipid antigens, playing important role in differentiating different subsets of cells 
(Fenderson et al. 1987). Differentiation induced by HMBA also results in downregulation of 
the antigens induced HMBA are different by those induced by retinoic acid do which 
strengthens the view that HMBA and retinoic acid induce differentiation in distinct cell 
lineages (Andrews et al. 1990). Therefore, retinoic acid and HMBA holds much potential for 
cancer therapy by inducing reprogramming of EC stem cell lines in controlling tumour 
growth. 
 
4.1.1 Cancer-testis antigens (CTAs) and Stem Cells 
The expression of CTA genes has also been described in some types of stem cells such as 
CD34+ hematopoietic stem cells (Steinbach et al., 2002), Mesenchymal stem cells (MSCs) of 
different fetal and adult tissues (Cronwright et al., 2005; Saldanha-Araujo et al., 2010) and 
different ES cell lines (Lifantseva et al., 2011). However, the functional role of these CTAs 
in the stem cells remains to be defined yet, but some evidences suggests a potential role of 
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some CTA in self-renewal capability of stem cells during the early phases of embryonic 
development. In addition, it has been postulated that the expression of CTAs is limited only 
to the cells of a cancer tissue which possess stem cell properties (Ghafouri-Fard and 
Modarressi, 2009; Ghafouri-Fard et al., 2012a).  
Evidence of a higher expression of CTA genes in CSCs compared to differentiated cells were 
revealed from epigenetic studies, shows promoters hypomethylation of CTA genes and 
higher acetylation of histones in CSCs compared with differentiated cells (Yawata et al., 
2010). Therefore the CSCs with a higher expression of CT genes possess great potential in 
providing special therapeutic targets for treatment of cancer recurrences and metastasis 
(Ghafouri-Fard, 2012a; Ghafouri-Fard and Modarressi, 2012). Moreover, in certain tumour 
types, the CTA genes have been investigated as immunotherapy targets against CSCs 
(Yawata et al., 2010). However, it will be of much significance that the MSCs potential for 
possessing CTA genes as target for such therapies could be established. 
A study on mouse suggest that TEX19.1 (one of two isoforms in mouse and related to human 
TEX19 gene) may play a role in the self-renewal of pluripotent stem cells self-renewal. This 
proposal based on localisation of Tex19 protein in mouse ES cell nucleus using 
immunofluorescence technique (Kuntz et al., 2008). Moreover, our data show a link between 
some CTAs genes such as TEX19 and stem cells in human cancer tissue, but the functional 
role and more characterisation are yet achieved. 
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4.2 Results 
4.2.1 Correlation of stem cell markers with TEX19 knockdown 
Based on TEX19 expression profile in cancer cells (Chapter 3)  
We validate Tex19 antibody used by knockdown of TEX19 in SW480 cancer cell-line using 
four different siRNAs. The protein level of Tex19 were observed in the untreated cells along 
with the non-interference RNA, which serves as negative control. However, no (or low) 
protein signals of Tex19 protein were detected in the four TEX19 siRNAs that were used to 
knockdown protein level. And, the detected protein signals of Tubulin were similar in all 
samples (Figure 4.1) consistent three experiments were performed. 
To determine whether there was a correlation between TEX19 and stem cell marker 
expression in NTERA2 cells we knockdown Tex19 with one of the of TEX19 siRNAs, 
(HS_FL35767_6) in NTERA2 cancer cell-line and quantify the expression of stem cells 
markers using qRT PCR.. TEX19 expression was significantly decreased in the siRNA treated 
cells compared to both untreated and non-interference RNA samples. With TEX19 
knockdown, a significant decrease of OCT4 expression was observed compared to untreated 
and non-interfering samples. This finding was consistent with the analysis of further stemness 
markers, SOX2, NANOG, PIWIL1 and PIWIL2 (Figure 4.2) The experiment were done once 
for PIWIL1 and PIWIL2. Therefore, based on qRT-PCR results, there might be a correlated 
expression between TEX19 and stem cell markers such as OCT4, SOX2 and NANOG. 
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Figure 4.1 Knockdown of TEX19 in SW480 cancer cell-line using four siRNAs. It shows all siRNA work 
to knockdown Tex19 in SW480 cells. Untreated and Non-interference samples work as negative 
control. α tubulin was used as a loading control for our western blot. Protein markers (kDa). 
 
 
Table 4.1: quantification of western blot bands of Figure 4.1 including 4 TEX19 siRNA, Non-
interference RNA and Untreated samples. P value <0.01 
Sample Tubulin Density Tubulin Peaks Tex19 Density Tex19 Peaks p value 
HS-1 10051.775 13.948 28.243 0.013 0.005271924 
HS-6 10012.534 13.587 74.607 0.015 0.004455708 
HS-7 4144.861 5.573 14.536 0.007 0.005792518 
HS-8 9472.3 12.676 5.799 0.003 0.001108174 
Ni-1 9864.802 11.901 4472.82 2.104 
 
Ni-6 10201.332 13.012 6852.941 3.224 
 
Ni-7 9450.001 12.802 5901.113 2.776 
 
Ni-8 9420.321 12.001 5448.527 2.563 
 
Un-1 9650.832 11.335 4113.426 1.935 
 
UN-6 10123.666 12.922 7094.698 3.337 
 
UN-7 10113.121 13.202 7743.941 3.643 
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Figure 4.2 qRT-PCR of TEX19 knockdown (S) in NTERA2 cancer cell-line with quantification of 
expression of some stem cell marker genes including OCT4, SOX2, NANOG. Untreated (U) and non-
interfering (N) samples work as a control 
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Table 4.2 qRT-PCR of TEX19 knockdown (S) in NTERA2 cancer cell-line with quantification of 
expression of some stem cell marker genes including OCT4, SOX2, NANOG. showing quantification 
cycle reading (Cq) and standard deviation reading (SEM). The readings were normalised against 
TUBULIN and LAMIN. siRNA sample (S), untreated sample (U) and non-interfering sample (N) 
Target Sample Expression Expression SEM Corrected Expression SEM Mean Cq Cq SEM 
LAMIN N 
   
21.93 0.03062 
LAMIN S 
   
21.24 0.00951 
LAMIN U 
   
24.09 1.45737 
NANOG N 0.84918 0.07009 0.07009 24.83 0.11586 
NANOG S 0.14750 0.02735 0.02735 27.06 0.25442 
NANOG U 2.73833 1.42665 1.42665 24.25 0.18320 
OCT4 N 0.71308 0.05378 0.05378 23.52 0.10526 
OCT4 S 0.07489 0.01414 0.01414 26.47 0.25956 
OCT4 U 2.73833 1.43723 1.43723 22.69 0.20488 
PIWIL1 N 0.90584 0.15618 0.15618 33.86 0.24721 
PIWIL1 S 0.31215 0.07112 0.07112 35.10 0.31817 
PIWIL1 U 2.73833 1.48543 1.48543 33.37 0.28474 
PIWIL2 N 1.26848 0.02992 0.02992 25.06 0.02003 
PIWIL2 S 0.78967 0.04974 0.04974 25.44 0.03795 
PIWIL2 U 1.70924 0.91043 0.91043 25.74 0.24318 
SOX2 N 1.10442 0.07606 0.07606 28.90 0.09547 
SOX2 S 0.18206 0.01731 0.01731 31.20 0.10956 
SOX2 U 2.73833 1.47477 1.47477 28.70 0.26892 
TEX19 N 0.70285 0.06602 0.06602 34.02 0.13270 
TEX19 S 0.10060 0.02602 0.02602 36.52 0.36384 
TEX19 U 2.73833 1.38945 1.38945 33.17 0.06697 
TUBULIN N 
   
18.41 0.04572 
TUBULIN S 
   
18.50 0.16485 
TUBULIN U 
   
18.47 0.04023 
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4.2.2 Evaluation of TEX19 in differentiated NTERA2 cells using RA and HMBA  
With TEX19 knockdown in NTERA2 cancer cells, we observe consequential reduction of 
OCT4 expression in our previous experiment. This suggest a functional association between 
TEX19 and stemness. To determine if Tex19 protein is correlated with Oct4, we carried out 
differentiation of NTERA2 using HMBA and RA conditions. Undifferentiated and DMSO 
conditions were used as a control in this experiment. 
After differentiating NTERA2 using HMBA and RA, the protein level of Tex19 was similar 
and no changes were observed during the differentiation over 6 days in the four conditions 
including untreated, DMSO, RA and HMBA protein lysate of cells (Figure 4.3). Similar 
results were observed for the Tubulin protein, where the level of tubulin protein signals were 
detected in all conditions from day 1 to day 6, which is consistent with the number of cells, 
acquired for the extraction of protein lysate of the samples (Figure 4.5). However, a gradual 
decrease in the protein level of OCT4 were observed throughout the differentiation of 
NTERA2 with RA and HMBA indicating successful differentiation had been induced. After 
four days of the differentiation, no Oct4 protein could be detected in both differentiated 
samples (Figure 4.4). 
The effect of the differentiation process on the growth rate of NTERA2 cells was noted due 
to the reduction of cell proliferation and driving the cells to differentiate. The proliferation 
rate of the untreated cells and DMSO was high compared to the cells differentiated with RA 
and HMBA (Figure 4.6) The experiment was repeated three times for reproducibility of the 
results. 
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Figure 4.3 differentiation of NTERA2 cancer cell-line using RA and HMBA over six days show Tex19 
unaffected after the differentiation. Undifferentiated samples work as a control and DMSO work as a 
control for the differentiated RA samples. Protein markers (kDa) and Undifferentiated sample work 
as loading control. 
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Figure 4.4 Differentiation of NTERA2 cancer cell-line using RA and HMBA over six days show Oct4 
decreased from day 2 and no signals observed after day 4 of the differentiation. Undifferentiated 
samples work as a control and DMSO work as a control for the differentiated RA samples. Protein 
markers (kDa) 
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Figure 4.5 Differentiation of NTERA2 cancer cell-line using RA and HMBA over six days show αTubulin 
signals consistence through the course of differentiation indication level of protein loading. 
Undifferentiated samples work as a control and DMSO work as a control for the RA samples. Protein 
markers (kDa) 
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Figure 4.6 Graph show the proliferation rate of NTERA2 cancer cell-line during the differentiation 
using RA and HMBA over six days. Undifferentiated samples work as a control and DMSO work as a 
control for the RA samples. 
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4.2.3 Influence of TEX19 on NTERA2 differentiation 
To determine whether TEX19 control the ability of stem-like cells to undergo differentiation, 
we depleted TEX19 in NTERA2 cells followed by induction of differentiation. This achieved 
by siRNA-mediated depletion of TEX19 in NTERA2 cells followed by differentiation using 
HMBA and RA for six days. Protein lysate were extracted for western blot and total RNA 
isolated to synthesis cDNA for qRT-PCR. 
The expression level of stem cell marker genes such as OCT4, NANOG and SOX2 declines 
with differentiation of cells with HMBA after TEX19 knockdown compared to the untreated 
sample. This result was similar in all markers used including OCT4, NANOG and SOX2. 
Whereas, TEX19 expression was decrease with differentiation using HMBA after TEX19 
knockdown comparing with the untreated sample (Figure 4.7) The experiment were repeated 
three times for reproducibility of the results. However, the Tex19 protein were detected in the 
HMBA differentiated sample after the knockdown and show no significant changes in the 
protein levels in both sample and the protein signals of HMBA treated cells were similar to 
the untreated one (Figure 4.9). In addition, Oct4 protein decreased in HMBA treated cells 
compared to the untreated cells. Similar tubulin protein levels were detected in both HMBA 
and untreated sample which as consistent with the number of cells used for protein lysate 
(Figure 4.9) 
In contract, the differentiation of NTERA2 using RA after knockdown TEX19 (were repeated 
three times for reproducibility) show an increasing level of TEX19 expression comparing to 
the DMSO. While, stem cell markers expression were decreased in the differentiated cells 
using RA after TEX19 knockdown comparing to DMSO treated cells. Expression of stem cell 
markers decreased including OCT4, NANOG and SOX2 (figure 4.8). Interestingly, Tex19 
80 
 
protein was not detected in RA induced differentiation after TEX19 knockdown compared to 
the DMSO treated cells regardless the overexpression detection of TEX19 using qRT-PCR. 
Similarly, Oct4 protein was not detected in RA induced differentiation after TEX19 
knockdown (Figure 4.9). In addition, Tubulin protein levels were similar in both RA and 
DMSO samples.   
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Figure 4.7: qRT-PCR results of differentiated NTERA2 cancer cell-line using HMBA after knockdown of 
TEX19 and quantification of some stem cell markers including OCT4, SOX2, NANOG. Undifferentiated 
samples provide a control. 
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Table 4.3 TEX19 knockdown followed by HMBA differentiation of NTERA2 cells. qRT PCR of some 
stem cell markers including OCT4, SOX2, NANOG. show quantification cycle reading (Cq) and 
standard deviation reading (SEM). The readings were normalised against TUBULIN and LAMIN. siRNA 
sample (S), untreated sample (U) and non-interfering sample (N) 
Target Sample Expression Expression 
SEM 
Corrected 
Expression 
SEM 
Mean Cq Cq SEM 
LAMIN HMBA 
   
25.04 0.02707 
LAMIN NORMAL 
   
24.75 0.05291 
NANOG HMBA 0.00642 0.00221 0.00221 34.65 0.49508 
NANOG NORMAL 1.08468 0.09070 0.09070 27.22 0.03048 
OCT4 HMBA 0.00172 0.00009 0.00009 32.75 0.07089 
OCT4 NORMAL 1.08468 0.10179 0.10179 23.42 0.06861 
SOX2 HMBA 0.05487 0.00914 0.00914 31.18 0.23941 
SOX2 NORMAL 1.08468 0.21321 0.21321 26.85 0.25844 
TEX19 HMBA 0.77171 0.01197 0.01197 30.07 0.01080 
TEX19 NORMAL 1.08468 0.09500 0.09500 29.55 0.04838 
TUBULIN HMBA 
   
20.06 0.02837 
TUBULIN NORMAL 
   
20.30 0.22737 
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Figure 4.8: qRT-PCR results of differentiated NTERA2 cancer cell-line using RA after knockdown of 
TEX19 and quantify some stem cell markers including OCT4, SOX2, NANOG. DMSO treated sample 
provide a control. 
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Table 4.4 show quantification cycle reading (Cq) and standard deviation reading (SEM). The readings 
were normalised against TUBULIN and LAMIN. siRNA sample (S), untreated sample (U) and non-
interfering sample (N) 
Target Sample Expression Expression 
SEM 
Corrected 
Expression 
SEM 
Mean Cq Cq SEM 
LAMIN DMSO 
   
26.39 0.04243 
LAMIN R.A 
   
28.40 0.37825 
NANOG DMSO 1.00000 0.24413 0.24413 27.03 0.02389 
NANOG R.A 0.47226 0.06813 0.06813 29.58 0.08539 
OCT4 DMSO 1.00000 0.26571 0.26571 25.58 0.15321 
OCT4 R.A 0.04446 0.00632 0.00632 31.53 0.07742 
SOX2 DMSO 1.00000 0.25086 0.25086 29.60 0.08664 
SOX2 R.A 0.28848 0.12302 0.12302 32.85 0.58519 
TEX19 DMSO 0.47802 0.12911 0.12911 31.15 0.16841 
TEX19 R.A 2.75489 0.74902 0.74902 30.09 0.31595 
TUBULIN DMSO 
   
20.91 0.70151 
TUBULIN R.A 
   
21.83 0.03200 
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Figure 4.9 differentiation of NTERA2 cancer cell-line using RA and HMBA after knockdown of TEX19. 
Oct4 protein was detected in undifferentiated and DMSO samples. Tex19 was observed in 
undifferentiated and DMSO and HMBA treated samples. Undifferentiated samples provide a control 
and DMSO provide a control for the RA treated cells. Tubulin was used as control for loading. 
 
Table 4.5: densitometry data of figure 4.9 shows reduction of Oct-4 in RA and HMBA compared 
with UT and DMSO p value <0.05 which reveal the significance of the Oct-4 reduction after 
differentiation. However, no significance of Tex19 in RA and HMBA samples compared with UT 
and DMSO p value <0.899 
 
Sample Tubulin 
density 
Tubulin 
peaks 
Oct-4 density    Oct-4 peaks Tex19 density Tex19 peaks 
UT 31030.288 29.313 36704.874 64.996 4312.548 54.8 
DMDO 16781.368 15.853 18664.811 33.051 749.163 9.52 
RA 31716.158 29.961 0 0 0 0 
HMBA 26330.459 24.873 1103.062 1.953 2807.941 35.681 
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4.2.4 Evaluate TEX19 expression in IPSCs 
In this experiment, IPSCs was prepared by Dr. Faisal Alzahrani, we carry out the knockdown 
of TEX19 in IPSCs. The stem cell marker genes expression were uncorrelated with TEX19 
expression despite the previous experiment results using NTERA2 cell. Here, all stem cell 
marker genes including OCT4, NANOG and SOX2 show high expression in the TEX19 
knockdown sample compared to the non-interference treated sample (Figure 4.10). 
However, differentiate the IPSCs using RA show clear decline in stem cell marker genes 
expression including OCT4, SOX2 and NANOG compared to the undifferentiated sample. 
Interestingly, the expression of TEX19 was correlated with the inhibition of stem cell marker 
genes and show a decreasing of its expression compared to the undifferentiated sample 
(Figure 4.11)   
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Figure 4.10: qRT-PCR of TEX19 knockdown in IPSCs and quantification of stem cell marker genes 
OCT4, SOX2 AND NANOG. Non-interfering sample was used as a control. 
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Figure 4.11: qRT-PCR of TEX19 expression after differentiate IPSCs using RA over 6 days and 
quantification of stem cell marker genes OCT4, SOX2 and NANOG. Undifferentiated sample was used 
as a control 
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Table 4.6 qRT-PCR of TEX19 expression after differentiating IPSCs using RA over 6 days and 
quantification of stem cell marker genes OCT4, SOX2 and NANOG. Quantification cycle reading (Cq) 
and standard deviation reading (SEM). The readings normalised against TUBULIN and GAPDH. siRNA 
sample (S), untreated sample (U) and non-interfering sample (N) 
Target Sample Expression Expression 
SEM 
Corrected 
Expression 
SEM 
Mean Cq Cq SEM 
GAPDH RA 
   
19.96 0.29670 
GAPDH UNDIFF 
   
20.14 0.26976 
NANOG RA 0.00050 0.00019 0.00019 35.68 0.50452 
NANOG UNDIFF 1.06544 0.10007 0.10007 24.05 0.00277 
OCT4 RA 0.00064 0.00009 0.00009 31.30 0.08560 
OCT4 UNDIFF 1.06544 0.11654 0.11654 20.01 0.08094 
SOX2 RA 
     
SOX2 UNDIFF 1.06544 0.27225 0.27225 27.39 0.34286 
TEX19 RA 0.48237 0.07489 0.07489 33.92 0.13838 
TEX19 UNDIFF 1.06544 0.14547 0.14547 32.19 0.14300 
TUBULIN RA 
   
21.15 0.18994 
TUBULIN UNDIFF 
   
19.79 0.02525 
 
 
 
 
 
90 
 
 
4.3 Discussion 
An essential step for studying TEX19 is to test and validate the antibodies in use. For this 
reason, we applied four different small interfering RNA including (HS_FL35767_1, 
HS_FL35767_6, HS_FL35767_7 and HS_FL35767_8) to knockdown TEX19 to validate the 
specificity of our anti-Tex19 antibody (figure 4.1). Densitometry performed and reveal a 
significant knockdown of Tex19 in all four siRNA samples compared with untreated and 
non-interference samples with p value < 0.01. 
Another important step in the characterisation of TEX19 is applying different conditions and 
treatments including differentiated cells using HMBA and RA, and undifferentiated sample 
and DMSO sample control. In addition, we used non-interfering and untreated cells as a 
control for TEX19 depletion. 
Some research studies, investigate the relationship between TEX19 and pluripotency in mice. 
One study carried out on TEX19.1 knockout mice and observed no effect of TEX19.1 deletion 
on the ability to grow unaffected ES cells. In addition, the stem cell marker genes were 
unaffected as well including Oct4, Nanog and Sox2 (Tarabay, et al., 2013). However, another 
study carried out in mouse pluripotent stem cells suggests a similar expression pattern 
between Tex19.1 and the stem cell marker Oct4 (Kuntz et al., 2008). Therefore, to study the 
correlation of TEX19 expression and stem cell markers in NTERA2, which represent a human 
cancer cell-line model that possess stem cell-like features; is important to understand this 
expression pattern. 
The knockdown of TEX19 in NTERA2 consequently affected expression level all stem cell 
marker genes including OCT4, SOX2 and NANOG. This may suggest that expression of these 
genes in NTERA2 requires TEX19. In contrast, the expression of stem cell marker genes was 
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unaffected after TEX19 knockdown in IPSCs, which suggests an independency of stem cells 
marker genes in the IPSCs from TEX19 interaction, which is unlike the NTERA2 model. 
The expression of TEX19 was linked with stem cell markers after differentiation using RA in 
IPSCs. In which, the depletion of TEX19 expression affected those markers; which may 
suggest a pluripotency regulation role for TEX19 in IPSCs (Figure 4.11). However, Tex19 
protein was detected after NTERA2 was differentiated with RA and HMBA (Figure 4.3) and 
the differentiation were succeeded and gradual decrease of Oct4 protein were observed after 
24 hours of the treatment and no Oct4 detected from day 4 of western blot result (Figure 4.4). 
 While, in the NTERA2 model the differentiation with RA after knockdown TEX19 show 
different result; where an increasing level of TEX19 expression accompanied by decreasing 
expression of stem cell marker genes including OCT4, NANOG and SOX2 (Figure 4.8). 
Which may due to a negative feedback loop mechanism activated due to the decreasing 
amount of Tex19 protein in NTERA2 cells that affected by the knockdown and/ or 
differentiation (Figure 4.9). 
Unlikeness, differentiation NTERA2 cells with HMBA after TEX19 knockdown show a 
decrease in expression for both stem cell marker genes and TEX19, which is consistence with 
the findings in the IPSCs experiment that suggest the hypothesized role of TEX19 in 
regulation stemness (Figure 4.7). This conclusion does not contradict with negative feedback 
loop, were high TEX19 expression accompanied by no protein detection in RA differentiation 
after TEX19 knockdown in NTERA2 cells. This clearly seen in the Tex19 protein detected in 
HMBA differentiated cells after knockdown (Figure 4.9). Densitometry data reveal the 
significance of Oct-4 reduction after differentiating the cells using RA and HMBA p value 
<0.05. but, the knockdown of Tex19 with differentiation process show no significance 
change p value <0.899 (table 4.5).  
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5. Evaluation of the effect of TEX19 depletion on transposable 
elements (TE) in cancer cells 
5.1 Transposable Elements (TE) 
Historically, repetitive genetic elements within the human genome were considered as ‘junk 
DNA’. But after the discovery of TEs by Barbara McClintock, the importance of these 
elements has increasingly been recognized. TEs can modify gene structure and expression by 
the process of mobilization, transposition promoted ectopic rearrangements, reshuffle 
sequences all of which can result in conditions leading to genetic disease. 
5.1.1 Introduction 
On the basis of their distinct mechanism of transposition, the TEs are placed into two major 
classes, Class I and Class. The class I transposons are also known as retrotransposons and 
these elements mobilise by a ‘copy and paste’ mechanism, where the process of transposition 
involves an RNA intermediate which, after reverse transcription, is inserted at a new position 
in the genome. Examples include long terminal repeat (LTR) elements in the form of 
endogenous retroviruses (leftovers of viruses which lost their capability to be infectous) and 
non-LTR retrotransposons. These elements make approximately 8% of human genome and 
carryout reverse transcription as a cytoplasmic virus (Lander et al., 2001). Non-LTR 
retrotransposons adopt a different mechanism of transposition, where the RNA copies are 
reverse transcribed and integrated to the genomic DNA through a coupled process (O'Donnell 
and Burns, 2010). Class II or DNA transposons follow the mechanism of 'cut-and-paste' for 
their mobilization, which means the DNA part (transposon) is removed from a site and then 
inserted at a new location. TEs are relatively inactive in mammals, but accompanied with 
some exceptions such as a piggyBac element was first identified to be active in bats (Ray et 
al., 2008). The percentage of DNA transposons in human is as low as 3% of the genome 
(Lander et al., 2001).  
The genome sequences of different mammals have revealed that amongst all of the TE 
families, the retrotransposons can be seen mobile actively in genomes. Moreover, these 
retrotransposons constitute a significant percentage of human genome; LINEs (long 
interspersed nucleotide elements) are the most abundant (18%) and autonomous amongst all 
the retrotransposons in humans. Whereas, the non-autonomous TEs including SINEs (short 
interspersed nucleotide elements) and SVAs [hybrid SINE-R-VNTR (variable number of 
tandem repeat)-Alu elements] mobilization is dependent on a protein encoded by LINE-1 
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(L1) encoded proteins are ~13% of the human genome (Lander et al., 2001; Cordaux and 
Batzer, 2009). 
5.1.2 Link between CT genes in cancer and TE 
There are many tumour antigens but many of those which are presented to human cytotoxic T 
lymphocytes (CTL) by human leukocyte antigen (HLA) class I molecules have been emerged 
as safe immunotherapy targets due to their absence in normal tissues. Amongst such tumour 
specific antigens an important category is CTAs, including; the BAGE, CAGE, GAGE, 
HAGE, LAGE, MAGE, PAGE, NY-ESO-1, SCP and SSX gene families (Simpson et al., 2005; 
see introduction). Expression of CT genes in cancer cells involves a unique mechanism 
through epigenetic regulations. Amongst these epigenetic events DNA methylation has been 
found to have a crucial role in gene expression and correlating with hypomethylated CpG 
dinucleotides in CTA promoters. Moreover, CT gene expression has been evident in some 
types of cancer (Cho et al., 2003; Grunau et al., 2005; Lim et al., 2005; Wang et al., 2006). 
Therefore, CT genes expressed in different tumour can be induced by DNA demethylation or 
by inhibiting deacetylation of histone documented for cutaneous melanoma (Sigalotti et al., 
2004). It has also been reported that in chronic myeloid leukemia (CML) the promotor 
hypomethylation of CT genes result in activation of the LINE1 retrotransposon and often 
related with the disease progression to the advanced phase (Roman-Gomez et al., 2007). 
Hypomethylation is constantly related with LINE1. Therefore, it can tentatively be suggested 
that a genome-wide hypomethylation can be used to reactivate the silenced genes by DNA 
methylation such as CT genes in CML patients (Roman-Gomez et al., 2007).  
 
5.1.3 TEX19 and Retrotransposons in DNA methylation 
The expression profile of TEX19 has been associate with  pluripotency and fertility 
(Ollinger et al., 2008; Tarabay et al., 2013). The underlaying molecular mechanism is still 
unknown. Knockout studies of TEX19.1 in mouse have revealed an over-expression of 
MMERVK10C retrotransposons and the heterogeneous spermatogenic that was initially 
described as TEX19.1 deficient (Ollinger et al., 2008).  
 
DNA hypomethylation can induce retrotransposon activity resulting in genome instability 
reported in the developing germline (Hackett et al., 2012). In addition, the DNA 
hypomethylation in primordial germ cells may induce the expression of genome-defence 
genes including Tex19.1, Mov10l1, Piwil2,  Asz1 and  Dazl  that are sensitive to 
94 
 
hypomethylation and protect the germline DNA from retrotransposon activity (Hackett et al., 
2012). Whereas, inhibition of retrotransposons in testicular germ cells may lead to male 
sterility, which can be induced through mutations in some genes such as Tex19.1, Mov10l1, 
Piwil2  or Asz1 genes. This mutation results in reduction of retrotransposons in testicular 
germ cells. And finally cause male sterility (Reichmann et al., 2013).  
 
Placenta cell genomes are hypomethylated in a fashion similar to primordial germ cells, and 
this hypomethylated condition of the placenta is related to retrotransposons (Reichmann et 
al., 2013). The cytosine in CpG is almost of 40–50% methylated within different classes of 
transposons including LTRs, LINEs and SINEs in the mouse placentas, compared with 
approximately 75–80% in the embryo (Popp et al., 2010). Moreover, the other specific 
classes of retrotransposon, including LINE-1 have also been documented for hypomethylation 
in the placenta.Therefore, DNA hypomethylation of placenta cells can possibly result in 
retrotransposon activation (Reichmann et al., 2013).  
The microarray expression profile of TEX19.1−/− mice from placentas demonstrated that an  
increased expression of LINE-1 retrotransposons has been evident with the loss of Tex19.1 in 
placenta tissue. In addition, a study show that LINE-1 transposons are inhibited in 
trophectoderm-derived cells with hypomethylated epigenetic state, while these cells normally 
express Tex19.1 (Reichmann et al., 2013). 
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5.2 Results 
To commence investigations into the possible functional role of TEX19 in cancer cell, we 
knockdown TEX19 using HS_FLJ35767_6 one of the TEX19 siRNA, in two cancer cell-lines 
including NTERA2 and A2780. Then we quantified the gene expression of human ERVK 
genes and TEX19 using qRT-PCR analysis to determine whether the depletion of TEX19 
resulted in changes to retroelements expression. The data were normalized using TUBULIN 
and LAMIN expression. Untreated and non-interference conditions were applied as a control 
for TEX19 knockdown. In addition, no template control (NTC) and no reverse transcription 
(NRT) samples were applied as a control in both NTERA2 and A2780 cancer cells. 
 
5.2.1 Effect of TEX19 knockdown on ERVK genes expression in NTERA2 
The knockdown of TEX19 was successful and clear reduction of TEX19 expression was 
observed in the siRNA sample compared to the untreated and non-interfering samples (Figure 
5.1). The H ERVK family was reduced after TEX19 knockdown. It is clearly ERVK genes 
expression was reduced including ERVK ENV, ERVK GAG, ERVK HML2RE, ERVK POL 
and ERVK PRO. Their expression was decreased in TEX19 knockdown samples compared to 
a higher level of expression in untreated and non-interfering samples (Figure 5.1) 
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5.1 qRT PCR normalised result of TEX19 knockdown in NTERA2 cancer cell-line show the expression of 
ERVK family TE in three different conditions including untreated, siRNA TEX19 and non-intereferance 
samples. 
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Table 5.1 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
H ERV K ENV N 1.45549 0.21738 0.21738 26.95 0.04595 
H ERV K ENV S 0.68597 0.03093 0.03093 27.41 0.06264 
H ERV K ENV U 1.34324 0.09669 0.09669 26.87 0.01994 
H ERV K GAG N 1.53844 0.32818 0.32818 32.03 0.22450 
H ERV K GAG S 0.52915 0.05243 0.05243 32.95 0.14188 
H ERV K GAG U 1.24837 0.20207 0.20207 32.13 0.21012 
H ERV K HML2 RE N 1.39811 0.35140 0.35140 25.28 0.25497 
H ERV K HML2 RE S 0.33935 0.00455 0.00455 26.70 0.00821 
H ERV K HML2 RE U 1.34324 0.11616 0.11616 25.14 0.07197 
H ERV K POL N 1.53844 0.54536 0.54536 26.86 0.46609 
H ERV K POL S 0.26090 0.02269 0.02269 28.80 0.12425 
H ERV K POL U 0.98122 0.09360 0.09360 27.32 0.09248 
H ERV K PRO N 1.53844 0.28206 0.28206 27.60 0.05910 
H ERV K PRO S 0.40068 0.11915 0.11915 28.92 0.42865 
H ERV K PRO U 1.20195 0.10316 0.10316 27.76 0.07032 
LAMIN N 
   
23.16 0.28049 
LAMIN S 
   
22.30 0.02324 
LAMIN U 
   
23.04 0.12367 
TEX19 N 1.53844 0.38095 0.38095 33.32 0.28863 
TEX19 S 0.53344 0.01953 0.01953 34.22 0.04983 
TEX19 U 1.25445 0.10633 0.10633 33.41 0.06758 
TUBULIN N 
   
18.54 0.31398 
TUBULIN S 
   
18.15 0.02620 
TUBULIN U 
   
18.27 0.16203 
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5.2.2 Effect of TEX19 knockdown on ERVK genes expression in A2780 cancer cells 
In ovarian cancer cell-line A2780, the knockdown of TEX19 was unsuccessful and no 
inhibition of TEX19 expression was observed in the siRNA sample compared with the 
untreated and non-interfering samples. Human ERVK family gene expression were 
significantly increased in TEX19 knockdown samples compared to the untreated and non-
interfering samples. It is clearly shown the expression of ERVK ENV, ERVK GAG, ERVK 
HML2RE, ERVK POL and ERVK PRO were all highly elevated in TEX19 knockdown sample 
comparing with lower level of expression in untreated and non-interfering samples regardless 
the failure knockdown of TEX19 (Figure 5.2) 
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Figure 5.2 qRT PCR normalised result of TEX19 knockdown in A2780 cancer cell-line show the 
expression of ERVK family TE in three different samples including untreated, siRNA TEX19 and non-
intereferance samples. 
 
 
 
 
 
 
100 
 
Table 5.2 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression SEM Corrected 
Expression SEM 
Mean Cq Cq SEM 
ERVK GAG NI 0.41131 0.06340 0.06340 30.02 0.19942 
ERVK GAG SI 1.39636 0.43103 0.43103 28.74 0.29033 
ERVK GAG UT 0.14197 0.03926 0.03926 31.71 0.37043 
ERVK HML2RE NI 0.82043 0.10254 0.10254 28.21 0.15107 
ERVK HML2RE SI 1.39636 0.36393 0.36393 27.92 0.16539 
ERVK HML2RE UT 0.31547 0.03354 0.03354 29.74 0.03906 
ERVK ENV NI 0.70720 0.05032 0.05032 27.14 0.02920 
ERVK ENV SI 1.39636 0.32686 0.32686 26.64 0.00443 
ERVK ENV UT 0.17473 0.03738 0.03738 29.31 0.27070 
ERVK POL NI 0.81196 0.07647 0.07647 27.99 0.09368 
ERVK POL SI 1.39636 0.32820 0.32820 27.69 0.03093 
ERVK POL UT 0.49741 0.05791 0.05791 28.85 0.07884 
ERVK PRO NI 0.57614 0.19845 0.19845 28.11 0.48708 
ERVK PRO SI 1.39636 0.33330 0.33330 27.31 0.06753 
ERVK PRO UT 0.14557 0.01926 0.01926 30.25 0.12008 
LAMIN NI 
   
23.35 0.06471 
LAMIN SI 
   
24.14 0.67005 
LAMIN UT 
   
23.64 0.28996 
TEX19 NI 1.00000 0.07947 0.07947 27.58 0.05880 
TEX19 SI 1.01545 0.24009 0.24009 28.04 0.04831 
TEX19 UT 0.93684 0.11701 0.11701 27.83 0.10231 
TUBULIN NI 
   
17.90 0.18590 
TUBULIN SI 
   
18.08 0.08439 
TUBULIN UT 
   
17.92 0.06263 
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5.2.3 Evaluation of cancer cellular proliferation after TEX19 knockdown using 
ELDA 
In this study, we are trying to assess the effect of TEX19 knockdown on the cellular 
proliferation of NTERA2 and A2780. The ELDA (extreme limiting dilution analysis) assay is 
a method for the assessment of the self-renewal potential of cells. A series of cellular dilution 
were applied in cell seeding including 1000, 100 and 10 cells per well for each condition. 
Light microscope were used to assess the morphological growth of the cells and an image 
were taken from each condition starting from the first day of treatment and on the tenth day 
from both treated cancer cell-line including NTERA2 and A2780. Knockdown TEX19 in 
NTERA2 and A2780 cells were performed using four TEX19 siRNA including 
HS_FLJ35767_1, HS_FLJ35767_6, HS_FLJ35767_7 and HS_FLJ35767_8. Three different 
conditions were applied as a control for this experiment including Hiperfect transfection, 
non-interferance RNA and untreated. These conditions were applied in both cancer cell-line 
with 12 wells repetition per condition for each cancer cell-line. The evaluation of cellular 
proliferation frequency were determined by ELDA web-tool 
(http://bioinf.wehi.edu.au/software/elda/). 
 
5.2.3.1 ELDA assay of TEX19 knockdown in NTERA2 
The knockdown of TEX19 using HS_FLJ35767_1 show significant reduction of cellular 
proliferation in NTERA2 comparing to non-interfering condition (P <.0.01) and the effect of 
transfection agent show no significant effect on cell proliferation (Figure 5.3 and Table 5.3 
and 5.4) this clearly show in pairwise comparison between untreated condition versus non-
interferance or Hiperfect sample which show similar cellular proliferation (P<0.01). In 
contrast, no significance difference was observed in HS_FLJ35767_6 comparing to non-
interferance sample (Figure 5.4, Table 5.3 and Table 5.4). Both HS_FLJ35767_7 and 
HS_FLJ35767_8 show significant reduction in cellular proliferation of NTERA2 comparable 
to non-interfering sample conditions (P<0.01) (Figure 5.5, Figure 5.6, Table 5.3 and Table 
5.4). 
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Figure 5.3. light microscopy images of NTERA2 cancer cells in four conditions including 
HS_FLJ35767_1, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well. Some images were clear during taking the image but after printing 
were not.   
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Figure 5.4. light microscopy images of NTERA2 cancer cells in four conditions including 
HS_FLJ35767_6, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well.   
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Figure 5.5. light microscopy images of NTERA2 cancer cells in four conditions including 
HS_FLJ35767_7, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well. 
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Figure 5.6. light microscopy images of NTERA2 cancer cells in four conditions including 
HS_FLJ35767_8, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well.    
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Table 5.3 show the effect of four TEX19 siRNA effect on NTERA2 cellular proliferation. untreated (U), 
siRNA TEX19 (S), non-intereferance samples (N) and Hiperfect (H) 
TREATMENT POSITIVE TESTED HS_FLJ35767_1 
U 12 12 1000 
U 12 12 100 
U 8 12 10 
S 6 12 1000 
S 2 12 100 
S 0 12 10 
N 10 12 1000 
N 6 12 100 
N 0 12 10 
H 10 12 1000 
H 6 12 100 
H 0 12 10 
TREATMENT POSITIVE TESTED HS_FLJ35767_6 
U 12 12 1000 
U 11 12 100 
U 9 12 10 
S 10 12 1000 
S 8 12 100 
S 0 12 10 
N 10 12 1000 
N 8 12 100 
N 0 12 10 
H 11 12 1000 
H 9 12 100 
H 0 12 10 
TREATMENT POSITIVE TESTED HS_FLJ35767_7 
U 12 12 1000 
U 12 12 100 
U 11 12 10 
S 10 12 1000 
S 6 12 100 
S 0 12 10 
N 11 12 1000 
N 9 12 100 
N 0 12 10 
H 11 12 1000 
H 8 12 100 
H 0 12 10 
TREATMENT POSITIVE TESTED HS_FLJ35767_8 
U 12 12 1000 
U 12 12 100 
U 3 12 10 
S 8 12 1000 
S 4 12 100 
S 0 12 10 
N 10 12 1000 
N 8 12 100 
N 0 12 10 
H 10 12 1000 
H 5 12 100 
H 0 12 10 
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Table 5.4 ELDA pairwise test for differences in NTERA2 cellular proliferation frequency. Untreated 
cells (U), non-interferance (N) and Hiperfect (H). degrees of freedom (DF) and the probability value 
(Pr) 
Group 1 Group 2 Chisq DF Pr(>Chisq) 
H N 1.20 1 0.273 
H HS_FLJ35767_1 1.20 1 0.273 
H U 29.8 1 4.89e-08 
N HS_FLJ35767_1 0 1 1 
N U 43.7 1 3.81e-11 
HS_FLJ35767_1 U 43.7 1 3.81e-11 
H N 0.0758 1 0.783 
H HS_FLJ35767_6 1.55 1 0.213 
H U 61.8 1 3.89e-15 
N HS_FLJ35767_6 2.35 1 0.125 
N U 58.7 1 1.85e-14 
HS_FLJ35767_6 U 81.3 1 1.89e-19 
H N 0.0758 1 0.783 
H HS_FLJ35767_7 1.55 1 0.213 
H U 61.8 1 3.89e-15 
N HS_FLJ35767_7 2.35 1 0.125 
N U 58.7 1 1.85e-14 
HS_FLJ35767_7 U 81.3 1 1.89e-19 
H N 0.498 1 0.48 
H HS_FLJ35767_8 1.36 1 0.244 
H U 33.8 1 6.02e-09 
N HS_FLJ35767_8 3.63 1 0.0568 
N U 28.1 1 1.13e-07 
HS_FLJ35767_8 U 46.7 1 8.46e-12 
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5.2.3.2 ELDA assay of TEX19 knockdown in A2780 cells 
No significant cellular proliferation frequency of A2780 cancer cells were observed using 
four TEX19 siRNA including HS_FLJ35767_1 (Figure 5.7), HS_FLJ35767_6 (Figure 5.8), 
HS_FLJ35767_7 (Figure 5.9) and HS_FLJ35767_8 (Figure 5.10) compared with non-
interferance condition, Hiperfect transfection and untreated. The cellular proliferation of 
A2780 cells keep increasing regardless transfection or siRNA applied. 
Relative decrease in cellular proliferation were observed only in low number of cells plated 
such as 10 cells per well. (Table 5.5) However, ELDA assay web-tool did not show data with 
statistically significant differences. 
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Figure 5.7. Light microscopy images of A2780 cancer cells in four conditions including 
HS_FLJ35767_1, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well.   
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Figure 5.8. light microscopy images of A2780 cancer cells in four conditions including 
HS_FLJ35767_6, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well.   
 
 
 
HS_FLJ35767_6 UNTREATED 
NON 
INTERFERENCE HIPERFECT 
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. light microscopy images of A2780 cancer cells in four conditions including 
HS_FLJ35767_7, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well.   
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Figure 5.10 light microscopy images of A2780 cancer cells in four conditions including 
HS_FLJ35767_8, non-interferance, Hiperfect and untreated cells. Numbers on the right hand side 
denote cell number per well.   
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Table 5.5 show the effect of four TEX19 siRNA effect on A2780 cellular proliferation. This experiment 
was repeated 12 times per condition in 6 well plate from confluent A2780 cells. untreated (U), siRNA 
TEX19 (S), non-intereferance samples (N) and Hiperfect (H) 
TREATMENT POSITIVE TESTED HS_FLJ35767_1 
U 12 12 1000 
U 12 12 100 
U 12 12 10 
S 12 12 1000 
S 10 12 100 
S 10 12 10 
N 12 12 1000 
N 12 12 100 
N 12 12 10 
H 12 12 1000 
H 12 12 100 
H 12 12 10 
TREATMENT POSITIVE TESTED HS_FLJ35767_6 
U 12 12 1000 
U 12 12 100 
U 12 12 10 
S 12 12 1000 
S 10 12 100 
S 10 12 10 
N 12 12 1000 
N 12 12 100 
N 12 12 10 
H 12 12 1000 
H 12 12 100 
H 12 12 10 
TREATMENT OPSITIVE TESTED HS_FLJ35767_7 
U 12 12 1000 
U 12 12 1000 
U 12 12 1000 
S 12 12 1000 
S 12 12 1000 
S 10 12 1000 
N 12 12 1000 
N 12 12 1000 
N 12 12 1000 
H 12 12 1000 
H 12 12 1000 
H 12 12 1000 
TREATMENT POSITIVE TESTED HS_FLJ35767_8 
U 12 12 1000 
U 12 12 1000 
U 12 12 1000 
S 12 12 1000 
S 10 12 1000 
S 10 12 1000 
N 12 12 1000 
N 12 12 1000 
N 12 12 1000 
H 12 12 1000 
H 12 12 1000 
H 12 12 1000 
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5.3 Discussion 
The correlation of expression of ERVK family of TEs with TEX19 expression in the NTERA2 
cancer cell line was clearly shown in this experiment. The reduction of the expression of 
ERVK family genes using TEX19 knockdown in NTERA2 was observed, including ERVK 
ENV, ERVK GAG, ERVK HML2RE, ERVK POL and ERVK PRO. The expression of ERVK 
family genes are consistent with ERVK genes profiles, since,the ERVK family genes show 
high expression profile in ESCs (Kelley and  Rinn, 2012) In addition, NTERA2 is a well-
characterised cancer cell-line that is composed of pluripotent embryonal carcinoma (EC) cells 
capable of differentiation into neuron cells using RA induction (Andrews  et al., 1982). In 
addition, human ESCs and EC cells share some pluripotency characteristics (Abu Dawud et 
al., 2012) However, the reduction of ERVK genes expression after knockdown of TEX19 
expression in NTERA2 were contradictory with some other studies including activation of 
LINE-1 transposonas after TEX19.1 deletion in the mouse placenta (Reichmann et al., 2013). 
Moreover, deletion of TEX19.1 in the mouse causes upregulation of retrotransposons 
including mouse ERVK genes (Ollinger et al., 2008). Therefore, collectively, we suggest that 
TEX19 may be involve in ERVK genes regulation in EC cells of NTERA2 differently from its 
role in testis. Alternatively, this might reveal difference between the mouse and human. 
In contrast, attempted TEX19 knockdown in A2780 show an increasing expression of ERVK 
genes including ERVK ENV, ERVK GAG, ERVK HML2RE, ERVK POL and ERVK PRO. 
Regardless the failure of TEX19 expression knockdown in A2780, the elevation of human 
ERVK genes after TEX19 knockdown were consistence with some studies including the 
upregulation of retrotransposons in mouse after deletion TEX19.1 gene (Ollinger et al., 2008). 
In addition, the activation of LINE-1 transposons in placenta after TEX19.1 deletion 
(Reichmann et al., 2013). Here, the activation of human ERVK genes in A2780 cancer cells 
after attempted kncockdown TEX19 may support a hypothetical role of TEX19 in transposons 
suppression. 
Overall, these two opposite findings of upregulation and down-regulation of human ERVK 
genes after knockdown of TEX19 in A2780 and NTERA2 may be related to role that TEX19 
may play in EC cells of NTERA2.  
The apparent failure of TEX19 expression reduction should be treated with caution, however, 
and these experiments should be repeated to confirm these findings. 
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The effect on cell proliferation of NTERA2 cancer cells following TEX19 depletion was 
significant using TEX19 siRNA  including HS_FLJ35767_1, HS_FLJ35767_7 and 
HS_FLJ35767_8 compared with non-interference. This significant changes in cell 
proliferation of NTERA may suggest the important role of TEX19 in NTERA2 cancer cells. 
In addition, the significant cell proliferation frequency of NTERA2 after knockdown TEX19 
is consistence with previous q-RT-PCR and western blot, which assume the neccecity of 
TEX19 gene in NTERA2 cells. However, knockdown of TEX19 expression in A2780 cancer 
cells did not show cellular proliferation frequency using four TEX19 siRNA including 
HS_FLJ35767_1, HS_FLJ35767_6, HS_FLJ35767_7 and HS_FLJ35767_8. This may 
indicate that A2780 cells proliferation does not require TEX19. Moreover, morphological 
comparisons of A2780 cells show no significant cell proliferation frequency between 
untreated, siRNA, non-interference and Hiperfect. 
The failure to demonstrate TEX19 expression reduction in A2780, however, should be treated 
with caution and these experiment should be repeated. Moreover, the success of crispr 
technology developments means gene deletions could be applied to these cell systems to 
further explore function. The data presented here provide clues to a possible need for TEX19 
in cancer cells based on a retroelements regulation control, but further investigation is 
required. 
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Chapter 6. Evaluation the influence of TEX19 depletion in cancer 
cell based on RNA sequencing data 
6.1. RNA Sequencing 
RNA sequencing is important for studying the transcriptome, which is the total complement 
of transcripts in a cell. Knowing the RNA sequence helps in understanding some mechanisms 
of inheritance and functional genetic regulations. Several techniques are used to characterize 
the cellular transcriptome including techniques based on Sanger sequencing (Bertone et al., 
2004; David et al., 2006). With the introduction of high-throughput sequencing methods the 
study of the genome and the transcriptome has become easier and faster. RNA sequencing is 
performed by direct sequencing of cDNAs, and the cDNA sequencing results are then 
followed by mapping of the sequencing reads to the genome. The resulting cDNA sequences 
are helpful to understand the eukaryotic transcriptomes. Moreover, this sequence is used to 
find the transcription start sites (Tsuchihara et al., 2009), identifying splice variants, and 
detecting expression. In addition, the sequence can be used for estimating the expression and 
splice variants of exons (Cloonan et al., 2008; Wang et al., 2009). RNA sequencing involves 
formation of a cDNA library using oligo (dT) or random primers. The generation of cDNA is 
carried out by using polyA+ RNA followed by fragmentation through DNase I and ligated to 
the adapters. Sequencing is usually completed using an Illumina Genome Analyzer. 
(Nagalakshmi et al., 2010). 
6.1.1 Preparation of cDNA library from hydrolyzed or fragmented RNA 
RNA molecules to be sequenced are fragmented by partial hydrolysis instead of cDNA 
fragmentation. These fragmented RNA molecules are used to generate cDNA library using 
reverse transcriptase along with oligo(dT) or random hexamers primers followed by 
sequencing by Illumina Genome Analyzer (Nagalakshmi et al., 2010).  
6.1.2 DNA sequencing and data analysis 
There are many sequencing methods available for DNA sequencing including Roche/454 
FLX, Illumina genome analyser, Applied Biosystems SOLiDTM System, the Helicos 
HeliscopeTM, Pacific Biosciences SMRT (Mardis, 2008). All these methods have some 
specific differences at different steps but main scheme almost the same. Here the details of 
Illumina genome analyser is described as RNA-Seq uses this method.  
The RNA-Sequencing uses Illumina genome analyzer for DNA sequencing. Mapping of 
sequence reads utilises bioinformatics for analyzing the sequencing (Wang et al., 2009). 
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cDNA sequencing reads utilising Illumina Genome Analyzer is done in two steps. The first 
step includes preparation of flow-cell, utilizing a cluster station, which involves loading of 
double-stranded template sequence to flow-cell with covalently bound oligos. The template 
strands are hybridized with the oligos on flow-cell surface. The second strand of template 
will be synthesized here. This double stranded template is again denatured and free end of 
separated strand again bound to oligos from complementary region and again synthesises 
double stranded template. In this way a second template strand is synthesized. The process is 
repeated to create clusters of identical DNA strands.  In second step the Genome Analyzer 
synthesize the sequence through the process of synthesis of complementary strand by adding 
one nucleotide at a time to the DNA bound to fluorophore.  
The software of Illumina analyser converts the fluorophore information to sequence data. The 
RNA-Seq data can be analysed using many tools of bioinformatics. Firstly, a combination of 
BLAT (Kent, 2002) and SOAP (Li et al., 2008) is used for mapping sequence reads. SOAP 
program is used as a fast mapping of sequence reads tool whereas BLAT is useful for 
mapping gapped reads. 
6.1.3 RNA sequencing in cancer 
One of important tools to explore transcriptome and identify variation of genes expression is 
RNA sequencing, which have been employed in cancer research. For example, identification 
of some microbial pathogens related to prostate cancer were achieved using RNA sequencing 
(Chen and Wei, 2015). In esophageal squamous cell carcinoma, RNA sequencing reveal 
genes that were dysregulated in this cancer. These identified genes may serve in early 
diagnosis and therapy (Fu et al., 2015). Moreover, in breast cancer, 24 newly identified 
fusion genes were achieved using RNA sequencing (Edgren et al., (2011). 
Using RNA sequencing, genes affected by CTCFL expression were identified. CTCFL is a 
CT gene involve in dysregulation of some genes, which affect TGFP pathway in the mouse, 
which consequently lead to growth retardation and fatality (Sati et al., 2015).  
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6.2 Results 
Initially TEX19 knockdown were performed, using HS_FLJ35767_6 one of TEX19 siRNA, in 
SW480 cancer cells (this was carried out by a colleague in the group Vicente Planells Palop). 
Then, total RNA isolation were performed to synthesize cDNA. qRT-PCR was used to 
validate TEX19 knockdown. Then, RNA samples of TEX19 knockdown and non-interference 
control were sent for RNA sequencing. Dr. Julia Feichtinger performed the computation 
analysis of RNA sequencing data. 
In addition, TEX19 knockdown were performed, using HS_FLJ35767_ in another three 
cancer cells including H460, NTERA2 and A2780. Then, total RNA isolation were 
performed to synthesize cDNA. qRT-PCR was used to validate TEX19 knockdown. Vicente 
Planells Palop performed the treatment and RNA isolation for SW480, A2780 and H460. 
Where this experiment was carried out by me and cDNA was achieved for these cells, 
however, our laboratory sent Mr Vincenta’s samples for RNA sequencing due to cost issue 
and no significance to do so.  
Based on RNA sequencing data analysis from SW480, we identified a cohort of 80 genes 
with altered expression in response to TEX19 depletion were identified. From this list, we set 
out to validate these expression changes in H460, A2780, SW40 and NTERA2 to identify 
common gene changes in response to TEX19 depletion. I was allocated 20 of these genes 
including 10 upregulated genes and 10 downregulated genes (Table 6.1).  
The quantification of gene expression for the 20 selected genes from RNA sequencing data 
were normalized against TUBULIN and LAMIN. Moreover, untreated and non-interference 
conditions were applied as a control for TEX19 knockdown. No template control (NTC) and 
no reverse transcription (NRT) samples were also applied as a control in all qRT-PCR 
analysis.  
6.2.1 Evaluation the genetic expression influence of TEX19 knockdown in SW480 
Knockdown of TEX19 expression in SW480 influences some genes in this study; GALNT2 
expression was increased with TEX19 expression knockdown compared to both untreated and 
non-interference sample (Figure 6.1). This elevation of expression in TEX19 knockdown 
sample were observed for other genes in this study, including ELK4, ASB2, CD22, CALB2, 
CPS1, LY96, SLC17A7 and TRIM54 (Figure 6.2, Figure 6.3 and Figure 6.4). In contrast, some 
show correlated low expression in the TEX19 expression knockdown sample including 
NAPB, RIPA, MRP523 and SAA2 compared to the untreated and non-interference sample 
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(Figure 6.1 and Figure 6.2). Some gene expression show no significant changes, however, 
such as MPEP, PGM1, ATP5C1 and ZBTB5 compared to both treated and non-interfering 
samples (Figure 6.1 and Figure 6.2). In addition, NOS3 shows higher expression compared to 
untreated sample and no comparable significant expression changes were observed to non-
interference sample (Figure 6.3). Moreover, both TAGLN and ZNF367 show no expression 
difference compared to untreated sample. While, a clear expression inhibition were observed 
for TAGLN compared to non-interfering sample, and high expression of ZNF367 were 
observed compared to non-interfering sample (Figure 6.3). 
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Table 6.1 RNA sequence data analysis of selected 20 genes affected by TEX19 knockdown in SW480 
cancer cells.  
Gene  Adjusted 
p Value 
Average count 
KO 
Average count 
N 
Fold 
change 
log2 fold 
change 
Stran
d 
MIPEP 0 826 1804.666667 0.45770225 -1.1275187 -1 
PGM1 0 708.6666667 1910 0.37102967 -1.430393542 1 
NAPB 0 344.3333333 784 0.43920068 -1.187047806 -1 
GALNT2 0 1081 2472.666667 0.43717983 -1.193701244 1 
TAGLN 0 944.3333333 342 2.76120858 1.465299871 1 
RPIA 0 853 2431.666667 0.35078821 -1.511327831 1 
ELK4 0 721.6666667 1463.333333 0.49316629 -1.019853915 -1 
NOS3 0 366 179.3333333 2.04089219 1.029199976 1 
ZNF367 0 2090.666667 923.3333333 2.26425993 1.179039583 -1 
ATP5C1 0 2328 6496 0.35837438 -1.480460574 1 
ZBTB5 0 398.3333333 847 0.47028729 -1.088385757 -1 
MRPS23 0 1460 2959.333333 0.49335436 -1.019303839 -1 
SAA2 2.88E-11 138.6666667 280.3333333 0.49464923 -1.015522272 -1 
CD22 1.23E-09 162.6666667 77 2.11255411 1.078988296 1 
SLC17A
7 
2.95E-08 117 51.33333333 2.27922078 1.18854068 -1 
ASB2 8.59E-07 200.6666667 81 2.47736626 1.308807173 -1 
CPS1 0.000178
6 
57.33333333 21.66666667 2.64615385 1.403896942 1 
CALB2 0.000265
1 
87.66666667 38.33333333 2.28695652 1.193428938 1 
TEX19 0.009333 20.66666667 45 0.45925926 -1.122619287 1 
TRIM54 0.02034 3 13.33333333 0.225 -2.152003093 1 
LY96 0.03967 26.66666667 13 2.05128205 1.036525876 1 
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Figure 6.1 qRT PCR in SW480 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.2 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading was 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and untreated 
sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
GALNT-2 N 1.00000 0.02829 0.02829 27.15 0.03355 
GALNT-2 S 1.14351 0.04020 0.04020 27.27 0.01807 
GALNT-2 U 0.96611 0.03859 0.03859 27.51 0.02497 
LAMIN N 
   
21.58 0.02324 
LAMIN S 
   
21.89 0.04739 
LAMIN U 
   
21.89 0.05193 
MIPEP N 1.00000 0.14041 0.14041 26.39 0.20124 
MIPEP S 1.15421 0.12659 0.12659 26.49 0.15097 
MIPEP U 1.13716 0.10326 0.10326 26.51 0.12027 
NAPB N 1.00000 0.06205 0.06205 28.74 0.08645 
NAPB S 0.88000 0.03341 0.03341 29.24 0.02747 
NAPB U 1.19439 0.07410 0.07410 28.79 0.07290 
PGM1 N 1.00000 0.05491 0.05491 26.27 0.07574 
PGM1 S 1.08898 0.07362 0.07362 26.46 0.08525 
PGM1 U 1.02854 0.09933 0.09933 26.54 0.12929 
RIPA N 1.00000 0.02235 0.02235 24.73 0.02236 
RIPA S 0.79208 0.03615 0.03615 25.38 0.04572 
RIPA U 0.91934 0.03586 0.03586 25.16 0.02166 
TEX19 N 1.00000 0.06862 0.06862 31.89 0.09624 
TEX19 S 0.19130 0.01646 0.01646 34.59 0.11475 
TEX19 U 1.09067 0.09108 0.09108 32.07 0.10871 
 
 
123 
 
 
 
 
 
 
Figure 6.2 qRT PCR in SW480 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.3 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
ATP5C1 N 1.00000 0.04337 0.04337 22.95 0.05970 
ATP5C1 S 1.08789 0.11356 0.11356 23.12 0.14435 
ATP5C1 U 1.18830 0.06073 0.06073 22.99 0.03829 
ELK4 N 0.79701 0.04296 0.04296 26.31 0.07547 
ELK4 S 1.22273 0.04112 0.04112 25.98 0.02256 
ELK4 U 0.76715 0.05251 0.05251 26.66 0.07602 
LAMIN N 
   
21.10 0.02715 
LAMIN S 
   
21.42 0.08371 
LAMIN U 
   
21.34 0.02614 
MRP523 N 1.00000 0.02885 0.02885 23.66 0.03716 
MRP523 S 0.92216 0.03539 0.03539 24.07 0.03494 
MRP523 U 1.06955 0.05841 0.05841 23.86 0.04728 
SAA2 N 1.00000 0.01900 0.01900 22.76 0.02000 
SAA2 S 0.31751 0.03401 0.03401 24.71 0.14843 
SAA2 U 1.11093 0.06430 0.06430 22.90 0.05479 
TEX19 N 0.96804 0.01873 0.01873 31.42 0.02069 
TEX19 S 0.20946 0.03256 0.03256 33.92 0.22013 
TEX19 U 1.22403 0.09280 0.09280 31.38 0.08940 
TUBULIN N 
   
18.10 0.02583 
TUBULIN S 
   
18.36 0.01929 
TUBULIN U 
   
18.45 0.12329 
ZBTB5 N 1.00000 0.13151 0.13151 28.04 0.18880 
ZBTB5 S 0.96706 0.02981 0.02981 28.38 0.01150 
ZBTB5 U 0.82774 0.05921 0.05921 28.60 0.08173 
125 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 qRT PCR in SW480 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.4 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Relative 
Quantity 
Relative 
Quantity SEM 
Corrected Relative 
Quantity SEM 
Mean 
Cq 
Cq SEM 
ASB2 N 0.26824 0.16970 0.16970 32.41 0.91273 
ASB2 S 1.00000 0.07060 0.07060 30.51 0.10185 
ASB2 U 0.28554 0.05747 0.05747 32.32 0.29038 
CD22 N 0.60687 0.01821 0.01821 30.01 0.04328 
CD22 S 1.00000 0.08822 0.08822 29.29 0.12728 
CD22 U 0.56460 0.07402 0.07402 30.12 0.18915 
LAMIN N 1.00000 0.02131 0.02131 21.20 0.03075 
LAMIN S 0.86918 0.02462 0.02462 21.40 0.04087 
LAMIN U 0.86990 0.03226 0.03226 21.40 0.05351 
NOS3 N 0.95022 0.06921 0.06921 28.55 0.10508 
NOS3 S 1.00000 0.02290 0.02290 28.47 0.03304 
NOS3 U 0.51407 0.11194 0.11194 29.43 0.31415 
TAGLN N 1.00000 0.11390 0.11390 32.62 0.16433 
TAGLN S 0.61637 0.04799 0.04799 33.32 0.11232 
TAGLN U 0.69666 0.10389 0.10389 33.14 0.21514 
TEX19 N 1.00000 0.05079 0.05079 31.36 0.07328 
TEX19 S 0.14870 0.00615 0.00615 34.11 0.05966 
TEX19 U 0.78798 0.04538 0.04538 31.71 0.08308 
TUBULIN N 1.00000 0.01446 0.01446 18.31 0.02086 
TUBULIN S 0.75274 0.02168 0.02168 18.72 0.04154 
TUBULIN U 0.81439 0.02915 0.02915 18.61 0.05164 
ZNF367 N 0.74008 0.02848 0.02848 25.87 0.05551 
ZNF367 S 0.96313 0.00909 0.00909 25.49 0.01362 
ZNF367 U 1.00000 0.07998 0.07998 25.43 0.11539 
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Figure 6.4 qRT PCR in SW480 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.5 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). p value <0.05 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
CALB2 N 0.87144 0.06097 0.06097 32.73 0.09530 
CALB2 S 1.20439 0.10933 0.10933 32.53 0.12741 
CALB2 U 0.65341 0.03756 0.03756 33.42 0.07908 
CPS1 N 0.34873 0.04607 0.04607 32.22 0.18766 
CPS1 S 1.20439 0.03668 0.03668 30.70 0.03184 
CPS1 U 0.42142 0.05605 0.05605 32.23 0.19026 
LAMIN N 
   
21.01 0.05262 
LAMIN S 
   
21.23 0.03476 
LAMIN U 
   
21.28 0.03273 
LY96 N 0.33747 0.02065 0.02065 30.75 0.08179 
LY96 S 1.20439 0.27020 0.27020 29.18 0.32224 
LY96 U 0.42905 0.03429 0.03429 30.68 0.11256 
SLC17A7 N 0.57800 0.04247 0.04247 30.07 0.10067 
SLC17A7 S 1.20439 0.02618 0.02618 29.28 0.00814 
SLC17A7 U 0.60882 0.07680 0.07680 30.27 0.18027 
TEX19 N 1.00000 0.02578 0.02578 31.15 0.01667 
TEX19 S 0.22851 0.02480 0.02480 33.55 0.15364 
TEX19 U 0.96837 0.09477 0.09477 31.48 0.13897 
TRIM54 N 0.89928 0.05951 0.05951 32.69 0.08949 
TRIM54 S 1.20439 0.07628 0.07628 32.53 0.08620 
TRIM54 U 0.62160 0.09768 0.09768 33.50 0.22534 
TUBULIN N 
   
18.14 0.04067 
TUBULIN S 
   
18.46 0.04961 
TUBULIN U 
   
18.43 0.03768 
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6.2.2 Evaluation the genetic expression influence of TEX19 knockdown in A2780 
qRT PCR results shows expression of some genes is not affected with TEX19 knockdown in 
A2780 cancer cells including MPEP, NAPB, PGM1, RIPA, ATP5C1, SLC17A7, CPS1 and 
CALB2 where the expression did not changed significantly compared to both untreated and 
non-interference samples except GALANT2 (Figure 6.5, Figure 6.6 and Figure 6.8). However, 
four genes had expression elevated in the knockdown sample compared to both untreated and 
non-interfering samples including GALANT2, ZBTB5, ZNF367 and TRIM54 (Figure 6.5, 
Figure 6.6, Figure 6.7 and Figure 6.8).  In addition, SAA2 show an increasing expression with 
TEX19 expression knockdown in A2780 compared to untreated sample and lower expression 
compared to non-interference sample. Moreover, MRP523 show lower expression with 
TEX19 knockdown compared to non-interfering sample. Nevertheless, the expression 
changes were insignificant compared to untreated sample (Figure 6.6). Another result was 
observed in ASB2 expression with TEX19 expression knockdown, an increasing expression 
comparable to untreated sample and reversely low expression comparable to non-interfering 
sample (Figure 6.7). SLC17A7 expression in TEX19 knockdown sample were elevated 
compared to non-interference sample and low expression observed compared to untreated 
sample (Figure 6.8). CD22 and NOS3 show no difference in their expression compared to 
non-interfering sample and both were highly expressed compared to untreated sample (Figure 
6.7). Insignificant expression change were observed in TAGLN compared to untreated 
sample, and low expression were observed compared to non-interfering sample (Figure 6.7).  
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Figure 6.5 qRT PCR in A2780 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.6 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Ctrl Expressio
n 
Expressio
n SEM 
Corrected 
Expressio
n SEM 
Mean Cq Cq SEM 
GALNT2 N 
 
0.87729 0.02481 0.02481 26.04 0.03390 
GALNT2 S 
 
1.20762 0.04038 0.04038 25.85 0.04362 
GALNT2 U 
 
1.06116 0.03549 0.03549 25.92 0.03866 
LAMIN N 
    
24.39 0.03210 
LAMIN S 
    
24.75 0.02207 
LAMIN U 
    
24.70 0.05648 
MIPEP N 
 
1.00148 0.03157 0.03157 26.45 0.03941 
MIPEP S 
 
1.04258 0.03475 0.03475 26.67 0.04345 
MIPEP U 
 
0.93295 0.07289 0.07289 26.71 0.10896 
NAPB N 
 
1.00148 0.02401 0.02401 30.75 0.02057 
NAPB S 
 
1.07285 0.08804 0.08804 30.92 0.11658 
NAPB U 
 
0.93492 0.07961 0.07961 30.99 0.11941 
PGM1 N 
 
1.00148 0.18506 0.18506 25.64 0.26563 
PGM1 S 
 
1.13485 0.06084 0.06084 25.73 0.07456 
PGM1 U 
 
1.01391 0.07558 0.07558 25.77 0.10359 
RPIA N 
 
1.00148 0.17268 0.17268 24.55 0.24771 
RPIA S 
 
1.10139 0.02006 0.02006 24.69 0.01633 
RPIA U 
 
1.09750 0.06742 0.06742 24.57 0.08379 
TEX19 N 
 
1.00148 0.05390 0.05390 30.99 0.07426 
TEX19 S 
 
0.73518 0.09499 0.09499 31.71 0.18527 
TEX19 U 
 
0.96540 0.03266 0.03266 31.19 0.03934 
TUBULIN N 
    
19.39 0.03211 
TUBULIN S 
    
19.58 0.03477 
TUBULIN U 
    
19.39 0.01202 
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Figure 6.6 qRT PCR in A2780 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.7 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Relative 
Quantity 
Relative 
Quantity SEM 
Corrected Relative 
Quantity SEM 
Mean 
Cq 
Cq SEM 
ATP5C1 N 1.00000 0.01971 0.01971 22.36 0.02843 
ATP5C1 S 0.80242 0.06002 0.06002 22.68 0.10791 
ATP5C1 U 0.89708 0.08350 0.08350 22.52 0.13428 
ELK4 N 0.89851 0.05726 0.05726 25.99 0.09194 
ELK4 S 1.00000 0.08478 0.08478 25.84 0.12231 
ELK4 U 0.77410 0.05216 0.05216 26.21 0.09722 
LAMIN N 1.00000 0.03434 0.03434 24.39 0.04955 
LAMIN S 0.75901 0.02793 0.02793 24.79 0.05309 
LAMIN U 0.75544 0.02249 0.02249 24.80 0.04295 
MRPS23 N 1.00000 0.02946 0.02946 24.09 0.04250 
MRPS23 S 0.84725 0.04899 0.04899 24.33 0.08341 
MRPS23 U 0.83656 0.07051 0.07051 24.34 0.12160 
SAA2 N 1.00000 0.01934 0.01934 26.82 0.02790 
SAA2 S 0.76577 0.02037 0.02037 27.21 0.03837 
SAA2 U 0.62928 0.03781 0.03781 27.49 0.08668 
TEX19 N 1.00000 0.04568 0.04568 31.29 0.06590 
TEX19 S 0.60110 0.05371 0.05371 32.02 0.12891 
TEX19 U 0.90278 0.00671 0.00671 31.44 0.01072 
TUBULIN N 1.00000 0.05000 0.05000 19.36 0.07214 
TUBULIN S 0.89798 0.05511 0.05511 19.52 0.08854 
TUBULIN U 0.98442 0.02010 0.02010 19.38 0.02945 
ZBTB5 N 0.90273 0.06016 0.06016 28.92 0.09614 
ZBTB5 S 1.00000 0.03360 0.03360 28.77 0.04847 
ZBTB5 U 0.85258 0.02337 0.02337 29.00 0.03955 
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Figure 6.7 qRT PCR in A2780 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.8 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean Cq Cq SEM 
ASB2 N 1.00000 0.03564 0.03564 33.61 0.02566 
ASB2 S 0.83411 0.05007 0.05007 34.22 0.07515 
ASB2 U 0.32588 0.00780 0.00780 35.41 0.00944 
CD22 N 1.00000 0.09969 0.09969 36.89 0.13675 
CD22 S 0.93884 0.03962 0.03962 37.33 0.00000 
CD22 U 0.24376 0.05295 0.05295 39.11 0.31160 
LAMIN N 
   
24.67 0.02801 
LAMIN S 
   
25.11 0.06737 
LAMIN U 
   
25.03 0.05348 
NOS3 N 1.00000 0.11256 0.11256 31.00 0.15826 
NOS3 S 0.94309 0.03618 0.03618 31.43 0.03477 
NOS3 U 0.63854 0.09278 0.09278 31.83 0.20698 
TAGLN N 1.00000 0.10747 0.10747 31.71 0.15071 
TAGLN S 0.61645 0.07468 0.07468 32.76 0.17120 
TAGLN U 0.65836 0.01620 0.01620 32.50 0.01257 
TEX19 N 1.00000 0.03795 0.03795 30.43 0.03183 
TEX19 S 0.98446 0.03455 0.03455 30.80 0.02665 
TEX19 U 0.52368 0.01409 0.01409 31.55 0.02779 
TUBULIN N 
   
19.58 0.06715 
TUBULIN S 
   
19.84 0.02011 
TUBULIN U 
   
19.59 0.00899 
ZNF367 N 1.00000 0.05768 0.05768 28.02 0.07484 
ZNF367 S 1.25836 0.07188 0.07188 28.03 0.07453 
ZNF367 U 1.06171 0.02517 0.02517 28.11 0.00822 
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Figure 6.8 qRT PCR in A2780 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.9 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sampl
e 
Expressio
n 
Expression SEM Corrected 
Expression SEM 
Mean Cq Cq SEM 
CALB2 N 1.00000 0.21953 0.21953 35.71 0.31643 
CALB2 S 1.12404 0.17199 0.17199 35.82 0.21946 
CALB2 U 0.87093 0.12518 0.12518 36.17 0.20393 
CPS1 N 1.00000 0.05049 0.05049 30.59 0.07161 
CPS1 S 1.14679 0.05092 0.05092 30.67 0.05946 
CPS1 U 1.08495 0.08930 0.08930 30.73 0.11264 
LAMIN N 
   
24.18 0.01707 
LAMIN S 
   
24.54 0.03167 
LAMIN U 
   
24.59 0.07453 
LY96 N 0.20228 0.04452 0.04452 39.68 0.31708 
LY96 S 0.51099 0.01477 0.01477 38.63 0.02975 
LY96 U 1.20122 0.27424 0.27424 37.38 0.32614 
SLC17A7 N 1.00000 0.03138 0.03138 29.78 0.04328 
SLC17A7 S 1.16437 0.08293 0.08293 29.85 0.09994 
SLC17A7 U 1.07890 0.14339 0.14339 29.94 0.18802 
TEX19 N 1.00000 0.04009 0.04009 30.59 0.05628 
TEX19 S 0.77166 0.02928 0.02928 31.25 0.04928 
TEX19 U 1.02066 0.08622 0.08622 30.82 0.11593 
TRIM54 N 0.80385 0.08962 0.08962 34.58 0.16029 
TRIM54 S 1.21846 0.15781 0.15781 34.27 0.18532 
TRIM54 U 0.61223 0.08292 0.08292 35.24 0.19175 
TUBULIN N 
   
19.05 0.02042 
TUBULIN S 
   
19.26 0.03567 
TUBULIN U 
   
19.17 0.00992 
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6.2.3 Evaluation the gene expression profile of TEX19 knockdown in H460 
In H460 cancer cell, knockdown TEX19 show an increasing expression level of some genes 
compared with untreated and non-interference samples including MPEP (Figure 6.9), 
ATP5C1 (Figure 6.10), CALB2, CPS1, LY96, SLC17A7 and TRIM54 (Figure 6.12). Inhibition 
of expression of PGM1 was observed in the TEX19 knockdown sample compared with both 
untreated and non-interference samples (Figure 6.9). In addition, no expression changes were 
quantified in TEX19 knockdown sample compared with untreated and non-interfering 
samples of RIPA (Figure 6.9), ASB2 and ZNF367 (Figure 6.11). However, a significant 
elevation in expression of GALNT2, MRP524 (Figure 6.10) and CD22 (Figure 6.11) was 
observed in TEX19 knockdown sample compared with untreated condition. In addition, low 
expression of ELK4 and ZBTB5 was observed in TEX19 depleted sample compared to non-
interfering sample, and insignificant expression changes compared to untreated cells was 
observed (Figure 6.10). In contrast, NAPB and NOS3 expression were reduced relative to 
untreated sample and show similar expression to non-interfering sample (Figure 6.9 and 
Figure 6.11). Moreover, SAA2 show low expression in TEX19 knockdown sample compared 
with non-interference and high level of expression were observed compared with untreated 
sample (Figure 6.10). In addition, high expression in TEX19 knockdown sample compared 
with non-interfering were observed in TAGLN and no expression difference observed 
compared to untreated sample (Figure 6.11). 
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Figure 6.9 qRT PCR in H460 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.10 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against  TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected Expression 
SEM 
Mean 
Cq 
Cq SEM 
GALNT2 N 1.00000 0.11188 0.11188 25.40 0.01855 
GALNT2 S 1.14616 0.15861 0.15861 25.90 0.15003 
GALNT2 U 0.65405 0.09541 0.09541 26.57 0.13094 
LAMIN N 
   
22.12 0.17556 
LAMIN S 
   
22.63 0.14375 
LAMIN U 
   
22.69 0.10944 
MIPEP N 0.73808 0.10689 0.10689 27.71 0.16284 
MIPEP S 1.61859 0.18229 0.18229 27.28 0.01942 
MIPEP U 1.00916 0.16716 0.16716 27.81 0.12800 
NAPB N 0.80516 0.25829 0.25829 31.32 0.43414 
NAPB S 0.84436 0.13864 0.13864 31.95 0.19689 
NAPB U 1.46536 0.25707 0.25707 31.01 0.15274 
PGM1 N 0.59560 0.13451 0.13451 28.18 0.28363 
PGM1 S 0.33193 0.45007 0.45007 29.72 1.94952 
PGM1 U 1.46536 0.20941 0.20941 27.43 0.04222 
RPIA N 1.00000 0.13114 0.13114 25.87 0.13658 
RPIA S 1.11999 0.17717 0.17717 26.40 0.16143 
RPIA U 0.89856 0.13574 0.13574 26.58 0.14263 
TEX19 N 1.00000 0.18300 0.18300 31.58 0.20974 
TEX19 S 0.46729 0.05379 0.05379 33.37 0.03948 
TEX19 U 0.73672 0.18179 0.18179 32.57 0.31557 
TUBULIN N 
   
19.44 0.19426 
TUBULIN S 
   
20.32 0.23583 
TUBULIN U 
   
19.97 0.31720 
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Figure 6.10 qRT PCR in H460 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.11 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Relative 
Quantity 
Relative 
Quantity SEM 
Corrected Relative 
Quantity SEM 
Mean 
Cq 
Cq SEM 
ATP5C1 N 0.77930 0.13422 0.13422 23.48 0.24848 
ATP5C1 S 1.00000 0.00643 0.00643 23.12 0.00928 
ATP5C1 U 0.87607 0.04855 0.04855 23.31 0.07995 
ELK4 N 1.00000 0.02489 0.02489 25.96 0.03591 
ELK4 S 0.62548 0.06670 0.06670 26.64 0.15384 
ELK4 U 0.70802 0.06653 0.06653 26.46 0.13556 
LAMIN N 1.00000 0.04860 0.04860 21.55 0.07011 
LAMIN S 0.85810 0.01584 0.01584 21.77 0.02663 
LAMIN U 0.95298 0.00952 0.00952 21.62 0.01441 
MRPS23 N 1.00000 0.02888 0.02888 24.42 0.04167 
MRPS23 S 0.96361 0.03536 0.03536 24.47 0.05294 
MRPS23 U 0.70026 0.07429 0.07429 24.93 0.15306 
SAA2 N 1.00000 0.08500 0.08500 34.37 0.12263 
SAA2 S 0.63300 0.13831 0.13831 35.02 0.31523 
SAA2 U 0.41633 0.04376 0.04376 35.63 0.15164 
TEX19 N 1.00000 0.03850 0.03850 31.93 0.05555 
TEX19 S 0.11832 0.01417 0.01417 35.01 0.17275 
TEX19 U 0.34814 0.02937 0.02937 33.45 0.12169 
TUBULIN N 1.00000 0.08887 0.08887 18.91 0.12821 
TUBULIN S 0.75489 0.05474 0.05474 19.32 0.10462 
TUBULIN U 0.90969 0.00626 0.00626 19.05 0.00992 
ZBTB5 N 1.00000 0.14903 0.14903 28.71 0.21501 
ZBTB5 S 0.57845 0.02959 0.02959 29.50 0.07379 
ZBTB5 U 0.54556 0.02714 0.02714 29.58 0.07177 
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Figure 6.11 qRT PCR in H460 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.12 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sam
ple 
Expressio
n 
Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
ASB2 N 1.00000 0.25890 0.25890 35.74 0.35002 
ASB2 S 1.21754 0.34152 0.34152 35.79 0.29846 
ASB2 U 1.14858 0.13233 0.13233 35.84 0.13404 
CD22 N 0.78888 0.09524 0.09524 36.11 0.06961 
CD22 S 1.26466 0.41492 0.41492 35.76 0.00000 
CD22 U 0.15203 0.06464 0.06464 38.78 0.60147 
LAMIN N 
   
22.31 0.06258 
LAMIN S 
   
22.52 0.06374 
LAMIN U 
   
22.86 0.18632 
NOS3 N 0.92010 0.33870 0.33870 29.26 0.50651 
NOS3 S 0.56393 0.14551 0.14551 30.30 0.16297 
NOS3 U 1.23048 0.18452 0.18452 29.14 0.17977 
TAGLN N 0.40195 0.12182 0.12182 31.79 0.40706 
TAGLN S 1.24611 0.26827 0.26827 30.50 0.14759 
TAGLN U 1.23048 0.26081 0.26081 30.48 0.28111 
TEX19 N 1.00000 0.09239 0.09239 31.28 0.02780 
TEX19 S 0.25112 0.05755 0.05755 33.61 0.18613 
TEX19 U 0.65979 0.06032 0.06032 32.17 0.08796 
TUBLAIN N 
   
19.73 0.25310 
TUBLAIN S 
   
20.19 0.54283 
TUBLAIN U 
   
19.78 0.06263 
ZNF367 N 0.92355 0.08542 0.08542 27.46 0.02849 
ZNF367 S 1.05577 0.28481 0.28481 27.61 0.19861 
ZNF367 U 1.23048 0.10433 0.10433 27.35 0.02175 
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Figure 6.12 qRT PCR in H460 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.13 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sampl
e 
Expressio
n 
Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
CALB2 N 0.45505 0.02072 0.02072 32.64 0.05708 
CALB2 S 1.49575 0.31480 0.31480 31.51 0.12981 
CALB2 U 0.78573 0.03836 0.03836 32.05 0.05347 
CPS1 N 1.00000 0.04027 0.04027 22.04 0.04814 
CPS1 S 1.33289 0.31121 0.31121 22.20 0.02113 
CPS1 U 0.99863 0.04054 0.04054 22.23 0.01666 
LAMIN N 
   
21.64 0.04815 
LAMIN S 
   
22.42 0.54772 
LAMIN U 
   
21.86 0.04192 
LY96 N 0.33346 0.02351 0.02351 32.39 0.09356 
LY96 S 1.49575 0.30508 0.30508 30.81 0.10602 
LY96 U 0.31288 0.02750 0.02750 32.67 0.11371 
SLC17A7 N 0.90377 0.04262 0.04262 33.07 0.05513 
SLC17A7 S 1.49575 0.28767 0.28767 32.93 0.04052 
SLC17A7 U 0.86691 0.10618 0.10618 33.32 0.17065 
TEX19 N 1.00000 0.07415 0.07415 32.45 0.10190 
TEX19 S 0.21451 0.04181 0.04181 35.25 0.06113 
TEX19 U 0.82291 0.04038 0.04038 32.92 0.05394 
TRIM54 N 0.83100 0.08771 0.08771 32.61 0.14875 
TRIM54 S 1.49575 0.30868 0.30868 32.34 0.11533 
TRIM54 U 0.64215 0.02870 0.02870 33.17 0.03168 
TUBULIN N 
   
19.08 0.04379 
TUBULIN S 
   
19.46 0.03714 
TUBULIN U 
   
19.24 0.08155 
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6.2.4 Evaluation the genetic expression influence of TEX19 knockdown in NTERA2 
TEX19 depletion in NTERA2 showed significant reduction in expression of 14 genes 
compared to untreated and non-interfering samples, these are GALNT2, MPEP, NAPB, 
PGM1,RIPA (Figure 6.13), ATP5C1, ELK4, MRP523, ZBTB5 (Figure 6.14), ASB2, NOS3, 
ZNF367 (Figure 6.15), CPS1 and SLC17A7 (Figure 6.16). However, SAA2 showed higher 
expression following TEX19 expression knockdown compared to both untreated and non-
interfering samples (Figure 6.14). In addition, low expression was observed for TAGLN 
(Figure 6.15), CALB2 and LY96 (Figure 6.16) in TEX19 depleted cells accompanied with 
high expression compared to untreated sample. Moreover, TRIM54 showed insignificant 
expression change in TEX19 knockdown sample compared to non-interfering sample and low 
expression were observed compared to untreated sample. 
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Figure 6.13 qRT PCR in NTERA2 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.14 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
GALNT N 1.64139 0.09162 0.09162 24.72 0.04543 
GALNT S 0.05149 0.00387 0.00387 29.00 0.07766 
GALNT U 1.37256 0.07500 0.07500 25.58 0.05228 
LAMIN N 
   
22.57 0.11180 
LAMIN S 
   
21.72 0.06640 
LAMIN U 
   
23.19 0.07363 
MIPEP N 1.37934 0.08870 0.08870 26.70 0.06470 
MIPEP S 1.00000 0.06697 0.06697 26.45 0.05996 
MIPEP U 1.47967 0.10007 0.10007 27.19 0.07770 
NAPB N 1.18774 0.06129 0.06129 30.99 0.03350 
NAPB S 1.00000 0.06276 0.06276 30.52 0.04957 
NAPB U 1.38419 0.07892 0.07892 31.37 0.05731 
PGM1 N 1.32002 0.07598 0.07598 24.38 0.04975 
PGM1 S 1.00000 0.05699 0.05699 24.06 0.03194 
PGM1 U 1.34088 0.10275 0.10275 24.95 0.09349 
RIPA N 1.64139 0.07986 0.07986 25.23 0.02249 
RIPA S 0.67773 0.06891 0.06891 25.79 0.12562 
RIPA U 1.49210 0.08269 0.08269 25.97 0.05395 
TEX19 N 1.64139 0.13265 0.13265 32.66 0.09577 
TEX19 S 0.78408 0.12134 0.12134 33.01 0.21002 
TEX19 U 1.71185 0.13290 0.13290 33.20 0.09520 
TUBULIN N 
   
18.16 0.07200 
TUBULIN S 
   
17.58 0.13620 
TUBULIN U 
   
18.73 0.09223 
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Figure 6.14 qRT PCR in NTERA2 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.15 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
ATP5C1 N 1.23795 0.08403 0.08403 24.39 0.09557 
ATP5C1 S 0.87056 0.08960 0.08960 24.59 0.13916 
ATP5C1 U 1.44119 0.03523 0.03523 24.41 0.02164 
ELK4 N 1.23795 0.09005 0.09005 28.77 0.10275 
ELK4 S 0.61755 0.02877 0.02877 29.47 0.04285 
ELK4 U 1.37369 0.04236 0.04236 28.86 0.03470 
LAMIN N 
   
23.05 0.02823 
LAMIN S 
   
22.46 0.09979 
LAMIN U 
   
23.55 0.02704 
MRPS23 N 1.10511 0.19806 0.19806 26.71 0.25768 
MRPS23 S 0.86097 0.04298 0.04298 26.76 0.05005 
MRPS23 U 1.46043 0.06749 0.06749 26.55 0.06058 
SAA2 N 0.39482 0.03859 0.03859 31.77 0.13937 
SAA2 S 1.00000 0.05752 0.05752 30.12 0.06485 
SAA2 U 0.09218 0.02289 0.02289 34.11 0.35714 
TEX19 N 0.89145 0.03525 0.03525 33.98 0.05290 
TEX19 S 0.67451 0.03604 0.03604 34.08 0.05710 
TEX19 U 1.46043 0.04733 0.04733 33.51 0.03756 
TUBULIN N 
   
20.12 0.03209 
TUBULIN S 
   
20.09 0.02775 
TUBULIN U 
   
20.09 0.04867 
ZBTB5 N 1.23795 0.06721 0.06721 29.82 0.07535 
ZBTB5 S 0.48808 0.05299 0.05299 30.85 0.14783 
ZBTB5 U 1.38365 0.11652 0.11652 29.90 0.11826 
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Figure 6.15 qRT PCR in NTERA2 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.16 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
ASB2 N 1.22499 0.08483 0.08483 35.47 0.08395 
ASB2 S 1.00000 0.08444 0.08444 35.36 0.09905 
ASB2 U 1.48714 0.18751 0.18751 35.54 0.16645 
CD22 N 1.32258 0.08964 0.08964 32.53 0.08141 
CD22 S 0.40318 0.06820 0.06820 33.84 0.23350 
CD22 U 0.57126 0.08471 0.08471 34.09 0.20097 
LAMIN N 
   
23.32 0.10321 
LAMIN S 
   
22.53 0.02910 
LAMIN U 
   
24.00 0.14410 
NOS3 N 1.32258 0.08772 0.08772 32.77 0.07888 
NOS3 S 0.43903 0.06613 0.06613 33.96 0.20541 
NOS3 U 0.86530 0.10792 0.10792 33.73 0.16428 
TAGLN N 1.21167 0.05391 0.05391 30.85 0.03443 
TAGLN S 1.00000 0.06599 0.06599 30.72 0.06351 
TAGLN U 0.70573 0.05647 0.05647 31.97 0.08912 
TEX19 N 0.67621 0.08385 0.08385 37.88 0.17050 
TEX19 S 0.17088 0.01738 0.01738 39.46 0.12843 
TEX19 U 1.68335 0.56704 0.56704 36.92 0.48040 
TUBULIN N 
   
20.28 0.03293 
TUBULIN S 
   
20.27 0.13881 
TUBULIN U 
   
20.31 0.02778 
ZNF367 N 0.90845 0.03829 0.03829 30.04 0.02762 
ZNF367 S 0.56311 0.03297 0.03297 30.32 0.04591 
ZNF367 U 1.68335 0.10123 0.10123 29.49 0.04629 
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Figure 6.16 qRT PCR in NTERA2 cancer cell show TEX19 knockdown (S), untreated cells (U) and non-
interfering sample (N). 
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Table 6.17 quantification cycle reading (Cq) and standard deviation reading (SEM). The reading were 
normalized against TUBULIN and LAMIN. siRNA sample (S), non-interference sample (N) and 
untreated sample (U). 
Target Sample Expression Expression 
SEM 
Corrected 
Expression SEM 
Mean 
Cq 
Cq SEM 
CALB2 N 1.23913 0.07334 0.07334 28.26 0.03659 
CALB2 S 1.00000 0.12076 0.12076 28.15 0.17303 
CALB2 U 0.41269 0.01981 0.01981 30.18 0.06823 
CPS1 N 1.34279 0.12668 0.12668 29.87 0.11212 
CPS1 S 0.47072 0.04494 0.04494 30.95 0.13621 
CPS1 U 1.59866 0.14885 0.14885 29.94 0.13381 
LAMIN N 
   
23.20 0.15328 
LAMIN S 
   
22.38 0.03724 
LAMIN U 
   
23.75 0.00796 
LY69 N 1.21834 0.07196 0.07196 30.16 0.03617 
LY69 S 1.00000 0.05377 0.05377 30.02 0.07486 
LY69 U 0.30026 0.02401 0.02401 32.51 0.11477 
SLC17A7 N 1.18913 0.11515 0.11515 32.40 0.11647 
SLC17A7 S 1.00000 0.01991 0.01991 32.22 0.02025 
SLC17A7 U 1.52781 0.10993 0.10993 32.36 0.10313 
TEX19 N 1.26541 0.37785 0.37785 36.80 0.42029 
TEX19 S 0.14814 0.02933 0.02933 39.47 0.28450 
TEX19 U 1.68444 0.22195 0.22195 36.72 0.18955 
TRIM54 N 0.86912 0.07693 0.07693 32.59 0.10176 
TRIM54 S 0.78589 0.03401 0.03401 32.31 0.05901 
TRIM54 U 1.68444 0.23832 0.23832 31.96 0.20378 
TUBULIN N 
   
20.09 0.01782 
TUBULIN S 
   
20.06 0.01650 
TUBULIN U 
   
20.20 0.02220 
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6.3 Discussion 
The GALNT2 gene encodes a protein which is a member of the glycosyltransferase 2 protein 
family, which introduce mucin-type O-glycoslation of peptides in the Golgi apparatus 
(Pokrovskaya et al., 2011).. Dysregulation of this gene has been associated with many types 
of cancers, and overexpression of GALANT2 has been reported in some types of cancers 
particularly oral squamous cell carcinoma (Lin et al., 2014). GALNT2 expression has been 
downregulated in hepatocellular carcinoma (Wu et al., 2011). Our qRT-PCR analysis show 
high expression of GALNT2 in TEX19 knockdown samples in SW480 and A2780 cancer 
cells. The high expression of GALNT2 in these two-cancer cell-lines is consistence with RNA 
sequencing data that were performed in SW480. In contrast, low expression of GALNT2 were 
observed in NTERA2 cells, this low expression may due to the origin of the tissue in which 
the cancer arises; it may be an interaction between TEX19  and GALANT2 genes;  where both 
normally expressed in normal testis.  
Another gene, ELK4, showed low expression with TEX19 knockdown in NTERA2 and show 
high expression in SW480 cancer cells. ELK4 is a member of E Twenty Six family (ETS), 
which play important roles in cell cycle, proliferation, differentiation and apoptosis (Kerr et 
al., 2010; Day et al., 2011). High expression of ELK4 has been associated with some types of 
cancer, including prostate cancer (Shaikhibrahim et al., 2012). 
qRT-PCR results of SAA2 show high expression profile in NTERA2 cancer cell with TEX19 
knockdown and low expression in SW480. These inverted results recurrently observed 
between NTERA2 and SW480 including GALNT2, ELK4, ASB2, CD22, SLC17A7 and CPS1, 
where high expression detected in SW480 accompanied by low expression were observed in 
NTERA2 cells for these genes.  Saa2 protein is a member of serum amyloid A that usually 
responsible for amyloid deposit in chronic inflammation. In addition, this protein been 
upregulated in some types of malignancies (Malle et al., 2009). Moreover, SAA2 may play a 
possible a role in tumour initiation and promotion (Vlasova and Moshkovskii, 2006). 
The expression of ZBTB5 gene in the TEX19 knockdown sample show elevated expression in 
A2780 and inhibition of its expression in NTERA2. ZBTB5 is related to cancer progression 
particularly thyroid cancer (Xu et al, 2014). However, no significant expression differences 
were observed in SW480 or H460. 
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Figure 6.17 representation of 20 dysregulated genes based on RNA sequencing data. Genes shows 
upregulation and downregulation following TEX19 depletion in four cancer cell-lines.  
 
 
 
 
CANCER CELL-LINES
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MIPEP
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PGM1
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ATP5C1
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SAA2
ZBTB5
ASB2
CD22
NOS3
TAGLN
ZNF367
CALB2
CPS1
LY96
SLC17A7
TRIM54
UPREGULATED DOWNREGULATED
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The ASB2 gene encodes an Ankyrin repeat protein and SOCS box protein 2, the activation of 
this protein in acute promyelocytic leukemia consequently cause inhibition of cell growth and 
chromatin condensation (Guibal et al., 2002). In our experiment, we observe elevated ASB2 
expression in NTERA2 following TEX19 knockdown, which is opposing the RNA 
sequencing data. However, ASB2 expression was reduced in SW480 following TEX19 
knockdown, which shows complementarity with the RNA sequence data. 
qRT PCR result of CD22 show that increased expression was observed in SW480 with 
TEX19 knockdown and low expression was observed in NTERA2 cells. While, our RNA 
sequencing analysis show down-regulation of CD22 after knockdown TEX19. CD22 is 
member of sialic acid-binding Ig-like lectin, which normally expressed in B-lymphocytes and 
associated with lung cancer (Tuscano et al., 2012).  
Over-expression of NOS3 (nitric oxide synthase 3) plays a role in DNA damage by inhibiting 
the mechanism of DNA repair (Yan et al., 2014). In addition, NOS3 shown to be involved in 
cancer development. Moreover, NOS3 dysregulation has been reported in some types of 
tumours (Ying and Hofseth, 2007). However, in our study, NOS3 show low expression after 
knockdown of TEX19 in NTERA2, which is consistent with RNA sequencing data. However, 
no significant gene expression changes were observed in SW480, A2780 and H460 cancer 
cells. 
TAGLN have been associated with tumourgenesis; one study showed the influence of TAGLN 
expression indirectly causing regular cancer cells proliferation and growth in osteosarcoma 
(Zhao et al., 2014). However, in our experiment, TAGLN show lower expression profile in 
A2780, NTERA2 and SW480 following TEX19 knockdown compared to non-interference 
sample. These findings are consistence with the data of RNA sequencing. In contrast, TAGLN 
show high expression in H460 after TEX19 knockdown compared with non-interfering 
sample. 
Consistent expression profile of five genes in SW480 and H460, this including CALB2, 
CSP1, LY96, SLC17A7 and TRIM54 were highly expressed following TEX19 knockdown 
compared with untreated and non-interfering samples. These results are consistent with the 
RNA sequencing data, which indicate elevated expression profile after TEX19 knockdown, 
with the exception TRIM54. This may suggest the influencing role of TEX19 that may play in 
the regulation of these genes. 
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An interesting high expression of TRIM54 was observed following TEX19 depletion in 
SW480, A2780 and H460 compared with untreated and non-interfering samples. This high 
expression was inconsistent with RNA sequencing data which show approximately 80% 
reduction of TRIM54 after knockdown TEX19 in SW480 cancer cells. However, TRIM54 
expression in NTERA2 shows an insignificant expression change. The inconsistency findings 
of TRIM54 expression in qRT-PCR analysis and RNA sequencing after knockdown TEX19 
was previously noticed in some genes including ELK4, GALNT2, NOS3, CD22, ZBTB5, 
SAA2, and ASB2. In addition, the common factor or the cross point between these genes 
expression was NTERA2 cell-line, which is characterized by pluripotent EC cells. Moreover, 
in Chapter 4, we demonstrate TEX19 knockdown down-regulation effect on some stem cell 
marker genes including OCT4, NANOG and SOX2 in NTERA2 cells. Therefore, we suggest 
the down-regulation effect of TEX19 on some stem cell marker genes may indirectly involve 
in the dissimilarity of genes expression in NTERA2 cells.   
Some genes did not show consistence significant changes compared with untreated and non-
interference samples after Tex19 depletion such as MRPS23, SAA2, ZBTB5and ELK4 (figure 
6.10). however, a significant reduction of some of these genes compared to non-interference 
samples were observed in ELK4, SAA2 and ZBTB5, and elevated expression level of MRPS23 
compared to untreated sample. The inconsistence of these data of TEX19 knockdown 
compared with non-interference samples might be the involvement of non-interference RNA 
with these genes. Moreover, ATP5C1 shows increase level of expression after TEX19 
depletion compared with both untreated and non-interference samples (Figure 6.10) 
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7. Detection of Spo11 covalently bound to DNA in SW480 cells 
7.1 Background 
Meiosis is specialized cell division in sexual reproducing eukaryotes including single cell and 
multicellular organisms to generate haploid cells from diploid proginerator cells. This is 
achieved by meiotic recombination, which initiated by the programmed formation of DNA 
double strand breaks (DSBs), which are triggered by the conserved meiosis-specific protein 
Spo11 (Keeney et al., 2014). Then, Spo11 among other protein initiate meiotic recombination 
by introducing DNA DSB at specific area called recombination hotspot. The hotspot is 
determined by PRDM9 protein through DNA sequence-specific binding site of this hotspot 
(Smagulova et al., 2013). After DNA DSB, Spo11 is remain covalently bound to 5' of DNA 
strands resemble protein-DNA covalent complex. Endonuclease activity of some proteins 
mainly Mre11, release Spo11 bound to DNA resulting two Spo11-DNA complexes (Keeney 
et al., 2014). 
Several publish work, report the presence of some CTA including Spo11 in some types of 
cancer including colorectal cancer (Eldai, et al., 2013) and cutaneous T-cell lymphoma, 
(Litvinov et al., 2014) 
 Here, we are aiming to detect Spo11 covalent bound to DNA in SW480 colorectal cancer 
cells using modified DSB assay (Hartsuiker, 2011).  
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7.2 Result 
In this part, we knockdown SPO11 in SW480 cells using four SPO11 siRNA. Then, protein 
lysate were extracted from nuclear and cytoplasm. In addition, western blot were performed 
to detect Spo11 in the extracted protein lysate of SW480 cells. Moreover, DSB assay were 
carried out to verify Spo11 covalently binding to DNA in DNA fractions of colorectal cancer 
cell SW480. 
7.2.1 SPO11 knockdown in SW480 
The western blot result show clear inhibition of Spo11 protein detection in nuclear fractions 
using four SPO11 siRNA including siRNAs 1, 2, 4 and 6 compared to the corresponding 
untreated nuclear fraction protein lysate of SW480 and whole protein lysate as well (Figure 
7.1). In addition, no detection of Spo11 were observed in the cytoplasmic fraction of SW480 
protein lysate except the untreated cytoplasmic protein lysate fraction which may due to 
technical error during the protein extraction process. Lamin were detected in nuclear fractions 
of protein lysate reflect the accuracy of the amount of protein loading (Figure 7.1). 
7.1.2.2 Detection of Spo11-DNA binding 
This experiment carried out using modified DSB assay (Hartsuiker, 2011). Spo11 knockdown 
were applied in SW480 using SPO11 siRNA 4. Then, DNA gradient fractions were achieved 
after ultracentrifugation which mainly concentrated in gradient 3 and 4 in the slot blot. 
Western blot were performed and labelling the membrane using Spo11 antibody. Spo11 were 
detected in untreated fraction number 3, 4 and 5. In addition, Spo11 were also detected in 
siRNA and non-interference fractions number 3 and 4. However, re-labelling the membrane 
using α-Tubulin antibody were detected in untreated fraction in number 9 and 10. While, 
Tubulin were detected in fraction number 10 of siRNA fraction. Moreover, α-tubulin were 
detected in non-interference fraction number 8 and 9 of our membrane.  
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Figure 7.1 Western blot result show Spo11 in nuclear protein lysate fractions of SW480 were 
detected in whole and nuclear protein lysate after Spo11 knockdown using four SPO11 siRNA. Lamin 
was used as control for loading and fraction protein lysate accuracy. 
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Figure 7.2 Spo11-DNA binding detection. Spo11 was detected in untreated fraction number 3, 4 and 
5. Spo11 was also detected in siRNA and non-interference fractions number 3 and 4 which indicate 
Spo11 bound to DNA. In contrast, Tubulin was observed in the last fractions number 8, 9 or 10 which 
confirm presence of protein within these fractions. 
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7.1.3 Discussion 
Validation of Spo11 antibody were achieved by knockdown SPO11 in SW480 cells using 
four SPO11 siRNA. Western blot result show Spo11 detection in the extracted protein lysate 
of SW480 cells. In addition, detection of Spo11 in DNA fractions of SW480 cancer cells 
reflect protein-DNA binding of Spo11. This may suggest the possible mitotic role of SPO11 
in SW480 cells. The observation of Spo11 in SW480 cancer cells were correlated with many 
studies shows its detection in some cancer including colorectal cancer (Eldai, et al., 2013) 
and cutaneous T-cell lymphoma, (Litvinov et al., 2014). Spo11 association with some types 
of cancer may suggest its involvement in DSB in somatic tissue. In addition, escalating the 
question of its oncogenic activity in somatic tissue, this has been reported especially the 
expression of some CTA genes been correlated with poor prognosis in hepatocellular 
carcinoma (Wang et al., 2015). 
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8. Discussion 
8.1 Identification and validation potential CT genes using bioinformatics tools 
and RT-PCR analysis 
Significant mortality are encounter in cancer, due to cancer cells uncontrolled cell division 
leading to invasion and metastasis (Cancer Research UK, 2014). Therefore, early detection of 
neoplastic changes is crucial to treat cancer patient. In addition, tumour antigens have been 
used to target cancer via immunotherapy and cancer vaccination (Sharpeand and Mount, 
2015). CT genes are recognised for their confined expression in testis and limited expression 
in somatic tissue, and their abnormal activation in cancer including melanoma, liver, breast, 
ovarian, and lung cancer (Caballero and Chen, 2009; Wang et al., 2015; Whitehurst, 2014). 
This aberrant activation of CT genes in cancer emphasise their oncogenic involvement. 
Upregulation of CT gene MAGE-A4 in kidney tumour were associated with inhibition of 
apoptosis (Peikert et al., 2006). Also, in another study, reveal the inactivation of tumour 
suppressor gene P53 were related to CT gene MAGE-A2 (Monte et al., 2006). The oncogenic 
activity of CT genes lead to use them as cancer biomarkers for early diagnosis and prognosis 
of cancer. In solid tumours, some CT genes expression were used to predict the outcome of 
cancer (Wang et al., 2015). The significance of CT genes is their confined expression in testis 
supported by blood-testis barrier (BTB), where sertoli cells control and prevent immune cells 
and antibodies entry into testis (Mital et al., 2011). Therefore, the possible use of testis-
restricted genes to target some types of cancer through immunotherapy are achievable due to 
testicular immune-privilege and could be used as cancer biomarkers for cancer diagnosis and 
prognosis (Seoane and De Mattos-Arruda, 2014; Whitehurst, 2014). 
In our screening to identify and validate potential CT genes, two approaches were applied 
and show promising results. Both approaches including the manual search and in-silico 
pipeline provide us adequate data to identify novel CT genes. Bioinformatics were useful tool 
to identify novel CTA genes, and the validation of these novel cancer biomarkers by RT-PCR 
in in normal and cancer tissue reveal CT gene TEX19 expression in normal testis and many 
types of human tumours including colon cancer, lung cancer, breast cancer, ovarian cancer, 
leukaemia, melanoma and liver carcinoma (Feichtinger et al., 2012). These results 
questioning the possible functions of these genes that might play in cancer, and suggest the 
unknown role of some identified genes that might contribute in oncogenesis. 
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In a study on mouse, TEX19.1 expression were detected in germ and pluripotent cells, and 
show high expression in mitotic spermatogonia and gradually decreased expression through 
meiotic differentiation. In addition, TEX19.1 show low expression in differentiated 
pluripotent stem cells (Öllinger et al., 2008). Based on several studies, these germline genes 
normally involve in spermatogenesis functions such as differentiation, and maintaining the 
mitotic spermatogonia. In addition, according to CT genes classification, many of CT gene 
were located in X chromosome. They exhibit active expression in spermatogonia, and 
throughout the meiotic differentiation to spermatocyte become inactivated. Moreover, these 
germline genes are associated with many types of cancer and may contributes in 
carcinogenesis (McFarlane et al., 2015). Moreover, recent study show cancer cells using 
telomere maintenance pathway known as alternative lengthening of telomeres (ALT) to 
maintain telomere synthesis. This process is require two elements, the first one is Rad51 
which involve in DNA DSB repair, and secondly is Hop2-Mnd1 which are meiosis-specific 
factors required for pairing of homologous chromosomes in meiotic recombination (Cho  et 
al., 2014). This discovery emphasise the importance to comprehend the underlying 
mechanisms, that cause the activation of meiosis-specific genes and their interaction with 
variety of catalytic factors involved in oncogenesis, including meiotic mechanism 
(McFarlane et al., 2015). 
The successful production of T-cells specific to tumour-associated antigens open the door to 
target these tumours by immunotherapy. The development of CD4+ T-cells to target CTA 
gene NY-ESO-1 were expressed in melanoma patient, show positive result and trigger the 
immune system to produce T-cells specific to target the tumour (Hunder et al., 2008). 
Recently, study suggest that CT gene SLLP1 could be used to target multiple myeloma 
(Yousef, et al., 2015). 
Another CT gene we descried as testis-CNS selective gene CXorf27 were detected in the 
testis and spinal cord, whole brain, foetal brain and uterus of the normal tissue. In addition, 
this gene was expressed in many cancer tissues such as testicular, lung, breast, ovarian and 
melanoma cancer cells. This expression pattern suggests the possible use of CXorf27 as 
biomarker for cancer early detection, and immunotherapy applications due to its confined 
expression in the testis and CNS which characterised by their immune-privilege through 
blood brain barrier (BBB) of the CNS (Neuwelt et al., 2011).  
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8.2 Potential role of TEX19 in regulation of stemness 
In chapter 3, TEX19 exhibit interesting expression profile in many cancer tissues. However, 
not well known about TEX19 function in testis and cancer. TEX19 play an important role in 
spermatogenesis, this explain the impairment of spermatogenesis in mouse after knockout 
TEX19.1 (Zeng et al., 2009). 
We demonstrate in chapter 4 the effect of TEX19 knockdown on some stem cell marker genes 
including OCT4, SOX2 and NANOG in NTERA2 cancer cells. Which show down-regulation 
of these gene expression after the knockdown of TEX19. This finding might be related to a 
study in mouse pluripotent stem cells show the similar expression profile between Tex19.1 
and stem cell marker Oct4 (Kuntz et al., 2008). Therefore, to study the possible role of 
TEX19 that may contributes in regulation of stem cell markers in NTERA2, which represent a 
human cancer cell-line model that got stem cell-like features; is important to understand this 
relationship. 
In addition, our experiment in chapter 4, after the differentiation of NTERA2 using HMBA 
and RA show inhibition of stem cell markers including Oct4, Sox-2 and Nanog. However, 
Tex19 did not affected by the differentiation of NTERA2 cells. In contrast, TEX19 
knockdown in IPSc reveal the gene expression of OCT4, NANOG and SOX2 were unaffected. 
These results suggest that some stem cell marker genes expression is requires TEX19 in 
NTERA2 cells. Because, the expression of stem cell marker genes including OCT4, NANOG 
and SOX2 were unaffected after TEX19 knockdown in IPSc. This explained by TEX19.1 
deletion in mouse did not influence on the ability of unaffected ES cells to grow, and the stem 
cell marker genes were unaffected with TEX19.1 deletion including Oct4, Nanog and Sox2 
(Tarabay, et al., 2013). 
 
8.3 Influence of TEX19 depletion on TE in cancer cells 
We demonstrate the inhibition of ERVK family genes after TEX19 knockdown in NTERA2, 
down regulation of human ERVK genes were clear including ERVK ENV, ERVK GAG, ERVK 
HML2RE, ERVK POL and ERVK PRO. However, other study show activation of LINE-
1 transposons in placenta after deletion TEX19.1 (Reichmann et al., 2013). In addition, it was 
reported that deletion of TEX19.1 in mouse cause upregulation of retrotransposons including 
mouse ERVK genes (Ollinger et al., 2008). In addition, a study on TEs on mouse long 
intergenic noncoding RNAs (lincRNAs) show ERVK genes high expression profile and 
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strong effect in ESCs (Kelley and  Rinn, 2012) compared with NTERA2 that composed of 
pluripotent embryonal carcinoma (EC) cells that differentiate into neuron cells using RA 
(Andrews  et al., 1982). In addition, human ESCs and EC cells share some pluripotency 
characteristics (Abu Dawud et al., 2012). However, TEX19 knockdown in A2780 were 
unsuccessful, due to time limitation we could not repeat this experiment. The up-regulation of 
ERVK family genes are difficult to explain. Nevertheless, may TEX19 siRNA influence the 
overexpression of ERVK genes, while, non-interference RNA did not interfere with ERVK 
genes expression. 
Collectively, the effect of TEX19 depletion on NTERA2 cells were obvious compared to 
A2780. ELDA results show significant cell proliferation frequency when treated with TEX19 
in NTERA2 compared with unaffected cellular proliferation in A2780 cells after TEX19 
knockdown. Which may suggest that TEX19 may play a role in cell proliferation in NTERA2 
embryonic cancer cells, and not needed in A2780 cells.  
8.4 Influence of TEX19 depletion on differential gene expression based on RNA 
sequencing 
RNA Seq. were significant tool to explore the differential gene expression in NTERA2, 
H460, A2780 and SW480 cancer cells in response to TEX19 depletion. Here, we validate 20 
genes expression using qRT-PCR and reveal some significant upregulated and downregulated 
gene expression in response to knockdown TEX19 in these cancer cell-lines. We summarise 
the consistence and significant gene expression in four cancer cell-lines after knockdown 
TEX19. 
TRIM54 upregulated expression after TEX19 knockdown were observed in SW480, A2780 
and H460. This observation oppose the RNA sequencing data, which indicate approximately 
80% inhibition of TRIM54 after TEX19 depletion in SW480 cancer cells. However, TRIM54 
expression in NTERA2 show insignificant expression change. In addition, differential gene 
expression in NTERA2 after TEX19 depletion show downregulation of most of genes 
expression except SAA2 were upregulated. The conflicting results of TRIM54 gene expression 
in qRT-PCR analysis and RNA sequencing after TEX19 depletion were observed in some 
genes may be related to NTERA2 cell-line, which is characterized by pluripotent EC cells. 
suggest the down-regulation effect of TEX19 on some stem cell marker genes may indirectly 
involve in the dissimilarity of genes expression in NTERA2 cells. 
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The depletion of TEX19 in H460 cancer cells show upregulation in most of the genes 
including MIPEP, ATP5C1, SLC17A7, CPS1, CALB2, TRIM54 and LY96. This high 
expression were correlated with high expression of SLC17A7, CPS1, CALB2, TRIM54 and 
LY96 in SW480 cancer cells. In addition, except TRIM54, the upregulation in these genes are 
consistence with our data from RNA sequencing. Therefore, we suggest that TEX19 may 
involve in suppress regulation of these genes in H460 cancer cells. However, two genes 
including PGM1 and ELK4 were downregulated after depletion TEX19 in H460, and this 
downregulation of these two genes were observed also in NTERA2 cancer cells. In addition, 
the down regulation of PGM1 and ELK4 in H460 and NTERA2 were consistence with the 
RNA sequencing data. Moreover, the downregulation of PGM1 were only observed in 
NTERA2 cells, which suggest this gene expression requires TEX19 in these cancer cells.   
In A2780 cancer cells, we noticed that most of the genes were not affected by TEX19 
depletion. Out of 20 genes in our list, only 3 genes were upregulated in response to the 
knockdown of TEX19 including GALNT2, ZNF367 and TRIM54. Previously in Chapter 5, we 
evaluate the effect of TEX19 depletion on TE in A2780 and ELDA assay. In addition, we 
demonstrate the cell proliferation frequency after depletion TEX19 in A2780 were 
insignificant compared to NTERA2. In addition, the insignificant TE expression after 
knockdown TEX19 in A2780 compared to NTERA2. Moreover, based on RNA sequencing 
data, GALNT2 and TRIM54 were downregulated in SW480 cancer cells in response to TEX19 
depletion. Therefore, we suggest that depletion of TEX19 in A2780 cancer cells is not 
influencing cellular proliferation frequency changes, and no significant effect on the genes 
expression in A2780. 
In SW480 cancer cells, we observed that approximately half of the genes in our study show 
high expression upon TEX19 depletion. Out of 20 genes in our list, only 9 genes were 
upregulated in response to the knockdown of TEX19 including CD22, ASB2, SLC17A7, 
CPS1, GALNT2, CALB2, ELK4, TRIM54 and LY96. In addition, the expression of these genes 
were compatible with our RNA sequencing data with exception in ELK4, TRIM54 and 
GALNT2. Moreover, some of these upregulated genes were also exhibit similar expression in 
H460 cancer cells including SLC17A7, CPS1, CALB2, TRIM54 and LY96. In contrast, four 
genes were downregulated after TEX19 knockdown including NAPB, RIPA, MRPS23 and 
SAA2 in SW480 cells. In addition, NAPB and MRPS23 were downregulated only in SW480 
cancer cells and their expression were not affected in NTERA2, H460 and A2780 after 
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TEX19 depletion. Moreover, the expression of those two genes were consistence with RNA 
sequencing data. 
Out of 20 genes in our RNA sequencing, only TAGLN were not dysregulated after the 
depletion of TEX19 in four cell-lines including NTERA2, H460, A2780 and SW480. 
However, based on RNA sequencing, TAGLN were upregulated after TEX19 depletion in 
SW480. 
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